SPIRE-1: The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

• Sponsor: Pfizer (Industry)
• Overall Status: Terminated
• CT.gov ID: NCT01975376
• Collaborator: (none)
• Enrollment: 16,784
• Locations: 1746
• Arms: 2
• Actual Duration (Months): 40.7
• Patients Per Site: 9.6
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization, in high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C >/= 70 mg/dL (1.8 mmol/L) or non-HDL-C >/= 100 mg /dL (2.6 mmol/L).

Condition or Disease	Intervention/Treatment	Phase
Cardiovascular Disease	Drug: bococizumab (PF-04950615); Drug: Placebo	Phase 3

Detailed Description

The trial was terminated prematurely on November 1, 2016, due to the emerging clinical profile and the evolving treatment and market landscape for lipid-lowering agents. These indicated that bococizumab was not likely to provide value to patients, physicians, or shareholders. The decision was not based on a recommendation by the independent Data Monitoring Committee to stop the program.

Study Design

• Study Type: Interventional
• Actual Enrollment: 16784 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
• Actual Study Start Date: Oct 29, 2013
• Actual Primary Completion Date: Mar 22, 2017
• Actual Study Completion Date: Mar 22, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: bococizumab (PF-04950615) 150 mg, every 2 weeks, subcutaneous	Drug: bococizumab (PF-04950615); 150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.; Other Names: RN316
Placebo Comparator: Placebo Placebo comparator, every 2 weeks, subcutaneous.	Drug: Placebo; Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.

Outcome Measures

Primary Outcome Measures

1. Event Rate Per 100 Participant-Years For First Occurrence of Major Cardiovascular (CV) Event [From baseline until the date of first adjudicated and confirmed occurrence of major CV event (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of major CV event (adjudicated by Adjudication Committee) was reported. Major CV event was defined as any of the following: CV death (defined as sudden cardiac death, fatal myocardial infarction [MI], death due to heart failure, death due to stroke [fatal ischemic stroke or fatal stroke of undetermined etiology], or death due to other cardiovascular causes) non-fatal MI, non-fatal stroke, and hospitalization for unstable angina needing urgent revascularization. Event rate was calculated as the number of events per 100 participant-years at risk.

Secondary Outcome Measures

1. Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of Cardiovascular Death, Non-Fatal Myocardial Infraction, or Non-Fatal Stroke [From baseline until the date of first adjudicated and confirmed occurrence of the CV death, non-fatal MI or non-fatal stroke (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of composite endpoint of CV death, non-fatal MI or non-fatal stroke (adjudicated by Adjudication Committee) was reported. Cardiovascular death was defined as sudden cardiac death, fatal MI, death due to heart failure, death due to stroke (fatal ischemic stroke or fatal stroke of undetermined etiology), or death due to other cardiovascular causes. Event rate was calculated as the number of events per 100 participant-years at risk.

2. Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of All-Cause Death, Non-Fatal Myocardial Infraction, Non-Fatal Stroke, or Hospitalization for Unstable Angina Needing Urgent Revascularization [From baseline until the date of first adjudicated and confirmed occurrence of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for unstable angina needing urgent revascularization (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of composite endpoint of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for unstable angina needing urgent revascularization (adjudicated by Adjudication Committee) was reported. All-cause death was defined as the death due to any cause during the course of study. Event rate was calculated as the number of events per 100 participant-years at risk.

3. Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of All-Cause Death, Non-Fatal Myocardial Infarction, or Non-Fatal Stroke [From baseline until the date of first adjudicated and confirmed occurrence of the all-cause death, non-fatal MI, or non-fatal stroke (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of composite endpoint of all-cause death, non-fatal MI, or non-fatal stroke (adjudicated by adjudication committee) was reported. All-cause death was defined as the death due to any cause during the course of study. Event rate was calculated as the number of events per 100 participant-years at risk.

4. Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Unstable Angina Needing Urgent Revascularization [From baseline until the date of first adjudicated and confirmed occurrence of hospitalization for unstable angina needing urgent revascularization (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of hospitalization for unstable angina needing urgent revascularization (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

5. Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of Cardiovascular Death, Non-Fatal Myocardial Infarction, Non-Fatal Stroke and Hospitalization for Unstable Angina [From baseline until the date of first adjudicated and confirmed occurrence of cardiovascular death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina (adjudicated by adjudication committee) was reported. Cardiovascular death was defined as sudden cardiac death, fatal MI, death due to heart failure, death due to stroke (fatal ischemic stroke or fatal stroke of undetermined etiology), or death due to other cardiovascular causes. Event rate was calculated as the number of events per 100 participant-years at risk.

6. Event Rate Per 100 Participant-Years For Cardiovascular Death [From baseline until the date of adjudicated and confirmed occurrence of cardiovascular death (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for cardiovascular death (adjudicated by adjudication committee) was reported. Cardiovascular death was defined as sudden cardiac death, fatal MI, death due to heart failure, death due to stroke (fatal ischemic stroke or fatal stroke of undetermined etiology), or death due to other cardiovascular causes. Event rate was calculated as the number of events per 100 participant-years at risk.

7. Event Rate Per 100 Participant-Years For First Occurrence of Any Myocardial Infarction (Fatal or Non-Fatal) [From baseline until the date of first adjudicated and confirmed occurrence of any MI (fatal or non-fatal) (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of any MI (fatal or non-fatal) (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

8. Event Rate Per 100 Participant-Years For Fatal Myocardial Infarction [From baseline until the date of adjudicated and confirmed occurrence of fatal MI (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for fatal MI (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

9. Event Rate Per 100 Participant-Years For First Occurrence of Non-Fatal Myocardial Infarction [From baseline until the date of first adjudicated and confirmed occurrence of non-fatal MI (maximum duration: up to 3.4 years)]

   Event rate per 100 participant-years for first occurrence of non-fatal MI (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

10. Event Rate Per 100 Participant-Years For First Occurrence of Any Stroke (Fatal or Non-Fatal) [From baseline until the date of first adjudicated and confirmed occurrence of any stroke (fatal or non-fatal) (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of any stroke (fatal or non-fatal) (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

11. Event Rate Per 100 Participant-Years For First Occurrence of Any Stroke (Fatal or Non-Fatal), of Any Etiology [From baseline until the date of first adjudicated and confirmed occurrence of any stroke (fatal or non-fatal), of any etiology (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of any stroke (fatal or non-fatal), of any etiology (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

12. Event Rate Per 100 Participant-Years For Fatal Stroke [From baseline until the date of first adjudicated and confirmed occurrence of fatal stroke (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for fatal stroke (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

13. Event Rate Per 100 Participant-Years For First Occurrence of Non-Fatal Stroke [From baseline until the date of first adjudicated and confirmed occurrence of non-fatal stroke (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of non-fatal stroke (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

14. Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Unstable Angina [From baseline until the date of first adjudicated and confirmed occurrence of hospitalization for unstable angina (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of hospitalization for unstable angina (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

15. Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Congestive Heart Failure (CHF) [From baseline until the date of first adjudicated and confirmed occurrence of hospitalization for congestive heart failure (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of hospitalization for CHF (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

16. Event Rate Per 100 Participant-Years For First Occurrence of Coronary Revascularization [From baseline until the date of first adjudicated and confirmed occurrence of coronary revascularization (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of coronary revascularization (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

17. Event Rate Per 100 Participant-Years For First Occurrence of Coronary Artery Bypass Graft Surgery (CABG) [From baseline until the date of first adjudicated and confirmed occurrence of CABG (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of CABG (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

18. Event Rate Per 100 Participant-Years For First Occurrence of Percutaneous Coronary Intervention (PCI) [From baseline until the date of first adjudicated and confirmed occurrence of PCI (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of PCI (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

19. Event Rate Per 100 Participant-Years For First Occurrence of Any Arterial Revascularizations [From baseline until the date of first adjudicated and confirmed occurrence of any arterial revascularizations (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for first occurrence of any arterial revascularizations (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.

20. Event Rate Per 100 Participant-Years For All-Cause Death [From baseline until the date of adjudicated and confirmed occurrence of all-cause death (maximum duration: up to 3.4 years)]

    Event rate per 100 participant-years for all-cause death (adjudicated by adjudication committee) was reported. All-cause death was defined as the death due to any cause during the course of study. Event rate was calculated as the number of events per 100 participant-years at risk.

21. Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 14 [Baseline, Week 14]

22. Nominal Change From Baseline in Low Density Lipoprotein Cholesterol at Week 14 [Baseline, Week 14]

23. Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Last Post-Baseline Measurement [Baseline, last post-baseline measurement (any time up to Week 140)]

24. Percent Change From Baseline in Lipid Levels at Week 14 [Baseline, Week 14]

    Lipids included non-high density lipoprotein cholesterol (non-HDL-C), total cholesterol, very low density lipoprotein cholesterol (VLDL-C), remnant lipoprotein cholesterol (RLP-C), apolipoprotein B (Apo B), HDL-C and apolipoprotein A-I (Apo A-I).

25. Percent Change From Baseline in Log-Transformed Lipoprotein (a) (Lp[a]) and Triglycerides at Week 14 [Baseline, Week 14]

26. Percent Change From Baseline in Log-Transformed High Sensitivity C-Reactive Protein (Hs-CRP) at Week 14 [Baseline, Week 14]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Must be on background lipid lowering treatment.

• Must be at high risk of a CV event.

• Must have an LDL C >/=70 mg/dL (1.8 mmol/L) or non-HDL-C >/= 100 mg/dL (2.6 mmol/L).

Exclusion Criteria:

• Planned coronary (PCI or CABG) or other arterial revascularization.

• New York Heart Association Class IV congestive heart failure or left ventricular ejection fraction < 25% by cardiac imaging.

• Chronic renal insufficiency with creatinine clearance of <30 ml/min/1.73m^2 by MDRD formula or with end state renal disease on dialysis.

• History of hemorrhagic stroke.

• Prior exposure to bococizumab or other investigational PCSK9 inhibitor.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ernest Hendrix, MD, PC	Athens	Alabama	United States	35611
2	North Alabama Research Center LLC	Athens	Alabama	United States	35611
3	Central Alabama Research	Birmingham	Alabama	United States	35209
4	Clinical Research Advantage, Inc./Simon Williamson Clinic	Birmingham	Alabama	United States	35211
5	Birmingham Heart Clinic, P.C.	Birmingham	Alabama	United States	35235
6	Cardiovascular Associates of the Southeast, LLC	Birmingham	Alabama	United States	35243
7	University of Alabama at Birmingham	Birmingham	Alabama	United States	35294
8	Appalachian Cardiovascular Associates	Fort Payne	Alabama	United States	35967
9	Fundamental Research, LLC	Gulf Shores	Alabama	United States	36542
10	Avant Research Associates, LLC	Guntersville	Alabama	United States	35976
11	Boyett Health Services	Hamilton	Alabama	United States	35570
12	Saadat Ansari Internal Medicine	Huntsville	Alabama	United States	35801
13	CB Flock Research Corporation	Mobile	Alabama	United States	36608
14	Alaska Heart Institute	Anchorage	Alaska	United States	99508
15	Phoenix Heart, PLLC	Glendale	Arizona	United States	85306
16	Arrowhead Internal Medicine	Glendale	Arizona	United States	85308
17	Clinical Research Advantage, Inc./Family Practice Specialists, Ltd.	Phoenix	Arizona	United States	85018
18	Redpoint Research	Phoenix	Arizona	United States	85029
19	Cochise Clinical Research	Sierra Vista	Arizona	United States	85635
20	Clinical Research Advantage, Inc. (Administrative Mailing Only)	Tempe	Arizona	United States	85282
21	Southwest Heart Group	Tucson	Arizona	United States	85710
22	University of Arizona Medical Center South Campus	Tucson	Arizona	United States	85713
23	Arizona Endocrine and Rheumatology Associates	Tucson	Arizona	United States	85715
24	Arkansas Heart Hospital Clinic	Little Rock	Arkansas	United States	72211
25	Arkansas Site Management Services, LLC	Little Rock	Arkansas	United States	72211
26	Cardiology Consultants of Orange County Medical Group Inc.	Anaheim	California	United States	92801
27	Premier Valley Medical Group	Bakersfield	California	United States	93309
28	Cardiovascular Research Foundation of Southern California	Beverly Hills	California	United States	90210
29	Westside Medical Associates of Los Angeles	Beverly Hills	California	United States	90211
30	Southbay Pharma Research	Buena Park	California	United States	90620
31	Med Center	Carmichael	California	United States	95608
32	Pioneer Medical Group	Cerritos	California	United States	90703
33	John Muir Physician Network Clinical Research Center	Concord	California	United States	94520
34	Atlantic Ave Medical Clinic Inc.	Cudahy	California	United States	90201
35	Multani Medical Group	Downey	California	United States	90241
36	Triwest Research Associates, LLC	El Cajon	California	United States	92020
37	Diagnamics, Inc.	Encinitas	California	United States	92024
38	T. Joseph Raoof, Md, Inc/Encino Research Center	Encino	California	United States	91436
39	Aviva Research	Escondido	California	United States	92025
40	Med Investigations, Inc.	Fair Oaks	California	United States	95628
41	Valley Research	Fresno	California	United States	93720
42	St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare	Fullerton	California	United States	92835
43	Omnibus Clinical Research	La Palma	California	United States	90623
44	Alliance Research Centers	Laguna Hills	California	United States	92653
45	Prime Care Clinical Research Center	Laguna Hills	California	United States	92653
46	Clinical Trials Research	Lincoln	California	United States	95648
47	Long Beach Memorial Medical Center	Long Beach	California	United States	90806
48	American Institute of Research	Los Angeles	California	United States	90017
49	Intermed Group	Los Angeles	California	United States	90017
50	Academic Medical Research Institute	Los Angeles	California	United States	90022
51	Eastside Clinical Research Associates	Los Angeles	California	United States	90022
52	Richard S. Cherlin, MD	Los Gatos	California	United States	95032
53	Facey Medical Foundation	Mission Hills	California	United States	91345
54	California Medical Research Associates Inc.	Northridge	California	United States	91324
55	Valley Clinical Trials, Inc.	Northridge	California	United States	91325
56	Diabetes Associates Medical Group	Orange	California	United States	92868
57	Saviers Medical Group	Port Hueneme	California	United States	93041
58	Arch Health Partners	Poway	California	United States	92064
59	A. R. I. Clinical Trials, Inc.	Redondo Beach	California	United States	90277
60	California Research Foundation	San Diego	California	United States	92103-6204
61	San Diego Family Care dba Linda Vista Health Center	San Diego	California	United States	92111
62	San Diego Family Care	San Diego	California	United States	92111
63	Ritchken & First Md's	San Diego	California	United States	92117
64	Wetlin Research Associates, Inc.	San Diego	California	United States	92120
65	West Coast Research LLC	San Ramon	California	United States	94582
66	Syrentis Clinical Research	Santa Ana	California	United States	92705
67	Coastal Biomedical Research, Inc.	Santa Monica	California	United States	90404
68	Encompass Clinical Research	Spring Valley	California	United States	91978
69	St. Joseph's Medical Associates	Stockton	California	United States	95204
70	Westlake Medical Research	Thousand Oaks	California	United States	91360
71	Los Angeles Biomedical Research Institute at Harbor - UCLA Medical Center	Torrance	California	United States	90502
72	Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center	Torrance	California	United States	90502
73	Harbor - UCLA Medical Center	Torrance	California	United States	90509
74	Orange County Research Center	Tustin	California	United States	92780
75	Bayview Research Group	Valley Village	California	United States	91607
76	Coastal Metabolic Research Centre	Ventura	California	United States	93003
77	Ventura Clinical Trials	Ventura	California	United States	93003
78	Clinical Research Advantage, Inc. / Cassidy Medical Group - Vista	Vista	California	United States	92083
79	Allianz Research Institute	Westminster	California	United States	92683
80	American Institute of Research Studies	Whittier	California	United States	90603
81	Elite Clinical Trials, Inc.	Wildomar	California	United States	92595
82	Elite Clinical Trials, Incorporated	Wildomar	California	United States	92595
83	Colorado Springs Health Partners	Colorado Springs	Colorado	United States	80906
84	ExpressCare Clinical Research	Colorado Springs	Colorado	United States	80909
85	Lynn Institute of the Rockies	Colorado Springs	Colorado	United States	80909
86	Memorial Hospital: University of Colorado Health	Colorado Springs	Colorado	United States	80909
87	Lynn Institute of Denver	Denver	Colorado	United States	80246
88	Western Colorado Research, LLC	Glenwood Springs	Colorado	United States	81601
89	South Denver Cardiology Associates, PC	Littleton	Colorado	United States	80120
90	Connecticut Clinical Research, LLC	Bridgeport	Connecticut	United States	06606
91	Bridgeport Hospital	Bridgeport	Connecticut	United States	06610
92	Hartford Hospital	Hartford	Connecticut	United States	06102
93	Cardiology Associates of Fairfield County, PC	Stamford	Connecticut	United States	06905
94	Stamford Therapeutics Consortium	Stamford	Connecticut	United States	06905
95	Christiana Care Health Services, Inc.	Newark	Delaware	United States	19713
96	Alfieri Cardiology	Wilmington	Delaware	United States	19803
97	Capital Medical Associates, PC	Washington	District of Columbia	United States	20036
98	ACRC - Cardiology	Atlantis	Florida	United States	33462
99	Meridien Research	Brooksville	Florida	United States	34601
100	Gulf Coast Endocrine and Diabetes Center	Clearwater	Florida	United States	33756
101	Team Medical Research	Coral Gables	Florida	United States	33134
102	The Heart Group, PA	Daytona Beach	Florida	United States	32114
103	Cardiology Associates Research Company	Daytona Beach	Florida	United States	32117
104	Seidman Clinical Trials	Delray Beach	Florida	United States	33484
105	The Cardiology Center	Delray Beach	Florida	United States	33484
106	Continental Research Corp	Doral	Florida	United States	33126
107	Care Research Center Inc	Doral	Florida	United States	33166
108	Integrity Clinical Research, LLC	Doral	Florida	United States	33166
109	Moonshine Research Center, Inc.	Doral	Florida	United States	33166
110	Advanced Clinical Research of Miami (ACROM) International	Doral	Florida	United States	33172
111	Invesclinic, LLC	Fort Lauderdale	Florida	United States	33308
112	The Office of Alan Graff, MD, PA	Fort Lauderdale	Florida	United States	33308
113	The Center for Diabetes and Endocrine Care	Fort Lauderdale	Florida	United States	33312
114	Broward Health Medical Center (BHMC) (Broward General Medical Center (BGMC))	Fort Lauderdale	Florida	United States	33316
115	The Office of Maxine E. Hamilton, MD, PA	Fort Lauderdale	Florida	United States	33316
116	State Of The Art Research, LLC	Hialeah	Florida	United States	33010
117	Direct Helpers Medical Center Inc	Hialeah	Florida	United States	33012
118	Research Physicians Network Alliance	Hollywood	Florida	United States	33021
119	Pines Clinical Research, Inc.	Hollywood	Florida	United States	33024
120	East Coast Institute for Research, LLC	Jacksonville	Florida	United States	32204
121	Westside Center for Clinical Research	Jacksonville	Florida	United States	32205
122	River City Clinical Research	Jacksonville	Florida	United States	32207
123	East Coast Institute for Research, LLC	Jacksonville	Florida	United States	32216
124	Jacksonville Center for Clinical Research	Jacksonville	Florida	United States	32216
125	Baker-Gilmore Cardiovascular Institute	Jacksonville	Florida	United States	32223
126	Solutions Through Advanced Research, Inc.	Jacksonville	Florida	United States	32256
127	Meridien Research	Lakeland	Florida	United States	33805
128	The Heart Institute at Largo	Largo	Florida	United States	33770
129	South Florida Clinical Research Institute	Margate	Florida	United States	33063
130	Accelovance	Melbourne	Florida	United States	32934
131	Research Physicians Network Alliance	Miami Beach	Florida	United States	33140
132	G & I Medical Research LLC	Miami Lakes	Florida	United States	33014
133	Future Clinical Research, Inc.	Miami	Florida	United States	33122
134	Advanced Clinical Research of Miami (ACROM) International	Miami	Florida	United States	33125
135	Project4Research, Inc	Miami	Florida	United States	33125
136	A & L Clinical Research	Miami	Florida	United States	33126
137	Finlay Medical Research	Miami	Florida	United States	33126
138	Pharmax Research Clinic, Inc.	Miami	Florida	United States	33126
139	South Florida Research Center, Inc.	Miami	Florida	United States	33135
140	Florida Medical Center & Research, Inc.	Miami	Florida	United States	33142
141	Medical Research Center	Miami	Florida	United States	33144
142	Nuren Medical & Research Center	Miami	Florida	United States	33144
143	Doctors Research Institute	Miami	Florida	United States	33145
144	Advanced Pharma CR, LLC	Miami	Florida	United States	33147
145	Coast Research Institute	Miami	Florida	United States	33155
146	My Community Research Center, Inc.	Miami	Florida	United States	33155
147	Columbus Clinical Services LLC	Miami	Florida	United States	33165
148	Cardiovascular Research Center of South Florida	Miami	Florida	United States	33173
149	Research Institute of South Florida, Inc.	Miami	Florida	United States	33173
150	A & O Research Center, Inc.	Miami	Florida	United States	33174
151	BWell Research Center	Miami	Florida	United States	33175
152	Pharmacology International Research, Inc.	Miami	Florida	United States	33175
153	Advanced Clinical Research	Miami	Florida	United States	33176
154	South Florida Research Group, LLC	Miami	Florida	United States	33176
155	International Research Associates, LLC	Miami	Florida	United States	33183
156	Kendall South Medical Center, Inc.	Miami	Florida	United States	33185
157	M & M Medical Center, Inc	Miami	Florida	United States	33185
158	Med Research Of Florida, LLC	Miami	Florida	United States	33186
159	Southwest Florida Research	Naples	Florida	United States	34102
160	BayCare Medical Group	New Port Richey	Florida	United States	34653
161	The Heart & Vascular Institute of Florida	New Port Richey	Florida	United States	34653
162	Bravo Health Care Center	North Bay Village	Florida	United States	33141
163	Harmony Clincal Research, Inc.	North Miami Beach	Florida	United States	33162
164	Florida Hospital Cardiovascular Institute	Orlando	Florida	United States	32803
165	Omega Research Consultants, LLC	Orlando	Florida	United States	32806
166	Aba Family Medicine, LLC	Ormond Beach	Florida	United States	32174
167	Millennium Research	Ormond Beach	Florida	United States	32174
168	Ribo Research, LLC dba Peninsula Research	Ormond Beach	Florida	United States	32174
169	A&R Research Group, LLC	Pembroke Pines	Florida	United States	33024
170	Research Physicians Network Alliance	Pembroke Pines	Florida	United States	33025
171	South Broward Research	Pembroke Pines	Florida	United States	33027
172	DBC Research USA	Pembroke Pines	Florida	United States	33029
173	DBC Research	Pembroke Pines	Florida	United States	33029
174	Cardiology Consultants	Pensacola	Florida	United States	32501
175	DMI Research, Inc.	Pinellas Park	Florida	United States	33782
176	Clincal Research of Florida	Plant City	Florida	United States	33563
177	Clinical Research of Central Florida	Plant City	Florida	United States	33563
178	Dr. Jeffrey Greiff MD, Office Of	Plantation	Florida	United States	33313-6066
179	Nova Clinical Research Collaborative	Plantation	Florida	United States	33313
180	St. Johns Center for Clinical Research	Ponte Vedra	Florida	United States	32081
181	Charlotte Heart Group Research Center	Port Charlotte	Florida	United States	33952
182	Meridien Research	Saint Petersburg	Florida	United States	33709
183	Advance Medical Research	Saint Petersburg	Florida	United States	33713
184	Intercoastal Medical Group	Sarasota	Florida	United States	34232
185	Cardiovascular Center Of Sarasota	Sarasota	Florida	United States	34239
186	Heart & Vascular Center Research	Sarasota	Florida	United States	34239
187	Intercoastal Medical Group (Drug Shipment Address and Administrative)	Sarasota	Florida	United States	34239
188	The Office of Bridget Bellingar, DO	Seminole	Florida	United States	33777
189	Vita Health & Medical Center, Inc./Concept Clinical Trials, LLC	Tamarac	Florida	United States	33319
190	Interventional Cardiac Consultants	Trinity	Florida	United States	34655
191	Cardiology Partners Clinical Research Institute	Wellington	Florida	United States	33449
192	Cleveland Clinic Cardiology Associates	West Palm Beach	Florida	United States	33401
193	Metabolic Research Institute, Inc.	West Palm Beach	Florida	United States	33401
194	Clinical Research of Central Florida	Winter Haven	Florida	United States	33880
195	Atlanta Diabetes Associates	Atlanta	Georgia	United States	30318
196	Emory University Hospital	Atlanta	Georgia	United States	30322
197	Atlanta Center For Medical Research	Atlanta	Georgia	United States	30331
198	Columbus Regional Research Institute	Columbus	Georgia	United States	31904
199	Rockdale Medical Research Associates	Conyers	Georgia	United States	30094
200	Georgia Heart Specialists, LLC	Covington	Georgia	United States	30014
201	Neurostudies.Net, LLC	Decatur	Georgia	United States	30033
202	Alta Pharmaceutical Research Center	Dunwoody	Georgia	United States	30338
203	In-Quest Medical Research, LLC	Norcross	Georgia	United States	30071
204	Atlanta Center for Clinical Research / Internal Medicine	Roswell	Georgia	United States	30075
205	Dr. B. Abraham, P.C.	Snellville	Georgia	United States	30039
206	Georgia Clinical Research, LLC	Snellville	Georgia	United States	30078
207	Clinical Research Atlanta	Stockbridge	Georgia	United States	30281
208	East-West Medical Research Institute	Honolulu	Hawaii	United States	96814
209	Elite Clinial Trials, LLLP	Blackfoot	Idaho	United States	83221
210	Elite Clinial Trials	Blackfoot	Idaho	United States	83221
211	St. Luke's Idaho Cardiology Associates	Caldwell	Idaho	United States	83605
212	Solaris Clinical Research	Meridian	Idaho	United States	83646
213	Saltzer Medical Group, PA	Nampa	Idaho	United States	83686-6011
214	Northwest Heart Clinical Research, LLC	Arlington Heights	Illinois	United States	60005
215	Clinical Research Advantage, Inc./Michigan Avenue Internists	Chicago	Illinois	United States	60604
216	Apex Medical Research, AMR, Inc.	Chicago	Illinois	United States	60616
217	Clinical Research Advantage, Inc./Medical and Procedural Specialists of Illinois	Chicago	Illinois	United States	60631
218	Evanston Premier Healthcare Research, LLC	Evanston	Illinois	United States	60201
219	Clinical Investigation Specialists, Inc	Gurnee	Illinois	United States	60031
220	Heart Care Centers of Illinois	Mokena	Illinois	United States	60448
221	Advanced CardioVascular Consultants	Rock Island	Illinois	United States	61201
222	Investigators Research Group, LLC	Brownsburg	Indiana	United States	46112
223	Investigative Clinical Research of Indiana, LLC	Elwood	Indiana	United States	46036
224	Deaconess Clinic Downtown	Evansville	Indiana	United States	47713
225	Clinical Research Advantage, Inc. (IP Shipment and Research Site)	Evansville	Indiana	United States	47714
226	MediSphere Medical Research Center, LLC	Evansville	Indiana	United States	47714
227	Clinical Research Advantage, Inc. / Family Medicine Associates	Evansville	Indiana	United States	47725
228	Deaconess Clinic Mt. Pleasant	Evansville	Indiana	United States	47725
229	American Health Network of Indiana LLC	Franklin	Indiana	United States	46131
230	American Health Network of Indiana, LLC	Greenfield	Indiana	United States	46140
231	American Health Network of Indiana, LLC	Muncie	Indiana	United States	47304
232	Cardiovascular Research of Northwest Indiana, LLC	Munster	Indiana	United States	46321
233	Buynak Clinical Research, P.C.	Valparaiso	Indiana	United States	46383
234	West Broadway Clinic	Council Bluffs	Iowa	United States	51501
235	Clinical Research Advantage, Inc.	Council Bluffs	Iowa	United States	51503
236	Midwest Cardiovascular Research Foundation	Davenport	Iowa	United States	52803
237	University of Iowa College of Public Health - Preventive Intervention Center	Iowa City	Iowa	United States	52242
238	Northeast Iowa Medical Education Foundation	Waterloo	Iowa	United States	50702
239	The Iowa Clinic, PC	West Des Moines	Iowa	United States	50266
240	Hutchinson Clinic, P.A	Hutchinson	Kansas	United States	67502
241	University Of Kansas Medical Center	Kansas City	Kansas	United States	66160
242	Heartland Research Associates, LLC	Newton	Kansas	United States	67114
243	Midwest Heart & Vascular Specialists, LLC	Overland Park	Kansas	United States	66209
244	Women's & Family Care, LLC D.B.A GTC Research	Shawnee Mission	Kansas	United States	66218
245	Central Cardiology Associates Research	Elizabethtown	Kentucky	United States	42701
246	The Research Group of Lexington, LLC	Lexington	Kentucky	United States	40503
247	L-MARC Research Center	Louisville	Kentucky	United States	40213
248	Research Integrity, LLC.	Owensboro	Kentucky	United States	42303
249	Alexandria Cardiology Clinic	Alexandria	Louisiana	United States	71301
250	Avant Research Associates, LLC	Crowley	Louisiana	United States	70526
251	Centex Studies	Lake Charles	Louisiana	United States	70601
252	Imperial Health, LLC	Lake Charles	Louisiana	United States	70601
253	American Clinical Research, LLC	Marrero	Louisiana	United States	70072
254	West Jefferson Heart Clinic of Louisiana New Orleans Physician Services, Inc.	Marrero	Louisiana	United States	70072
255	Clinical Trials of America LA	Monroe	Louisiana	United States	71201
256	KAMP Medical Research Inc.	Natchitoches	Louisiana	United States	71457
257	Grace Research, LLC	Shreveport	Louisiana	United States	71105
258	Maine Research Associates	Auburn	Maine	United States	04210
259	Acadia Clinical Research, LLC	Bangor	Maine	United States	04401
260	Cranbrook Cardiology Research Associates	Westbrook	Maine	United States	04092
261	Anne Arundel Medical Center	Annapolis	Maryland	United States	21401
262	MedStar Cardiology Associates	Annapolis	Maryland	United States	21401
263	MedStar Chesapeake CardioVascular Associates	Baltimore	Maryland	United States	21204
264	MedStar Union Memorial Heart Specialists	Baltimore	Maryland	United States	21218
265	Maryland Cardiovascular Specialists	Baltimore	Maryland	United States	21229
266	Overlea Personal Physicians	Baltimore	Maryland	United States	21236
267	Shahid Saeed, MD, PC	Baltimore	Maryland	United States	21237
268	Maryland Heart Associates, LLC	Glen Burnie	Maryland	United States	21061
269	Lutherville Personal Physicians	Lutherville	Maryland	United States	21093
270	MD Medical Research	Oxon Hill	Maryland	United States	20745
271	Metro West Medical Center Research Clinic	Framingham	Massachusetts	United States	01702
272	Metro West Medical Center	Framingham	Massachusetts	United States	01702
273	MetroWest Medical Center - Pharmacy Department	Framingham	Massachusetts	United States	01702
274	Pentucket Medical Associates, LLC	Haverhill	Massachusetts	United States	01830
275	ActivMed Practices and Research, Inc.	Methuen	Massachusetts	United States	01844
276	Charles River Medical Associates	Natick	Massachusetts	United States	01760
277	Endeavor Medical Research	Alpena	Michigan	United States	49707
278	St. Joseph Mercy Health System	Ann Arbor	Michigan	United States	48106
279	University of Michigan - Domino Farms	Ann Arbor	Michigan	United States	48106
280	IHA Chelsea Family & Internal Medicine	Chelsea	Michigan	United States	48118
281	Healthy Heart Cardiology	Grandville	Michigan	United States	49418
282	Westside Family Medical Center, Pc	Kalamazoo	Michigan	United States	49009
283	Sparrow Clinical Research Institute	Lansing	Michigan	United States	48912
284	Sparrow Thoracic & Cardiovascular Institute	Lansing	Michigan	United States	48912
285	Detroit Clinical Research Center, PC	Livonia	Michigan	United States	48154
286	MidMichigan Medical Center Midland	Midland	Michigan	United States	48670
287	Michigan Cardio Vascular Institute	Saginaw	Michigan	United States	48601
288	Tri-County Research, Inc.	Sterling Heights	Michigan	United States	48310
289	Medical Research Associates, Inc.	Traverse City	Michigan	United States	49684
290	Oakland Medical Research Center	Troy	Michigan	United States	48085
291	Arcturus Healthcare, PLC, Troy Internal Medicine Research Division	Troy	Michigan	United States	48098
292	Michigan Heart & Vascular Institute	Ypsilanti	Michigan	United States	48197
293	Duluth Clinic, dba Essentia Health Duluth Clinic Investigational Drug Room	Duluth	Minnesota	United States	55805
294	St. Mary's Medical Center (Primary Practice Site)	Duluth	Minnesota	United States	55805
295	Radiant Research, Inc.	Edina	Minnesota	United States	55435
296	Minneapolis Clinic of Neurology	Golden Valley	Minnesota	United States	55422
297	Allina Health System, dba Abbott Northwestern Hospital	Minneapolis	Minnesota	United States	55407
298	Lillehei Clinical Research Unit, University of Minnesota	Minneapolis	Minnesota	United States	55455
299	CentraCare Heart and Vascular Center	Saint Cloud	Minnesota	United States	56303
300	HealthEast Medical Research Institute	Saint Paul	Minnesota	United States	55102
301	HealthEast St. Joseph's Hospital Pharmacy	Saint Paul	Minnesota	United States	55102
302	Phillips Medical Services, PLLC	Jackson	Mississippi	United States	39209
303	Olive Branch Family Medical Center	Olive Branch	Mississippi	United States	38654
304	Cardiology Associates Research, LLC	Tupelo	Mississippi	United States	38801
305	Missouri Cardiovascular Specialists, LLP	Columbia	Missouri	United States	65201
306	Saint Luke's Lipid and Diabetes Research Center	Kansas City	Missouri	United States	64111
307	Kansas City VA Medical Center	Kansas City	Missouri	United States	64128-2226
308	Mercy Research	Saint Louis	Missouri	United States	63141
309	Glacier View Research Institute	Kalispell	Montana	United States	55901
310	Glacier View Research Institute, Cardiology	Kalispell	Montana	United States	59901
311	Montana Medical Research Inc.	Missoula	Montana	United States	59808
312	Clinical Research Advantage, Inc./Skyline Medical Center, PC	Elkhorn	Nebraska	United States	68022
313	Bryan Heart	Lincoln	Nebraska	United States	68506
314	Creighton Diabetes Center	Omaha	Nebraska	United States	68131
315	University of Nebraska Medical Center	Omaha	Nebraska	United States	68198-4120
316	University of Nebraska Medical Center	Omaha	Nebraska	United States	68198-4130
317	AB Clinical Trials	Las Vegas	Nevada	United States	89119
318	Clinical Research Of South Nevada	Las Vegas	Nevada	United States	89121
319	Clinical Research Advantage, Inc.	Las Vegas	Nevada	United States	89128
320	John V. Bernard, MD dba Wellness and Research Center	Belvidere	New Jersey	United States	07823
321	Advanced Heart Care LLC	Bridgewater	New Jersey	United States	08807
322	Lourdes Cardiology Services	Cherry Hill	New Jersey	United States	08034
323	USMA Clinical Research	Elizabeth	New Jersey	United States	07201
324	Lourdes Cardiology Services	Hammonton	New Jersey	United States	08037
325	NJ Heart	Linden	New Jersey	United States	07036
326	Arysmed LLC	Lodi	New Jersey	United States	07644
327	Amici Clinical Research, LLC	Martinsville	New Jersey	United States	08836
328	Rutgers Biomedical and Health Sciences-Robert Wood Johnson Medical School	New Brunswick	New Jersey	United States	08901
329	Cardiac and Endovascular Associates	Ridgewood	New Jersey	United States	07450
330	The Valley Hospital	Ridgewood	New Jersey	United States	07450
331	Cardio Metabolic Institute	Somerset	New Jersey	United States	08873
332	TLB Research LLC	Trenton	New Jersey	United States	08611
333	Lourdes Cardiology Services	Voorhees	New Jersey	United States	08043
334	Westwood Cardiology Associates	Westwood	New Jersey	United States	07675
335	Albuquerque Clinical Trials, Inc.	Albuquerque	New Mexico	United States	87102
336	Albany Medical College, Division of Community Endocrinology	Albany	New York	United States	12206
337	Sorin Medical, P.C.	Brooklyn	New York	United States	11214
338	NY Total Medical Care, PC	Brooklyn	New York	United States	11215
339	NY Scientific	Brooklyn	New York	United States	11235
340	Buffalo Heart Group, Llp	Buffalo	New York	United States	14215
341	NYU Hudson Valley Cardiology	Cortlandt Manor	New York	United States	10567
342	Scott Research,Inc	Laurelton	New York	United States	11413
343	SJH Cardiology Associates	Liverpool	New York	United States	13088
344	Long Island Heart Associates	Mineola	New York	United States	11501
345	Mid Hudson Medical Research, PLLC	New Windsor	New York	United States	12553
346	Manhattan Medical Research Practice	New York	New York	United States	10016
347	Peters Medical Research NY, LLC	New York	New York	United States	10016
348	Weill Cornell Medical College	New York	New York	United States	10021
349	DiGiovanna Institute for Medical Education And Research	North Massapequa	New York	United States	11758-1802
350	Hudson Valley Cardiovascular Practice, PC	Poughkeepsie	New York	United States	12601
351	Rochester Clinical Research, Inc.	Rochester	New York	United States	14609
352	Institute for Clinical Studies	Rosedale	New York	United States	11422
353	Saratoga Clinical Research, LLC	Saratoga Springs	New York	United States	12866
354	Central New York Cardiology	Utica	New York	United States	13501
355	Great Lakes Medical Research	Westfield	New York	United States	14787
356	Buffalo Medical Group - Research Department	Williamsville	New York	United States	14221
357	Buffalo Medical Group	Williamsville	New York	United States	14221
358	Kernodle Clinic, Department of the Private Diagnostic Clinic, PLLC	Burlington	North Carolina	United States	27215
359	Novant Health Clinical Research	Charlotte	North Carolina	United States	28204
360	Novant Health Heart and Vascular Institute	Charlotte	North Carolina	United States	28204
361	PMG Research of Charlotte	Charlotte	North Carolina	United States	28209
362	Sensenbrenner Primary Care	Charlotte	North Carolina	United States	28277
363	NC Heart and Vascular	Clayton	North Carolina	United States	27520
364	LeBauer Cardiovascular Research Foundation	Greensboro	North Carolina	United States	27401
365	Clinical Trials of America, Inc.	Hickory	North Carolina	United States	28601
366	Carolina Cardiology Cornerstone	High Point	North Carolina	United States	27262
367	Clinical Trials of America- NC, LLC	Lenoir	North Carolina	United States	28645
368	Research Institute of the Carolinas of PiedmontHealthcare, PA	Mooresville	North Carolina	United States	28117
369	Burke Primary Care	Morganton	North Carolina	United States	28655
370	Eastern Nephrology Associates	New Bern	North Carolina	United States	28562
371	Boice Willis Clinic	Rocky Mount	North Carolina	United States	27804
372	PMG Research of Rock Mount, LLC - Patient Intake	Rocky Mount	North Carolina	United States	27804
373	Piedmont Healthcare/Research	Statesville	North Carolina	United States	28625
374	PMG Research of Wilmington, LLC	Wilmington	North Carolina	United States	28401
375	Wake Forest University School of Medicine	Winston-Salem	North Carolina	United States	27157
376	Lillestol Research LLC	Fargo	North Dakota	United States	58103
377	Radiant Research, Inc.	Akron	Ohio	United States	44311
378	The Lindner Center for Research and Education at The Christ Hospital	Cincinnati	Ohio	United States	45219
379	Metabolic and Atherosclerosis Research Center	Cincinnati	Ohio	United States	45227
380	Sterling Research Group, Ltd.	Cincinnati	Ohio	United States	45246
381	Rapid Medical Research, Inc.	Cleveland	Ohio	United States	44122
382	Cleveland Clinic - Taussig Cancer Institute	Cleveland	Ohio	United States	44195
383	Radiant Research, Inc.	Columbus	Ohio	United States	43212
384	Optimed Research, LTD	Columbus	Ohio	United States	43235
385	Premier Health Specialists, Inc (dba Dayton Heart Center)	Dayton	Ohio	United States	45414
386	PriMed Clinical Research	Dayton	Ohio	United States	45419
387	North Ohio Heart Center (Administrative Only)	Elyria	Ohio	United States	44035
388	North Ohio Heart Center	Elyria	Ohio	United States	44035
389	North Ohio Heart Center	Lorain	Ohio	United States	44053
390	SV Research, LLC	Marion	Ohio	United States	43302
391	Daniel G. Williams, MD	Perrysburg	Ohio	United States	43551
392	North Ohio Heart Center, Inc.	Sandusky	Ohio	United States	44870
393	North Ohio Heart Center	Sandusky	Ohio	United States	44870
394	ProMedica Northwest Ohio Cardiology Consultants	Toledo	Ohio	United States	43615
395	Mercy Health Youngstown, LLC d/b/a St. Elizabeth Youngstown Hospital	Youngstown	Ohio	United States	44501
396	LION Research	Norman	Oklahoma	United States	73072
397	COR Clinical Research LLC	Oklahoma City	Oklahoma	United States	73103
398	Oklahoma Heart Hospital Physicians	Oklahoma City	Oklahoma	United States	73120
399	Oklahoma Heart Hospital Research Foundation	Oklahoma City	Oklahoma	United States	73120
400	Oklahoma Heart Hospital	Oklahoma City	Oklahoma	United States	73120
401	South Oklahoma Heart Research, LLC	Oklahoma City	Oklahoma	United States	73135
402	Integrated Medical Research PC	Ashland	Oregon	United States	97520
403	Hillsboro Cardiology, P.C.	Hillsboro	Oregon	United States	97123
404	Portland Preventive Cardiology LLC	Portland	Oregon	United States	97225
405	Abington Memorial Hospital (administrative only)	Abington	Pennsylvania	United States	19001
406	Clinical Research Associates of Central PA	Altoona	Pennsylvania	United States	16602
407	Brandywine Clinical Research	Downingtown	Pennsylvania	United States	19335-2620
408	Doylestown Cardiology Associates - VIAA	Doylestown	Pennsylvania	United States	18901
409	Doylestown Health Cardiology, a division of Doylestown Health Physicians	Doylestown	Pennsylvania	United States	18901
410	AMH/Feasterville Family Health Care Center	Feasterville-Trevose	Pennsylvania	United States	19053
411	Greater Pittsburgh Vascular	Jefferson Hills	Pennsylvania	United States	15025
412	Detweiler Family Medicine & Associates, PC	Lansdale	Pennsylvania	United States	19446
413	Green and Seidner Family Practice Associates	Lansdale	Pennsylvania	United States	19446
414	Family Medical Associates	Levittown	Pennsylvania	United States	19056
415	Mercer Bucks Cardiology	Newtown	Pennsylvania	United States	18940
416	Philadelphia Health Associates-Adult Medicine	Philadelphia	Pennsylvania	United States	19146
417	Allegheny Endocrinology Associates	Pittsburgh	Pennsylvania	United States	15212
418	Preferred Primary Care Physicians	Pittsburgh	Pennsylvania	United States	15236
419	Guthrie Medical Group, PC	Sayre	Pennsylvania	United States	18840
420	SFM Clinical Trials, Inc.	Scotland	Pennsylvania	United States	17254
421	Fay-West Family Practice	Scottdale	Pennsylvania	United States	15683
422	Grand View - Lehigh Valley Health Services, Buxmont Cardiology Division	Sellersville	Pennsylvania	United States	18960
423	Montgomery Medical, Inc.	Smithfield	Pennsylvania	United States	15478
424	Preferred Primary Care Physicians	Uniontown	Pennsylvania	United States	15401
425	Berks Cardiologists, Ltd.	Wyomissing	Pennsylvania	United States	19610
426	Coastal Cardiolgy	Charleston	South Carolina	United States	29407
427	Upstate Pharmaceutical Research	Greenville	South Carolina	United States	29615
428	Mountain View Clinical Research, Inc.	Greer	South Carolina	United States	29651
429	Black Hills Cardiovascular-Regional Health Research	Rapid City	South Dakota	United States	57701
430	Mid-Cumberland Infectious Disease Consultants, PLC	Clarksville	Tennessee	United States	37043
431	Collierville Medical Specialists	Collierville	Tennessee	United States	38017
432	Stern Cardiovascular Foundation, Inc.	Germantown	Tennessee	United States	38138
433	Holston Medical Group	Kingsport	Tennessee	United States	37660
434	New Phase Research & Development	Knoxville	Tennessee	United States	37909
435	PMG Research,Inc d/b/a PMG Research of Knoxville	Knoxville	Tennessee	United States	37912
436	Cardiovascular Research of Knoxville	Knoxville	Tennessee	United States	37917
437	New Orleans Center for Clinical Research	Knoxville	Tennessee	United States	37920
438	Volunteer Research Group	Knoxville	Tennessee	United States	37920
439	Baptist Memorial Medical Group, Inc.	Memphis	Tennessee	United States	38119
440	The Green Clinic, PC	Memphis	Tennessee	United States	38119
441	Southwind Medical Specialists	Memphis	Tennessee	United States	38125
442	Tennessee Center for Clinical Trials	Tullahoma	Tennessee	United States	37388
443	Trinity Clinical Research, LLC	Tullahoma	Tennessee	United States	37388
444	PharmaTex Research	Amarillo	Texas	United States	79106
445	Arlington Family Research Center, Inc.	Arlington	Texas	United States	76012
446	Texas Diabetes & Endocrinology	Austin	Texas	United States	78731
447	Austin Heart, PLLC	Austin	Texas	United States	78756
448	Southeast Texas Cardiology Associates II, L.L.P.	Beaumont	Texas	United States	77702
449	Southeast Texas Clinical Research Center	Beaumont	Texas	United States	77702
450	Aztec Medical Research, LLC	Channelview	Texas	United States	77530
451	Corsicana Medical Research, PLLC	Corsicana	Texas	United States	75110
452	Baylor Research Institute IRB	Dallas	Texas	United States	75204
453	Protenium Clinical Research, LLC	Dallas	Texas	United States	75208
454	VA North Texas Health Care System - Dallas VAMC	Dallas	Texas	United States	75216
455	Baylor Heart and Vascular Institute	Dallas	Texas	United States	75226
456	Dallas Diabetes and Endocrine Center	Dallas	Texas	United States	75230
457	Cardiovascular Research Institute of Dallas	Dallas	Texas	United States	75231
458	Radiant Research, Inc.	Dallas	Texas	United States	75231
459	Research Institute of Dallas	Dallas	Texas	United States	75231
460	Parkland Health and Hospital System	Dallas	Texas	United States	75235
461	Baylor University Medical Center / Department of Pharmacy	Dallas	Texas	United States	75246
462	University of Texas Southwestern Medical Center	Dallas	Texas	United States	75390-8565
463	(For IP storage only)The University of Texas Southwestern Medical Center	Dallas	Texas	United States	75390-9034
464	The University of Texas Southwestern Medical Center	Dallas	Texas	United States	75390-9034
465	William P. Clements Jr. University Hospital	Dallas	Texas	United States	75390
466	Doctors Hospital At Renaissance	Edinburg	Texas	United States	78539
467	Amir Malik Research	Fort Worth	Texas	United States	76104
468	The Medical Group of Texas	Fort Worth	Texas	United States	76104
469	T & R Clinic, PA	Fort Worth	Texas	United States	76117
470	Rockwood Medical Clinic	Fort Worth	Texas	United States	76164
471	San Gabriel Clinical Research, LLC	Georgetown	Texas	United States	78626
472	East Texas Cardiology PA	Houston	Texas	United States	77002
473	Spring Clinical Research	Houston	Texas	United States	77002
474	Med Tech Research, LP	Houston	Texas	United States	77024
475	Prime Care Medical Group	Houston	Texas	United States	77024
476	Associates in Medicine, PA	Houston	Texas	United States	77027
477	Alan S. Hoffman, M.D.	Houston	Texas	United States	77030
478	Baylor College of Medicine	Houston	Texas	United States	77030
479	ICTR/Baylor College of Medicine	Houston	Texas	United States	77030
480	Investigational Drug Services	Houston	Texas	United States	77030
481	Memorial Hermann Hospital, Texas Medical Center- UT Health Clinical Research Unit	Houston	Texas	United States	77030
482	Memorial Hermann Hospital, Texas Medical Center	Houston	Texas	United States	77030
483	The University of Texas Health Science Center at Houston- UT Physicians	Houston	Texas	United States	77030
484	Centex Studies, Inc.	Houston	Texas	United States	77058
485	Northwest Houston Cardiology, P.A.	Houston	Texas	United States	77070
486	Texas Center for Drug Development, Inc	Houston	Texas	United States	77081
487	Private Practice Leadership, LLC	Houston	Texas	United States	77094
488	Protenium Clinical Research LLC	Hurst	Texas	United States	76054
489	South Texas Cardiovascular Consultants, PLLC	Kerrville	Texas	United States	78028
490	DCOL Center for Clinical Research	Longview	Texas	United States	75605
491	Caprock Cardiac Center Research Institute Inc.	Lubbock	Texas	United States	79410
492	Midland Clinical Research Center	Midland	Texas	United States	79707
493	Hill Country Medical Associates	New Braunfels	Texas	United States	78130
494	North Hills Medical Research, Inc.	North Richland Hills	Texas	United States	76180
495	Grace Research, LLC	Palestine	Texas	United States	75801
496	Med-Olam Clinical Research, LLC.	Pasadena	Texas	United States	77504
497	Austin Institute for Clinicla Research,Inc.	Pflugerville	Texas	United States	78660
498	Centex Studies, Inc	Pharr	Texas	United States	78577
499	South Texas Cardiovascular Consultants, PLLC	San Antonio	Texas	United States	78201
500	Sun Research Institute	San Antonio	Texas	United States	78215
501	Southwest Clinic	San Antonio	Texas	United States	78221
502	FIRST Outpatient Research Unit	San Antonio	Texas	United States	78229
503	University of Texas Health Science Center at San Antonio	San Antonio	Texas	United States	78229
504	University of Texas Health Science Center San Antonio	San Antonio	Texas	United States	78229
505	University of Texas Health Sciences Center at San Antonio	San Antonio	Texas	United States	78229
506	Victorium Clinical Research	San Antonio	Texas	United States	78231
507	Bandera Family Health Care, LLC	San Antonio	Texas	United States	78249
508	Northeast Clinical Research of San Antonio, LLC (NECRSA, LLC)	Schertz	Texas	United States	78154
509	Acacia Medical Research Institute, LLC/Royal Oaks Medcical Home and Wellness Clinics	Sugar Land	Texas	United States	77478
510	IP + Dry ice deliveries Sugar Lakes Family Practice	Sugar Land	Texas	United States	77478
511	Sugar Lakes Family Practice	Sugar Land	Texas	United States	77479
512	Northwest Houston Heart Center	Tomball	Texas	United States	77375-4536
513	Admin & Storage only:Northwest Heart Center	Tomball	Texas	United States	77375
514	Northwest Heart Center	Tomball	Texas	United States	77375
515	Northwest Houston Clinical Research, PLLC	Tomball	Texas	United States	77375
516	Victoria Heart & Vascular Center, PA	Victoria	Texas	United States	77901
517	Victoria Heart and Vascular Center, PA	Victoria	Texas	United States	77901
518	Utah Cardiology, PC	Bountiful	Utah	United States	84010
519	Utah Cardiology, P.C.	Layton	Utah	United States	84041
520	Paramount Medical Care	Ogden	Utah	United States	84405
521	Aspen Clinical Research LLC	Orem	Utah	United States	84058
522	Revere Health	Provo	Utah	United States	84604
523	Optimum Clinical Research, Inc	Salt Lake City	Utah	United States	84102
524	Wasatch Clinical Research, LLC	Salt Lake City	Utah	United States	84107
525	Holladay Family Practice	Salt Lake City	Utah	United States	84117
526	Heart Center at St. Mark's Hospital	Salt Lake City	Utah	United States	84124
527	Clinical Research Institute of Northern Virginia	Burke	Virginia	United States	22015-4202
528	Burke Internal Medicine & Research	Burke	Virginia	United States	22015
529	Virginia Heart	Falls Church	Virginia	United States	22042
530	Seven Corners Medical Research Center	Falls Church	Virginia	United States	22044
531	Heart Care Associates, P.C.	Hopewell	Virginia	United States	23860
532	Virginia Research Center	Midlothian	Virginia	United States	23114
533	Chippenham and Johnston Willis Hospitals, Inc. dba CJW Medical Center	Richmond	Virginia	United States	23225
534	Retreat Cardiology LLC, dba Cardiology Associates of Richmond	Richmond	Virginia	United States	23225
535	Roanoke Heart Institute	Roanoke	Virginia	United States	24014
536	Hampton Roads Center for Clinical Research	Suffolk	Virginia	United States	23435
537	The Office of Daniel W. Gottlieb, MD, PS	Burien	Washington	United States	98166
538	Premier Clinical Research	Spokane	Washington	United States	99202
539	Universal Research Group, LLC	Tacoma	Washington	United States	98405
540	Walla Walla Clinic	Walla Walla	Washington	United States	99362
541	Wenatchee Valley Hospital & Clinics	Wenatchee	Washington	United States	98801
542	Fairmont General Hospital	Fairmont	West Virginia	United States	26554
543	Prevea Clinic, Inc.	Green Bay	Wisconsin	United States	54303
544	Clinical Investigation Specialists, Inc.	Kenosha	Wisconsin	United States	53142
545	Waukesha Heart Foundation	Waukesha	Wisconsin	United States	53188
546	Instituto de Investigaciones Clinicas Bahia Blanca	Bahia Blanca	Buenos Aires	Argentina	B8000FTD
547	Hospital Italiano Regional del Sur	Bahia Blanca	Buenos Aires	Argentina	B8001BXM
548	Hospital Britanico De Buenos Aires	Ciudad Autonoma de B. Aires	Buenos Aires	Argentina	C1280AEB
549	CEDIC - Consultorios Medicos	Ciudad Autonoma de Buenos Aires	Buenos Aires	Argentina	C1425DES
550	Framingham Centro Medico	La Plata	Buenos Aires	Argentina	B1902COS
551	CIMeL CHAHIN CHAHIN S.A.	Lanus Este	Buenos Aires	Argentina	B1824KAJ
552	Instituto de Investigaciones Clinicas Mar del Plata	Mar del Plata	Buenos Aires	Argentina	B7600FZN
553	Instituto de Investigaciones Clinicas Quilmes	Quilmes	Buenos Aires	Argentina	B1878GEG
554	DIM Clinica Privada	Ramos Mejia	Buenos Aires	Argentina	B1704ETD
555	Instituto de Investigaciones Clinicas Zarate	Zarate	Buenos Aires	Argentina	B2800DGH
556	Consultorios Asociados de Endocrinologia e Investigacion Clinica Aplicada	C.a.b.a	C.a.b.a.	Argentina	C1425AGC
557	STAT Research S.A.	C.a.b.a	Caba	Argentina	C1023AAB
558	Clinica Privada de Especialidades Medicas	Villa Maria	Cordoba	Argentina	5901
559	CIPADI Centro Integral de Prevencion y Atencion en Diabetes	Godoy Cruz	Mendoza	Argentina	M5501ARP
560	Hospital Interzonal Gral. de Agudos Dr. Jose Penna	Bahia Blanca	PCIA DE Buenos Aires	Argentina	B8001DDU
561	IMEP Instituto Medico Elsa Perez	Ciudadela	PCIA DE Buenos Aires	Argentina	1702
562	Instituto Medico Aguero	Moron	PCIA DE Buenos Aires	Argentina	B1708CGU
563	Corporacion Medica de San Martin	San Martin	PCIA DE Buenos Aires	Argentina	B1650CSQ
564	Cordis - Instituto del Corazon	Resistencia	PCIA DE Chaco	Argentina	H3500CDM
565	Hospital de Alta Complejidad "Pte. Juan Domingo Peron"	Formosa	PCIA DE Formosa	Argentina	3600
566	Hospital Provincial Dr. Jose Maria Cullen	Santa Fe	PCIA DE Santa FE	Argentina	S3000EOZ
567	Centro De Investigaciones Clinicas Del Litoral S.R.L.	Santa Fe	PCIA DE Santa FE	Argentina	S3000FWO
568	Cedir S.A - Centro De Diagnostico Y Rehabilitacion S.A.	Santa Fe	PCIA DE Santa FE	Argentina	S3004CVS
569	Centro Modelo de Cardiologia	San Miguel De Tucuman	PCIA DE Tucuman	Argentina	T4000IFL
570	Instituto de Hematologia y Medicina Clinica "Dr. Ruben A. Davoli"	Rosario	Pcia. DE Santa FE	Argentina	S2000CFK
571	Clinica Coronel Suarez S.A.	Coronel Suarez	Provincia DE Buenos Aires	Argentina	B7540GHD
572	Instituto Medico CENICLAR - Central de Investigaciones Clinicas Argentina -Sanatorio de la Mujer	Rosario	Provincia DE Santa FE	Argentina	S2000QID
573	Instituto de Investigaciones Clinicas Rosario	Rosario	Santa FE	Argentina	S2000CVD
574	Centro Medico CCBR Tucuman	San Miguel de Tucuman	Tucuman	Argentina	T4000IAF
575	CIPREC - Centro de Investigacion y Prevencion Cardiovascular S.A.	C.a.b.a.		Argentina	C1119ACN
576	Instituto de Cardiologia y Cirugia Cardiovascular - Fundacion Favaloro	Ciudad Autonoma de B. Aires		Argentina	C1093AAS
577	Cicemo - Consultorio de Investigaciones Clinicas E.M.O. S.R.L.	Ciudad Autonoma De B. Aires		Argentina	C1405BUB
578	Instituto Cardiovascular De Buenos Aires	Ciudad Autonoma de B. Aires		Argentina	C1428ART
579	Investigaciones Medicas IMOBA S.R.L.	Ciudad Autonoma de Buenos Aires		Argentina	C1179AAB
580	Universidad Maimonides	Ciudad Autonoma De Buenos Aires		Argentina	C1405BCK
581	Centro de Investigacion: AXISMED S.R.L.	Ciudad Autonoma de Buenos Aires		Argentina	C1430CKE
582	ILAIM Instituto Latinoamericano de Investigaciones Medicas	Cordoba		Argentina	X5000BNB
583	Clinico Chutro SRL	Cordoba		Argentina	X5000EPU
584	Centro de Investigaciones Clinicas "Instituto del Corazon"	Cordoba		Argentina	X5000EVQ
585	Clinica Privada Colombo	Cordoba		Argentina	x5002AOQ
586	Instituto Medico DAMIC S.R.L.	Cordoba		Argentina	X5003DCE
587	Centro Medico Luquez	Cordoba		Argentina	X5006IKK
588	IPAC Caraffa	Cordoba		Argentina	X5008KKF
589	Instituto de Cardiologia de Corrientes "Juana Fca. Cabral"	Corrientes		Argentina	3400
590	Hospital Central de Mendoza	Mendoza		Argentina	5500
591	Cordis S.A.	Salta		Argentina	4400
592	Centro Cardiovascular Salta	Salta		Argentina	A4406BPF
593	Instituto Cardiovascular San Luis A.E.	San Luis		Argentina	D5702JRS
594	Canberra Hospital	Garran	Australian Capital Territory	Australia	2605
595	Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders	Camperdown	New South Wales	Australia	2050
596	Royal Prince Alfred Hospital	Camperdown	New South Wales	Australia	2050
597	Central Coast Neurosciences Research	Erina	New South Wales	Australia	2250
598	Gosford Hospital	Gosford	New South Wales	Australia	2250
599	Australian Clinical Research Network	Maroubra	New South Wales	Australia	2035
600	Royal North Shore Hospital	St Leonards	New South Wales	Australia	2065
601	Holy Spirit Northside Private Hospital Limited	Chermside	Queensland	Australia	4032
602	Royal Brisbane and Women's Hospital	Herston	Queensland	Australia	4029
603	Core Research Group Pty Ltd	Milton	Queensland	Australia	4064
604	Redcliffe Hospital	Redcliffe	Queensland	Australia	4020
605	Austrials Pty Ltd	Sherwood	Queensland	Australia	4075
606	Gold Coast University Hospital	Southport	Queensland	Australia	4215
607	Adelaide Medical Research	Ashford	South Australia	Australia	5035
608	SA Heart	Ashford	South Australia	Australia	5035
609	Southern Adelaide Diabetes and Endocrine Service	Daws Park	South Australia	Australia	5041
610	Department of Cardiology, Lyell McEwin Hospital	Elizabeth Vale	South Australia	Australia	5112
611	Heart and Vascular Research	Fullarton	South Australia	Australia	5063
612	Launceston General Hospital	Launceston	Tasmania	Australia	7250
613	Eastern Health - Box Hill Hospital	Box Hill	Victoria	Australia	3128
614	The Northern Hospital	Epping	Victoria	Australia	3076
615	Barwon Health-The Geelong Hospital	Geelong	Victoria	Australia	3220
616	Austin Health - Heidelberg Repatriation Hospital	Heidelberg West	Victoria	Australia	3081
617	Alfred Hospital	Melbourne	Victoria	Australia	3004
618	Royal Melbourne Hospital	Parkville	Victoria	Australia	3050
619	Fremantle Hospital	Fremantle	Western Australia	Australia	6160
620	HPS Pharmacies	Joondalup	Western Australia	Australia	6027
621	Joondalup Cardiovascular Trials Foundation Inc.	Joondalup	Western Australia	Australia	6027
622	Sir Charles Gairdner Hospital, Heart Research Institute	Nedlands	Western Australia	Australia	6009
623	VZW Algemeen Ziekenhuis KLINA	Brasschaat	Antwerpen	Belgium	2930
624	AZ Turnhout - campus St. Elisabeth	Turnhout	Antwerpen	Belgium	2300
625	Hopital Erasme-Universite Libre de Bruxelles (ULB)	Anderlecht	Brabant Flamand	Belgium	1070
626	Centre hospitalier de Jolimont-Lobbes - Centre de Recherche Medicale de Jolimont	La Louviere	Haine Saint PAUL	Belgium	7100
627	Algemeen Stedelijk Ziekenhuis	Aalst	Oost-vlaanderen	Belgium	9300
628	Az Sint Blasius	Dendermonde	Oost-vlaanderen	Belgium	9200
629	AZ Sint Lucas Gent-Campus Sint Lucas	Gent	Oost-vlaanderen	Belgium	9000
630	Az Glorieux	Ronse	Oost-vlaanderen	Belgium	9600
631	AZ Groeninge-Campus Loofstraat	Kortrijk	West-vlaanderen	Belgium	8500
632	Az Damiaan	Oostende	West-vlaanderen	Belgium	8400
633	A.Z. Sint-Augustinus Veurne	Veurne	West-vlaanderen	Belgium	8630
634	ZNA Campus Middelheim	Antwerpen		Belgium	2020
635	Imeldaziekenhuis Bonheiden	Bonheiden		Belgium	2820
636	A.Z. St.Jan AV Brugge	Brugge		Belgium	8000
637	University Hospital Brussels - Centrum voor hart- en vaatziekten	Brussels		Belgium	1090
638	University Hospital Brussels- Diabeteskliniek	Brussels		Belgium	1090
639	Private Practice 'Cardiovascular Detection Center'	De Pinte		Belgium	9840
640	ZOL Campus Sint-Jan	Genk		Belgium	3600
641	AZ Maria Middelares	Gent		Belgium	9000
642	Grand Hopital de Charleroi, Site St-Joseph	Gilly		Belgium	6060
643	Hygeia	Hasselt		Belgium	3500
644	Jessa Ziekenhuis	Hasselt		Belgium	3500
645	Sint-Franciskusziekenhuis	Heusden-Zolder		Belgium	3550
646	Centre Hospitalier Regional de Huy	Huy		Belgium	4500
647	Jan Yperman Ziekenhuis, Cardiology	Ieper		Belgium	8900
648	Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg	Leuven		Belgium	3000
649	University hospitals Leuven - Cardiology department	Leuven		Belgium	3000
650	Centre Hospitalier Chretien	Liege		Belgium	4000
651	Centre Hospitalier Universitaire de Liege	Liege		Belgium	4000
652	Huisartsenpraktijk Medilink	Linkebeek		Belgium	1630
653	Huisartsenpraktijk Luc Capiau	Massemen		Belgium	9230
654	AZ Sint-Maarten	Mechelen		Belgium	2800
655	C.H.U. Ambroise Pare	Mons		Belgium	7000
656	Mariaziekenhuis vzw	Overpelt		Belgium	3900
657	AZ Nikolaas	Sint-Niklaas		Belgium	9100
658	Dr. Luc De Wolf - Private Practice	Tienen		Belgium	3300
659	Instituto Cardiopulmonar da Bahia	Salvador	Bahia	Brazil	40170-130
660	Fundacao Bahiana De Cardiologia	Salvador	BA	Brazil	41810-010
661	HBA S/A ASSISTENCIA MEDICA E HOSPITALAR-Hospital da Bahia	Salvador	BA	Brazil	41810-011
662	Hospital Universitario Walter Cantidio	Fortaleza	Ceara	Brazil	60430-370
663	Hospital de Messejana Dr Carlos Alberto Studart Gomes	Fortaleza	Ceara	Brazil	60840-285
664	Centro de Pesquisas em Diabetes e Doencas Endocrino-Metabolicas Ltda	Fortaleza	CE	Brazil	60430-140
665	Instituto De Cardiologia Do Distrito Federal	Brasilia	Distrito Federal	Brazil	70658-700
666	CEDOES - Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo	Vitoria	Espirito Santo	Brazil	29055-450
667	INGOH - Instituto Goiano de Oncologia e Hematologia	Goiania	Goias	Brazil	74093-300
668	Via Medica - Clinica Medica Integrada Ltda - Barroso e Sebba Ltda	Goiania	GO	Brazil	74223-130
669	Hospital Lifecenter / Lifecenter Sistema de Saude S.A	Belo Horizonte	MG	Brazil	30110-921
670	Hospital Felicio Rocho	Belo Horizonte	MG	Brazil	30110-934
671	Hospital Universitário Sao José / FELUMA - MG	Belo Horizonte	MG	Brazil	30140-073
672	Liga Mineira de Ressuscitacao Cardiopulmonar	Belo Horizonte	Minas Gerais	Brazil	30110-021
673	Hospital Vera Cruz	Belo Horizonte	Minas Gerais	Brazil	30140-062
674	Hospital Universitario Ciencias Medicas / Fundacao Educacional Lucas Machado	Belo Horizonte	Minas Gerais	Brazil	30140-073
675	Liga Mineira de Ressucitacao cardiopulmonar	Belo Horizonte	Minas Gerais	Brazil	30150-320
676	CARDSEARCH/CARDRESEARCH - Cardiologia Assistencial e de Pesquisa LTDA	Belo Horizonte	Minas Gerais	Brazil	30150240
677	Universidade Federal de Uberlandia	Uberlandia	Minas Gerais	Brazil	38405-320
678	Eurolatino Pesquisas Medicas LTDA	Uberlandia	Minas Gerais	Brazil	38411-186
679	Hospital Santa Casa De Curitiba	Curitiba	Parana	Brazil	80010-030
680	Nucleo de Pesquisa Clínica	Curitiba	Parana	Brazil	80730-150
681	Hospital Parana - Parana Medical Research Center - MARIMED SERVICOS MEDICOS S.A.	Maringa	Parana	Brazil	87015-000
682	Universidade Federal do Para - Hospital Universitario Joao de Barros Barreto	Belem	PA	Brazil	66073-000
683	Hospital Agamenon Magalhaes	Recife	Pernambuco	Brazil	52051-380
684	Centro de Pesquisas Medicas Basica e Clinica LTDA	Recife	PE	Brazil	52020-010
685	Sociedade Hospitalar Angelina Caron/Hospital e Maternidade Angelina Caron	Campina Grande do Sul	PR	Brazil	83430-000
686	Irmandade da Santa Casa de Misericordia de Curitiba - Hospital Santa Casa de Misericordia	Curitiba	PR	Brazil	80010-100
687	Quanta Diagnostico e Terapia / Medicina Nuclear Alto da XV	Curitiba	PR	Brazil	80045-170
688	Hospital Universitario - Associacao Educadora Sao Carlos - AESC	Canoas	RIO Grande DO SUL	Brazil	92425-055
689	Santa Casa De Misericordia De Pelotas	Pelotas	RIO Grande DO SUL	Brazil	96015-290
690	Hospital de Clinicas de Porto Alegre	Porto Alegre	RIO Grande DO SUL	Brazil	90035-903
691	Hospital Mae de Deus/Associacao Educadora Sao Carlos AESC/IMV - Instituto de Medicina Vascular	Porto Alegre	RIO Grande DO SUL	Brazil	90110-270
692	CCBR - Centro de Pesquisas e Analises Clinicas LTDA	Rio De Janeiro	RJ	Brazil	22271-100
693	CCBR Brasil - Centro de Pesquisa e Analises Clinicas LTDA	Rio de Janeiro	RJ	Brazil	22271-100
694	Hemocardio S/S Ltda	Natal	RN	Brazil	59020-035
695	Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo	Passo Fundo	RS	Brazil	99010-080
696	Irmandade Da Santa Casa De Misericordia De Porto Alegre - ISCMPA	Porto Alegre	RS	Brazil	90020-090
697	Uniao Brasileira de Educacao e Assistencia (UBEA) - Hospital Sao Lucas da PUCRS	Porto Alegre	RS	Brazil	90610-000
698	Hospital Santa Isabel	Blumenau	Santa Catarina	Brazil	89010-906
699	Insituto de Cardiologia de Santa Catarina	Sao Jose	Santa Catarina	Brazil	88103-450
700	Loema Medicina e Bem Estar- Centro Especializado em Cardiologia Ltda	Campinas	SAO Paulo	Brazil	13010-001
701	Scentryphar Pesquisa Clinica	Campinas	SAO Paulo	Brazil	13020-431
702	Hospital E Maternidade Celso Pierro PUC - Campinas - Sociedade Campineira de Educacao e Instrucao	Campinas	SAO Paulo	Brazil	13060-904
703	ICM - Instituto do Coracao de Marilia	Marilia	SAO Paulo	Brazil	17515-000
704	Instituto Conceive	Paraiso	SAO Paulo	Brazil	04005-004
705	Hospital Estadual Mario Covas	Santo Andre	SAO Paulo	Brazil	09190-615
706	Instituto Domingo Braile _ Braile Hospital Dia LTDA	Sao Jose Do Rio Preto	SAO Paulo	Brazil	15015-750
707	IMC - Instituto de Molestias Cardiovasculares/Equipamentos Cardiovasculares Rio Preto Ltda	Sao Jose do Rio Preto	SAO Paulo	Brazil	15015210
708	Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto	Sao Jose do Rio Preto	SAO Paulo	Brazil	15090-000
709	Santa Casa de Misericordia de Votuporanga	Votuporanga	SAO Paulo	Brazil	15500-003
710	CAEP - Centro Avançado de Estudos e Pesquisas Ltda.	Campinas	SP	Brazil	13087-567
711	CPQuali Pesquisa Clinica LTDA	Sao Paulo	SP	Brazil	01228-000
712	Hospital Samaritano	Sao Paulo	SP	Brazil	01232-010
713	Instituto de Conhecimento, Ensino e Pesquisa (Administrative local)	Sao Paulo	SP	Brazil	01233-000
714	Comed Care Empresa de Atendimento Clinico Geral - LTDA - Hospital Total Care	Sao Paulo	SP	Brazil	01407-200
715	CCBR Sao Paulo	Sao Paulo	SP	Brazil	04062-001
716	CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda.	Sao Paulo	SP	Brazil	04266-010
717	CPClin- Centro de Pesquisas Clinicas Ltda./Clinica Dr. Freddy Goldberg Eliaschewitz	Sao Paulo		Brazil	01244-030
718	FGM-Clinica Paulista de Doencas Cardiovasculares	Sao Paulo		Brazil	01327-010
719	SPDM Associacao Paulista para o Desenvolvimento da Medicina	Sao Paulo		Brazil	04024-900
720	UNIFESP - Hospital Sao Paulo - Setor de Lipides, Aterosclerose e Biologia Vascular	Sao Paulo		Brazil	04040-001
721	Instituto Jaqueline Scholz Issa e Mario Issa de Cardiologia LTDA	Sao Paulo		Brazil	05017-000
722	LMC Diabetes & Endocrinology (Calgary)	Calgary	Alberta	Canada	T2H 2G4
723	Foothills Hospital/University of Calgary	Calgary	Alberta	Canada	T2N 4Z6
724	Nanji Professional Corporation	Calgary	Alberta	Canada	T2V 4J2
725	The Medical Arts Health Research Group	Kelowna	British Columbia	Canada	V1Y 1V6
726	Dr Stephen Pearce Inc	Surrey	British Columbia	Canada	V3V 0C6
727	Dr. Adam Yeung Inc.	Surrey	British Columbia	Canada	V3V 0C6
728	Dr. Micheal Kanakos Inc	Surrey	British Columbia	Canada	V3V 0C6
729	Dr. Raymond Dong Inc.	Surrey	British Columbia	Canada	V3V 0C6
730	Dr. Richard Bon Inc.	Surrey	British Columbia	Canada	V3V 0C6
731	Dr. Stephen S. Cheung Inc.	Surrey	British Columbia	Canada	V3V 0C6
732	SMH Cardiology Clinical Trials	Surrey	British Columbia	Canada	V3V 0C6
733	Dr Peter K.H. Tan Inc	Surrey	British Columbia	Canada	V3V 1N1
734	Dr. Dante E. Manyari Inc.	Surrey	British Columbia	Canada	V3V 1N1
735	Dr. Stephanie Au, Inc.	Surrey	British Columbia	Canada	V3V 1N1
736	SMH Cardiology Clinical Trials Inc.	Surrey	British Columbia	Canada	V3V 1N1
737	Dr. Kapil M. Bhagirath Medical Services Corporation	Surrey	British Columbia	Canada	V3W 3C3
738	Victoria Heart Institute Foundation	Victoria	British Columbia	Canada	V8R 4R2
739	Discovery Clinical Services Ltd.	Victoria	British Columbia	Canada	V8T 5G4
740	St. Boniface Hospital	Winnipeg	Manitoba	Canada	R2H 2A6
741	Unicity Laboratory Services	Winnipeg	Manitoba	Canada	R2V 3P4
742	Rivergrove Medical Clinic	Winnipeg	Manitoba	Canada	R2V 4W3
743	G.A. Research Associates Ltd.	Moncton	New Brunswick	Canada	E1G 1A7
744	Cardiology Research Associates of New Brunswick	Saint John	New Brunswick	Canada	E2L 4L2
745	Health Sciences Centre	St. John's	Newfoundland and Labrador	Canada	A1B 3V6
746	LMC Diabetes & Endocrinology (Brampton)	Brampton	Ontario	Canada	L6S 0C9
747	Aviva Clinical Trial Group Inc.	Burlington	Ontario	Canada	L7M 4Y1
748	JBN Medical Diagnostic Services Inc.	Burlington	Ontario	Canada	L7M 4Y1
749	Philippe R. Beaudry Medicine Professional Corporation	Burlington	Ontario	Canada	L7R 4E2
750	Cambridge Cardiac Care Centre	Cambridge	Ontario	Canada	N1R 6V6
751	Vizel Cardiac Research, Saul Vizel Professional Medicine Corporation	Cambridge	Ontario	Canada	N1R 7R1
752	Moran Medical Centre	Collingwood	Ontario	Canada	L9Y 1W3
753	C & L Research	Fort Erie	Ontario	Canada	L2A 1Z3
754	Parkdale Medical Centre	Hamilton	Ontario	Canada	L8K 3P3
755	Western University - WCPHFM	London	Ontario	Canada	N6G 2M1
756	Stroke Prevention & Atherosclerosis Research Centre (SPARC)-Siebens-Drake Research Institute	London	Ontario	Canada	N6G 2V4
757	LMC Diabetes & Endocrinology (Markham)	Markham	Ontario	Canada	L6B 0P9
758	Newmarket Cardiology Research Group	Newmarket	Ontario	Canada	L3Y 8C3
759	LMC Clinical Research Inc. (Oakville)	Oakville	Ontario	Canada	L6M 1M1
760	LMC Oakville	Oakville	Ontario	Canada	L6M 1M1
761	The Office of Dr. James Cha	Oshawa	Ontario	Canada	L1J 2K1
762	Kawartha Cardiology Clinical Trials	Peterborough	Ontario	Canada	K9J 0B2
763	London Road Diagnostic Clinic and Medical Centre	Sarnia	Ontario	Canada	N7T 4X3
764	Sarnia Institute of Clinical Research	Sarnia	Ontario	Canada	N7T 4X3
765	Scarborough Cardiology Research Associates Inc.	Scarborough	Ontario	Canada	M1E 5E9
766	Canadian Centre for Research on Diabetes	Smiths Falls	Ontario	Canada	K7A 4W8
767	Brian Y.L. Wong Medicine Professional Corporation	Sudbury	Ontario	Canada	P3E 2N8
768	LMC Diabetes & Endocrinology (Thornhill)	Thornhill	Ontario	Canada	L4J 8L7
769	JJ Dig Research LTD	Toronto	Ontario	Canada	M3J 1N2
770	Canadian Phase Onward, Inc.	Toronto	Ontario	Canada	M3J 2C5
771	LMC Diabetes & Endocrinology (Bayview)	Toronto	Ontario	Canada	M4G 3E8
772	Dr. Anil K. Gupta Medicine Professional Corporation	Toronto	Ontario	Canada	M9V 4B4
773	Dr. Mohan Babapulle Medicine Professional Corporation	Waterloo	Ontario	Canada	N2T 0C1
774	Dr. Louis Yao	Weston	Ontario	Canada	M9N 1W4
775	Ecogene-21	Chicoutimi	Quebec	Canada	G7H 7K9
776	Q & T Research Chicoutimi	Chicoutimi	Quebec	Canada	G7H 7Y8
777	Q&T Recherche Outaouais Inc.	Gatineau	Quebec	Canada	J8Y 6S8
778	Centre de Recherche Clinique de Laval	Laval	Quebec	Canada	H7T 2P5
779	Omnispec clinical research inc	Mirabel	Quebec	Canada	J7J 2K8
780	Montreal Heart Institute	Montreal	Quebec	Canada	H1T 1C8
781	Diex Research Montreal, Inc.	Montreal	Quebec	Canada	H2Y 1S1
782	Centre Hospitalier Universitaire de Sherbrooke- Hotel-Dieu	Sherbrooke	Quebec	Canada	J1G 2E8
783	Centre integre de sante et de services sociaux de Lanaudiere (CISSSL)	St Charles-Borromee	Quebec	Canada	J6E 6J2
784	Centre Integre de Sante et de services sociaux de Chaudiere-Appalaches (CISSS-CA)	St-Georges, Beauce	Quebec	Canada	G5Y 4T8
785	CISSS des Laurentides-Point de Service de St-Jerome- Comite d'ethique de la recherche	St-Jerome	Quebec	Canada	J7Z 5T3
786	St-Jerome Medical Research Inc.	St-Jerome	Quebec	Canada	J7Z 5T3
787	LMC Diabetes & Endocrinology (Montreal)	Ville Saint-Laurent	Quebec	Canada	H4T 1Z9
788	Recherche Clinique Sigma Inc	Quebec		Canada	G1G 3Y8
789	Clinique des maladies lipidiques de Quebec	Quebec		Canada	G1V 4W2
790	Biomedica Research Group	Providencia Santiago	Metropolitana	Chile	7500710
791	CICAB	Santiago	Metropolitana	Chile	7500021
792	SMOLAM	Santiago	Metropolitana	Chile	7500739
793	Hopsital y CRS El Pino	Santiago	Metropolitana	Chile	8053095
794	Complejo Asitencial Dr. Sotero del Rio	Santiago	Metropolitana	Chile	8207257
795	Centro de Investigacion Clínica del Sur	Temuco	Region DE LA Araucania	Chile	4781156
796	Corporacion de Beneficencia Osorno	Osorno	Region DE LOS Lagos	Chile	5311092
797	Hospital Clinico Magallanes	Punta Arenas	Region DE Magallanes	Chile	6210005
798	Servicios Medicos Godoy	Santiago	Region Metropolitana	Chile	7500710
799	Quantum Research	Puerto Varas		Chile	5550170
800	Guangdong General Hospital	Guangzhou	Guangdong	China	510080
801	Haikou People's Hospital	Haikou	Hainan	China	570208
802	The 2nd Affiliated Hospital Of Harbin Medical University	Harbin	Heilongjiang	China	150001
803	The First Affiliated Hospital of Habrin Medical University	Harbin	Heilongjiang	China	150001
804	The First Affiliated Hospital Of Harbin Medical University	Harbin	Heilongjiang	China	150001
805	The First Affiliated Hospital Of Zhengzhou University	Zhengzhou	Henan	China	450052
806	The Central Hospital Of Wuhan	Wuhan	Hubei	China	430014
807	Pu Ai Hospital of Wuhan City	Wuhan	Hubei	China	430033
808	Changde First People's Hospital	Changde	Hunan	China	415003
809	Changsha Central Hospital	Changsha	Hunan	China	410004
810	Hunan Provincial People's Hospital	Changsha	Hunan	China	410005
811	Xiangtan City Central Hospital	Xiangtan	Hunan	China	411100
812	Zhuzhou Central Hospital	Zhuzhou	Hunan	China	412007
813	Inner Mongolia Baogang Hospital	Baotou	Inner Mongolia	China	014010
814	Inner Mongolia Autonomous Region People's Hospital	Hohhot	Inner Mongolia	China	010017
815	Wuxi People's Hospital	Jiangsu	Jiangsu	China	214023
816	Suzhou Kowloon Hospital Shanghai Jiaotong University School of Medicine	Suzhou	Jiangsu	China	215021
817	The affiliated Hospital of Xuzhou Medical College	Xuzhou	Jiangsu	China	221002
818	Jilin Province People's Hospital	Changchun	Jilin	China	130021
819	The First Hospital of Jilin University	Changchun	Jilin	China	130021
820	China-Japan Union Hospital of Jilin University	Changchun	Jilin	China	130033
821	General Hospital Of Ningxia Medical University	Yinchuan	Ningxia	China	750001
822	The Affiliated Hospital of Qingdao University	Qingdao	Shandong	China	266003
823	The First Affiliated Hospital Of Xinjiang Medical University	Urumqi	Xinjiang	China	830054
824	Ningbo First hospital	Ningbo	Zhejiang	China	315010
825	Beijing Chao-yang Hospital	Beijing		China	100020
826	FuWai Hospital, CAMS & PUMC	Beijing		China	100037
827	Shanghai General Hospital	Shanghai		China	200080
828	Tianjin Union Medical Center	Tianjin		China	300120
829	Taizhou Hospital of Zhejiang Province	Zhejiang		China	317000
830	Hospital Pablo Tobon Uribe	Medellin	Antioquia	Colombia	00000
831	Centro de Investigacion Clinica Avanzada y Multidisciplinaria CICLAM	Medellin	Antioquia	Colombia
832	Centro de Medicina del Ejercicio y Rehabilitacion Cardiac - CEMDE S.A.	Medellin	Antioquia	Colombia
833	Rodrigo Botero S.A.S.	Medellin	Antioquia	Colombia
834	Clinica De La Costa Ltda	Barranquilla	Atlantico	Colombia	080020
835	Centro Cientifico Asistencial Jose Luis Accini S.A.S.	Barranquilla	Atlantico	Colombia	80020
836	Corazon Ips Sas.	Barranquilla	Atlantico	Colombia
837	Fundacion del Caribe Para La Investigacion Biomedica - Fundacion BIOS	Barranquilla	Atlantico	Colombia
838	Centro de Diagnostico Cardiologico LTDA.	Cartagena	Bolivar	Colombia
839	Asociacion IPS Medicos Internistas de Caldas	Manizales	Caldas	Colombia
840	Hospital Universitario San Ignacio	Bogota D C	Cundinamarca	Colombia	00
841	MedPlus Medicina Prepagada S.A.	Bogota D.C.	Cundinamarca	Colombia	110911
842	Instituto de Investigacion Endocrinologia y Prevencion Metabolica - ENDOCARE LTDA.	Bogota D.C.	Cundinamarca	Colombia
843	Simedics Ips Sas	Bogota D.C.	Cundinamarca	Colombia
844	Solano & Terront Servicios Medicos Ltda-Establecimiento Comercial UNIENDO	Bogota D.C.	Cundinamarca	Colombia
845	Dexadiab Servicios Medicos LTDA	Bogota D.C	Cundinamarca	Colombia	110221
846	Caja de Compensacion Familiar CAFAM, Sede Centro de Atencion en Salud CAFAM FLORESTA	Bogota D.C	Cundinamarca	Colombia	111211
847	Healthy Medical Center S.A.S	Zipaquira	Cundinamarca	Colombia	250252
848	Fundacion Centro de Obesidad y Metabolismo COMETA	Pasto	Narino	Colombia
849	Instituto del Corazon de Bucaramanga S.A.	Bucaramanga	Santander	Colombia
850	Fundacion Cardiovascular De Colombia - Instituto del Corazón Floridablanca	Floridablanca	Santander	Colombia	681004
851	Fundacion Cardiovascular De Colombia - Instituto del Corazón Floridablanca	Floridablanca	Santander	Colombia
852	Fundacion Reina Isabel	Cali	Valle DEL Cauca	Colombia	760001
853	Kardiologicka Ambulance	Brno	Jihomoravsky KRAJ	Czechia	638 00
854	Edumed S.R.O.	Broumov	Kralovehradecky KRAJ	Czechia	55001
855	EDUMED s.r.o.	Jaromer	Kralovehradecky KRAJ	Czechia	55101
856	Kardiologicka ambulance	Trutnov	Kralovehradecky KRAJ	Czechia	54101
857	Lekarna na Poliklinice	Trutnov	Kralovehradecky KRAJ	Czechia	54101
858	Mudr. Jan Vrkoc S.R.O.	Ostrava	Moravskoslezsky KRAJ	Czechia	70200
859	Pv-Kardiologie S.R.O.	Pardubice	Pardubicky KRAJ	Czechia	53002
860	CCBR Czech Brno, s.r.o.	Brno		Czechia	602 00
861	DIKa centrum s.r.o., Kardiologicka a interni ambulance	Havirov		Czechia	73601
862	Fakultni Nemocnice Hradec Kralove	Hradec Kralove		Czechia	500 05
863	Fakultni nemocnice Hradec Kralove	Hradec Kralove		Czechia	50005
864	Fremlova Apotheca s.r.o.	Litovel		Czechia	784 01
865	Kardio interna s.r.o.	Litovel		Czechia	784 01
866	Fakultni Nemocnice Olomouc	Olomouc		Czechia	775 20
867	CCBR Czech a.s.	Pardubice		Czechia	530 02
868	Kardiologie Plzen s.r.o.	Plzen		Czechia	326 00
869	Fakultni Nemocnice Kralovske Vinohrady	Praha 10		Czechia	100 34
870	Fakultni poliklinika Vseobecne fakultni nemocnice v Praze	Praha 2		Czechia	128 08
871	CCBR Czech Prague, s.r.o	Praha 3		Czechia	130 00
872	Kardiologie a interni lekarstvi	Praha 5		Czechia	158 00
873	NEFROMED, s.r.o.	Praha 6		Czechia	160 00
874	Centrum kardiovaskularni prevence 1. LF UK a TN	Praha		Czechia	14059
875	Interna a kardiologie s.r.o.	Roznov pod Radhostem		Czechia	756 61
876	Nemocnice Pardubickeho kraje, a.s., Svitavska nemocnice	Svitavy		Czechia	568 25
877	Ordinace V Tabacce s.r.o.	Tabor		Czechia	390 02
878	MUDr. Antonin Dufka, kardiologicka ambulance	Uherske Hradiste 1		Czechia	686 01
879	MUDr. Nina Zemkova s.r.o.	Uherske Hradiste 1		Czechia	686 01
880	KIGE s.r.o.	Znojmo		Czechia	66902
881	Aabenraa Hospital Hjertemedicinsk klinik Kredslobscentret, SHS	Aabenraa		Denmark	6200
882	Sygehus Sonderjylland Aabenraa	Aabenraa		Denmark	6200
883	Aalborg Universitetshospital, Lipidklinikken	Aalborg		Denmark	9000
884	CCBR Aalborg	Aalborg		Denmark	9000
885	Aarhus Universitetshospital Skejby, Hjertesygdomme ¿ Klinisk Forskning	Aarhus		Denmark	8200
886	CCBR Ballerup	Ballerup		Denmark	DK - 2750
887	Bispebjerg og Frederiksberg Hospital	Copenhagen NV		Denmark	2400
888	Sydvestjysk Sygehus, Hjertemedicinsk Projektgruppe	Esbjerg		Denmark	6700
889	Frederiksberg Hospital	Frederiksberg		Denmark	2000
890	Glostrup Hospital	Glostrup		Denmark	2600
891	Herlev Universitetshospital	Herlev		Denmark	2730
892	Regionshospitalet Herning	Herning		Denmark	7400
893	Hillerod Hospital	Hillerod		Denmark	3400
894	Hvidovre Universitetshospital	Hvidovre		Denmark	2650
895	Karkirurgisk Klinisk	Kobenhavn O		Denmark	2100
896	Amager Hospital	Kobenhavn S.		Denmark	2300
897	Region Sjaelland Sygehus Nord, Koge Sygehus	Koege		Denmark	4600
898	Kolding Sygehus	Kolding		Denmark	6000
899	Region Sjaelland Naestved Sygehus	Naestved		Denmark	4700
900	Nykobing F. Sygehus-Medicinsk afdeling	Nykobing F.		Denmark	4800
901	Regionshospitalet Randers	Randers		Denmark	8930
902	Regionshospitalet Silkeborg, Hjerte Projektkontor	Silkeborg		Denmark	8600
903	Slagelse Sygehus	Slagelse		Denmark	4200
904	Svendborg Sygehus	Svendborg		Denmark	5700
905	CCBR Vejle	Vejle		Denmark	DK 7100
906	Hospitalsenheden Midt, Regionshospital Viborg	Viborg		Denmark	8800
907	HYKS Jorvin sairaala	Espoo		Finland	02740
908	Linnan Klinikka Oy	Hameenlinna		Finland	13100
909	Geri-Med Oy	Helsinki		Finland	00180
910	Helsinki University Central Hospital	Helsinki		Finland	00290
911	Helsingin yliopistollinen keskussairaala, Sisaetaudit ja kuntoutus, Biomedicum 2U	Helsinki		Finland	FI-00290
912	Ita-Suomen laakarikeskus Oy	Joensuu		Finland	80100
913	StudyCor Oy	Jyvaskyla		Finland	40620
914	Laeaekaerikeskus Aava Kerava	Kerava		Finland	04200
915	Menoa oy	Kinkomaa		Finland	40930
916	Kokkolan Keskussairaala	Kokkola		Finland	67200
917	Mewell liikuntaklinikka	Kotka		Finland	48600
918	Itae-Suomen Laeaekaeritalo	Kuopio		Finland	70100
919	Terveystalo Kuopio	Kuopio		Finland	70100
920	Oulu Mentalcare Oy	Oulu		Finland	90100
921	Terveystalo Oulu, Diapolis	Oulu		Finland	90100
922	Oulu University Hospital	Oulu		Finland	90220
923	Porin Laakaritalo Oy	Pori		Finland	28100
924	Terveystalo Siilinjarvi	Siilinjarvi		Finland	71800
925	FinnMedi Oy	Tampere		Finland	33520
926	Terveystalo Pulssi	Turku		Finland	20100
927	Turku University hospital	Turku		Finland	20520
928	Vantaan Tutkimuskeskus	Vantaa		Finland	01600
929	Ylitornion Terveyskeskus	Ylitornio		Finland	95600
930	CHU Jean Minjoz Cardiologie	Besancon		France	25000
931	Groupe Hospitalier de Pellegrin Hopital Pellegrin	Bordeaux		France	33076
932	Centre Hospitalier De Bourg En Bresse - Hopital Fleyriat	Bourg En Bresse Cedex 10000		France	01012
933	centre hospitalier Sub-Francilien	Corbeil-Essonnes		France	91106
934	Scp Cardiovasculaire De L'Est	Essey-Les-Nancy		France	54270
935	Centre Hospitalier Louis Pasteur	Le Coudray		France	28630
936	Hopital La Louviere	Lille		France	59000
937	Centre Hospitalier Saint Philibert	Lomme		France	59462
938	Hopital Cardiovasculaire Et Pneumologique Louis Pradel	Lyon Cedex 03		France	69394
939	Hopital Arnaud de Villeneuve - CHU Montpellier	Montpellier cedex 5		France	34295
940	CHU de Nantes - Hopital Nord Laennec	Nantes		France	44093
941	Nouvelles Cliniques Nantaises	Nantes		France	44200
942	Chu De Nice - Hopital Pasteur	Nice Cedex 1		France	06002
943	Hopital Cardiologique	Pessac cedex		France	33604
944	CHU de Poitiers	Poitiers Cedex		France	86021
945	CHU de Renes Hopital de Pontchaillou	Rennes Cedex 9		France	35033
946	CHU de Toulouse	Toulouse cedex 9		France	31059
947	Hospital Cuy Chatilliez	Tourcoing		France	59200
948	Hopital Trousseau	Tours Cedex 9		France	37044
949	Centre Hospitalier (GH) de Valenciennes	Valenciennes		France	59300
950	Polyclinique Vauban	Valenciennes		France	59300
951	Universitaets Herzzentrum Freiburg Bad Krozingen	Bad Krozingen	Baden-wuerttemberg	Germany	79189
952	Medizinische Universitaetsklinik Heidelberg	Heidelberg	Baden-wurttemberg	Germany	69120
953	Gemeinschaftspraxis im Altstadt Carree	Fulda	Hessen	Germany	36037
954	Zentrum Klinische Studien Neuwied (ZKSN)	Neuwied	Rheinland Pfalz	Germany	56564
955	Gemeinschaftspraxis Schwabenheim	Schwabenheim	Rhineland-palatinate	Germany	55270
956	Klinikum Altenburger Land Gmbh	Altenburg		Germany	04600
957	Forschungszentrum Dr. med Irma Schoell	Bad Homburg		Germany	61348
958	Institut fuer Klinische Forschung und Entwicklung(IKFE) Berlin GmbH	Berlin		Germany	10115
959	Klinische Forschung Berlin- Mittte GmbH	Berlin		Germany	10117
960	POLIKUM Institut GmbH, Polikum Berlin Friedenau	Berlin		Germany	12157
961	DRK Kliniken Berlin Kopenick, Zentrum Klinische Forschung	Berlin		Germany	12559
962	Synexus Clinical Research GmbH	Berlin		Germany	12627
963	Deutsches Herzzentrum Berlin	Berlin		Germany	13353
964	Medizinisches Versorgungszentrum am Bahnhof Spandau	Berlin		Germany	13597
965	Staedtische Kliniken Bielefeld Gem. GmbH - Klinikum Mitte	Bielefeld		Germany	33604
966	Bochum Research Centre-Synexus Clinical Research GmbH	Bochum		Germany	44787
967	Synexus Clinical Research GmbH	Bochum		Germany	44787
968	MediClin Reha-Zentrum Spreewald	Burg-Spreewald		Germany	03096
969	Klinikum Coburg	Coburg		Germany	96450
970	Kardiologische Praxisgemeinschaft	Dortmund		Germany	44137
971	St. Johannes-Hospital	Dortmund		Germany	44137
972	Gemeinschaftspraxis fuer Kardiologie Dres. Med. Willgeroth/Wetzel	Dortmund		Germany	44141
973	Klinsche Forschung Dresden GmbH	Dresden		Germany	01069
974	Praxis Dr. med. Christoph Axthelm	Dresden		Germany	01277
975	GWT-TUD GmbH, Studienzentrum Professor Hanefeld	Dresden		Germany	01307
976	Gemeinschaftspraxis Dr. Hagemann/Breiderhoff/Durfeld	Essen		Germany	45355
977	Medizentrum Essen Borbeck	Essen		Germany	45355
978	Studienzentrum	Essen		Germany	45355
979	Gemeinschaftspraxis Dres. Dirk Weber, Ulrich Weber, Heiner Saueressig, Birte Turner und Georg	Essen		Germany	45359
980	Schwerpunktpraxis Dr. Luedemann fuer Diabetes Gefaess- und Ernaehrungsmedizin	Falkensee		Germany	14612
981	IKF Institut fuer klinische Forschung Frankfurt	Frankfurt am Main		Germany	60596
982	Synexus Clinical Research GmbH	Frankfurt		Germany	60313
983	Clinphenomics Gmbh & Co Kg, Studienzentrum	Frankfurt		Germany	60594
984	Klinik und Poliklinik fuer Innere Medizin B - Kardiologie, Angiologie, Pulmologie	Greifswald		Germany	17475
985	Cardiologicum Hamburg	Hamburg		Germany	22041
986	Praxis Dr. med Cornelia Brauer	Hamburg		Germany	22415
987	Klinische Forschung Hannover-Mitte GmbH	Hannover		Germany	30159
988	Universitaetsklinikum des Saarlandes Klinik fuer Innere Medizin III	Homburg		Germany	66421
989	Praxis Dr. Heister	Kamp-Lintfort		Germany	47475
990	Studienzentrum Dr. Appel	Kassel		Germany	34121
991	Zentrum fuer klinische Forschung	Koeln		Germany	51069
992	Gemeinschaftspraxis Dr. Klein / Minnich	Kuenzing		Germany	94550
993	Klinik fur Innere Medizin, Kardiologie und Angiologie MediClin Herzzentrum Lahr/Baden.	Lahr		Germany	77933
994	Synexus Leipzig Clinical Research Centre	Leipzig		Germany	04103
995	SIBAmed Studienzentrum GmbH & Co. KGKG	Leipzig		Germany	04109
996	Gemeinschaftspraxis Dr. med. Heidrun Taeschner und Dr. med. Susanne Bonigut	Leipzig		Germany	04249
997	Klinikum Leverkusen GgmbH	Leverkusen		Germany	51375
998	Klinikum der Stadt Ludwigshafen am Rhein gGmbH	Ludwigshafen		Germany	67063
999	Maerkische Kliniken GmbH, Klinikum Luedenscheid, Innere III	Luedenscheid		Germany	58515
1000	Klinikum Lunen, St. Marienhospital	Lunen		Germany	44534
1001	SMO.MD GmbH, Zentrum fuer klinische Studien Site Management and Clinical Research Unit	Magdeburg		Germany	39120
1002	Pfuetzner Science & Health Institute-Gmbh	Mainz		Germany	55116
1003	Ze:ro Arztpraxen Dr. med. Salbach	Mannheim		Germany	68165
1004	Klinikum fuer Herz- & Kreislauferkrankungen	Muenchen		Germany	80636
1005	Klinikum Der Universitat Munchen	Munchen		Germany	80336
1006	Klinikum Fur Herz- & Kreislauferkrankungen	Munich		Germany	80636
1007	Staedtisches Klinikum Muenchen GmbH, Klinikum Neuperlach	Munich		Germany	81737
1008	Kardiologische Praxis Northeim	Northeim		Germany	37154
1009	Gemeinschaftspraxis Drs Haggenmiller/Jeserich, Kardiologie, Angiologie, Innere Medizin	Nurnberg		Germany	90402
1010	Allgemeinmedizinisch-Internistische Praxisgemeinschaft	Offenbach		Germany	63071
1011	Praxis Dres. Med Naudts und Nowack	Rodgau		Germany	63110
1012	Klinik Am See - Klinik Am See - Rehabilitationszentrum Fur Innere Medizin	Rudersdorf		Germany	15562
1013	Klinische Forschung Schwerin GmbH	Schwerin		Germany	19055
1014	Kardiologische Gemeinschaftspraxis Dres Med. Gerke/Buerger	Soest		Germany	59494
1015	Praxisgemeinschaft Stuhr-Brinkum	Stuhr-Brinkum		Germany	28816
1016	Robert-Bosch-Krankenhaus	Stuttgart		Germany	70376
1017	Universitaetsklinikum Ulm	Ulm		Germany	89081
1018	Josephs-Hospital Warendorf Med. Klinik II, Kardiologie/Angiologie	Warendorf		Germany	48231
1019	Kardiologische Praxis	Wermsdorf		Germany	04779
1020	ForschungszentrumRuhr KliFoCenter GmbH	Witten		Germany	58455
1021	Bacs-Kiskun Megyei Korhaz	Kecskemet	Bacs-kiskun	Hungary	6000
1022	Pecsi Tudomanyegyetem AOK, II.	Pecs	Baranya	Hungary	7624
1023	Szegedi Tudomanyegyetem AOK, I. sz Belgyogyaszati Klinika	Szeged	Csongrad	Hungary	6720
1024	Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz	Szekesfehervar	Fejer	Hungary	8000
1025	DRC Kft.	Balatonfured		Hungary	8230
1026	DRC Kft.	Balatongyorok		Hungary	8313
1027	Kardiologiai Maganrendelo	Bekescsaba		Hungary	5600
1028	Grof Tisza Istvan Korhaz Berettyoujfalu	Berettyoujfalu		Hungary	4100
1029	Budapesti Szent Ferenc Korhaz	Budapest		Hungary	1021
1030	Synexus Magyarorszag Kft	Budapest		Hungary	1036
1031	Szent Rokus Korhaz	Budapest		Hungary	1085
1032	Semmelweis Egyetem	Budapest		Hungary	1088
1033	Gottsegen Gyorgy Orszagos Kardiologiai Intezet	Budapest		Hungary	1096
1034	Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet	Budapest		Hungary	1097
1035	Bajcsy-Zsilinszky Korhaz es Rendelointezet	Budapest		Hungary	1106
1036	Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, III. Belgyogyaszat-Kardiologiai Osztaly	Budapest		Hungary	1125
1037	Debreceni Egyetem, I. sz. Belgyogyaszati Klinika	Debrecen		Hungary	4032
1038	Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft.	Debrecen		Hungary	4032
1039	Synexus Magyarorszag Kft.	Gyula		Hungary	5700
1040	Edes Szivunk Egeszsegkozpont Kft.	Hajduszoboszlo		Hungary	4200
1041	BKS Research Kft., Albert Schweitzer Korhaz	Hatvan		Hungary	3000
1042	Somogy Megyei Kaposi Mór Oktató Kórház	Kaposvar		Hungary	7400
1043	Jutrix Egeszsegugyi Kft	Kecskemet		Hungary	6000
1044	Pest Megyei Flor ferenc Korhaz	Kistarcsa		Hungary	2143
1045	Josa Andras Oktatokorhaz	Nyiregyhaza		Hungary	4400
1046	Medifarma-98 Kft.	Nyiregyhaza		Hungary	4400
1047	Pecsi Tudomanyegyetem AOK, I. Belgyogyaszati Klinika	Pecs		Hungary	7624
1048	Mentahaz Maganorvosi Kozpont	Szekesfehervar		Hungary	8000
1049	Hetenyi Geza Korhaz	Szolnok		Hungary	5000
1050	Markusovszky Egyetemi Oktatokarhaz	Szombathely		Hungary	9700
1051	Dr. Sydo es Tsa Kft	Veszprem		Hungary	8200
1052	Zala Megyei Korhaz	Zalaegerszeg		Hungary	8900
1053	Dr. Jivraj Mehta Smarak Health Foundation, Bakeri Medical Research Centre	Ahmedabad	Gujarat	India	380007
1054	Apex Heart Institute (A Unit of TCVS Pvt. Ltd)	Ahmedabad	Gujarat	India	380054
1055	SAL Hospital	Ahmedabad	Gujarat	India	380054
1056	Apple Hospital	Surat	Gujarat	India	395 002
1057	Unicare Heart Institute & Research Center	Surat	Gujarat	India	395002
1058	BAPS - Pramukh Swami Hospital	Surat	Gujarat	India	395009
1059	Rhythm Heart Institute	Vadodara	Gujarat	India	390022
1060	Aster Aadhar Hospital (Prerana Hospital Ltd.)	Kolhapur	Maharashtra	India	416012
1061	Shri Krishna Hrudayalaya and Critical Care Centre	Nagpur	Maharashtra	India	440012
1062	Jehangir Clinical Development Centre Pvt. Ltd.	Pune	Maharashtra	India	411 001
1063	Mediciti Hospitals	Hyderabad	Telangana	India	500063
1064	M.V. Hospital And Research Centre	Lucknow	Uttar Pradesh	India	226003
1065	Beaumont Hospital	Dublin	Leinster	Ireland	9
1066	The Adelaide & Meath Hospital-Dublin Incorporating The National Children's Hospital	Dublin		Ireland	24
1067	Mater Misericordiae University Hospital	Dublin		Ireland	7
1068	St. James's Hospital	Dublin		Ireland	8
1069	Health Research Board	Galway		Ireland
1070	Portiuncula Hospital	Galway		Ireland
1071	Barzilai Medical Center	Ashkelon		Israel	7830604
1072	Gefen Institute for Research and Cardiac Health	Bat Yam		Israel	5955602
1073	The Soroka University Medical Center	Beer Sheva		Israel	84101
1074	Ben Yair Community Clinic - Clalit Health Services	Beer-Sheva		Israel	84350
1075	Heart Institute, Hillel Yaffe Medical Center	Hadera		Israel	38100
1076	Rambam Medical Center	Haifa		Israel	31096
1077	Cardiovascular Clinical Research Institute	Haifa		Israel	34362
1078	Edith Wolfson Medical Center	Holon		Israel	58100
1079	Heart Institute, Bikur Cholim Campus, Shaare Zedek Medical Center	Jerusalem		Israel	91004
1080	Hadassah Ein Kerem Medical Center	Jerusalem		Israel	91120
1081	Meir Medical Center	Kfar Saba		Israel	44281
1082	Meir Medical Center	Kfar-Saba		Israel	44281
1083	Galilee Medical Center, Cardiology Department	Nahariya		Israel	22100
1084	E.M.M.S Nazareth Hospital	Nazareth		Israel	16100
1085	Sha'aria Clinic, Clalit Health Services	Petach Tikva		Israel	4958202
1086	Rabin Medical Center, Beilinson Hospital	Petah Tikva		Israel	49100
1087	Rabin Medical Center-Beilinson Hospital	Petah Tikva		Israel	49100
1088	Rabin Medical Center	Petah Tikva		Israel	49100
1089	Shuali Community Clinic, Clalit Health Services	Raanana		Israel	43452
1090	Department of Neurology & Sagol Neuroscience Center	Ramat Gan		Israel	52621
1091	Heart Institute, Kaplan Medical Center	Rehovot		Israel	76100
1092	Kaplan Medical Center	Rehovot		Israel	76100
1093	Internal Medicine A, Ziv Medical Center	Safed		Israel	13100
1094	Assuta Medical Center	Tel Aviv		Israel	6789140
1095	The Chaim Sheba Medical Center	Tel HaShomer		Israel	5265601
1096	Tel Aviv Sourasky Medical Center	Tel-Aviv		Israel	64239
1097	A.O. Treviglio e Caravaggio	Treviglio (BG)	Bergamo	Italy	24047
1098	AOU Policlinico "Mater Domini" UOC di Medicina interna	Catanzaro	CZ	Italy	88100
1099	Ospedale S. L. Mandic di Merate	Merate	Lecco	Italy	23807
1100	IRCCS Centro Cardiologico Fondazione Monzino	Milano	MI	Italy	20138
1101	Ospedale Civile Di Piove Di Sacco	Piove Di Sacco	Padova	Italy	35028
1102	AOU Policlinico "P. Giaccone" Dipartimento delle Patologie Emergenti, Unita di Medicina Interna	Palermo	PA	Italy	90127
1103	Ospedale S. Maria della Misericordia Dipartimento di Medicina, Medicina Interna,	Perugia	PG	Italy	06132
1104	Azienda Ospedaliera Della Provincia Di Lecco - Ospedale Manzoni	Lecco	Province OF Lecco	Italy	23900
1105	Dept."Medicina lnterna e Specialita Mediche" dell' Universita degli	Roma	RM	Italy	00161
1106	Policlinico Umberto I di Roma	Rome	RM	Italy	00161
1107	Azienda Ospedaliera S'Andrea di Roma - UOC Cardiologia	Rome	RM	Italy	00189
1108	Presidioospedaliero di san dona 'di PIAVE	San Dona Di Paive	Venezia	Italy	30027
1109	Ospedale G. Fracastoro	San Bonifacio	Verona	Italy	37047
1110	AOUI di Verona - Ospedale Civile Maggiore Borgo Trento	Verona	VR	Italy	37126
1111	I.N.R.C.A. di Ancona Ospedale Geriatrico	Ancona		Italy	60124
1112	Ospedale Civile Regionale San Martino, Belluno	Belluno		Italy	32100
1113	Azienda Ospedaliera G. Brotzu	Cagliari		Italy	09124
1114	Divisione di Cardiologia con UTIC ed Emodinamica	Naples		Italy	80131
1115	Department of Clinical Medicines and Cardiovascular Sciences, Universita "Federico II" di Napoli	Napoli		Italy	80131
1116	Divisione di Cardiologia con Utic ed Emodinamica - AOU Federico II di Napoli	Napoli		Italy	80131
1117	A.O. di Reggio Emilia Arcispedale "S. Maria Nuova"/IRCCS	Reggio Emilia		Italy	42123
1118	AUSL Della Romagna-Ospedale Infermi	Rimini		Italy	47923
1119	Policlinico Umberto I di Roma - DAI Malattie Cardiovascolari e Respiratorie	Rome		Italy	00161
1120	Ospedale Santa Maria della Misericordia Azienda ULSS 18 of Rovigo	Rovigo		Italy	45100
1121	A.O.U. San Giovanni di Dio e Ruggi d'Aragona U.O.C. UTIC	Salerno		Italy	84100
1122	Azienda Ospedaliera Universitaria Santa Maria Della Misericordia	Udine		Italy	33100
1123	Chungbuk National University Hospital	Cheongju-si	Chungcheonbuk-do	Korea, Republic of	28644
1124	Kangwon National University Hospital	Chuncheon-si	Gangwon-do	Korea, Republic of	24289
1125	Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital	Wonju-Si	Gangwon-do	Korea, Republic of	26426
1126	Dongguk University Ilsan Hospital	Goyang-si	Gyeonggi-do	Korea, Republic of	10326
1127	Inje University Ilsan Paik Hospital	Goyang-Si	Gyeonggi-do	Korea, Republic of	10380
1128	MyongJi Hospital	Goyang-si	Gyeonggi-do	Korea, Republic of	10475
1129	Seoul National University Bundang Hospital	Seongnam-si	Gyeonggi-do	Korea, Republic of	13620
1130	Ajou University Hospital	Suwon-si	Gyeonggi-do	Korea, Republic of	16499
1131	Uijeongbu St. Mary's Hospital-The Catholic University of Korea	Uijeongbu-si	Gyeonggi-do	Korea, Republic of	11765
1132	Inha University Hospital	Jung-gu	Incheon	Korea, Republic of	400-711
1133	Inje University Busan Paik Hospital	Busan		Korea, Republic of	47392
1134	Dong-A University Hospital	Busan		Korea, Republic of	49201
1135	Daegu Catholic University Medical Center	Daegu		Korea, Republic of	42472
1136	Konyang University Hospital	Daejeon		Korea, Republic of	302-718
1137	Daejeon St. Mary's Hospital-The Catholic University of Korea	Daejeon		Korea, Republic of	34943
1138	Chonnam National University Hospital	Gwangju		Korea, Republic of	61469
1139	Gachon University Gil Medical Center	Incheon		Korea, Republic of	21565
1140	Hallym University Kangdong Sacred Heart Hospital	Seoul		Korea, Republic of	05355
1141	Gangnam Severance Hospital, Yonsei University Health System	Seoul		Korea, Republic of	06273
1142	SMG-SNU Boramae Medical Center	Seoul		Korea, Republic of	07061
1143	Asan Medical Center	Seoul		Korea, Republic of	138-736
1144	Consultorio Dr. Leocadio Gerardo Munoz Beltran	Cd. Juarez	Chihuahua	Mexico	32472
1145	Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares, S.C.	Mexico	D F	Mexico	11650
1146	Centro de Atencion e Investigacion en Factores de Riesgo Cardiovascular Omega S.C	Mexico	DF	Mexico	06700
1147	Consultorio de Endocrinologia y Nutriologia	Mexico	Distrito Federal	Mexico	07760
1148	Operadora de Hospitales Angeles S.A. de C.V.(Emergencies)	Mexico	Distrito Federal	Mexico	07760
1149	Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran"	Mexico	Distrito Federal	Mexico	14000
1150	Centro de Investigacion Clinica del Pacifico, S.A. de C.V.	Acapulco de Juarez	Guerrero	Mexico	39670
1151	Investigacion Biomedica Aplicada de Hidalgo S.A. de C.V.	Pachuca	Hidalgo	Mexico	42090
1152	Centro de Investigacion Medica Integral S.C.	Guadalajara	Jalisco	Mexico	44160
1153	Instituto de Terapeutica Experimental y Clinica (INTEC) Centro Universitario de Ciencias de la Salud	Guadalajara	Jalisco	Mexico	44340
1154	Hospital Mexico Americano S.C. (Emergencies)	Guadalajara	Jalisco	Mexico	44620
1155	Consultorio Privado del Dr. Gabriel Arturo Ramos Lopez	Guadalajara	Jalisco	Mexico	44657
1156	CICEJ Centro de Investigacion Clinica Endocrinologica de Jalisco SC	Guadalajara	Jalisco	Mexico	44670
1157	Unidad de Investigacion Clinica y Atencion Medica HEPA S.C.	Guadalajara	Jalisco	Mexico	44670
1158	Jardines Hospital de Especialidades S.A de C.V	Zapopan	Jalisco	Mexico	45040
1159	Instituto de Diabetes Obesidad y Nutricion, S.C.	Cuernavaca	Morelos	Mexico	62250
1160	Hospital Inovamed Cuernavaca (Emergencies)	Cuernavaca	Morelos	Mexico	62270
1161	Accelerium S. de R.L. de C.V.	Monterrey	Nuevo LEON	Mexico	64000
1162	Hospital y Clinica OCA, S.A. de C.V.	Monterrey	Nuevo LEON	Mexico	64000
1163	Monterrey International Research Center	Monterrey	Nuevo LEON	Mexico	64000
1164	Cardiolink Clin Trials, S.C.	Monterrey	Nuevo LEON	Mexico	64060
1165	Hospital Universitario "Dr. Jose Eleuterio Gonzalez"	Monterrey	Nuevo LEON	Mexico	64460
1166	Hospital Universitario De Monterrey- "Doctor Jose Eleuterio Gonzalez"	Monterrey	Nuevo LEON	Mexico	64460
1167	CRI Centro Regiomontano de Investigacion SC	Monterrey	Nuevo LEON	Mexico	64710
1168	Global Trial Research Center S.A. de C.V.	Monterrey	Nuevo LEON	Mexico	64718
1169	Fundacion Santos y de la Garza Evia I.B.P. (Centro Medico Zambrano Hellion)	San Pedro Garza Garcia	Nuevo LEON	Mexico	66278
1170	Centro Integral Medico SJR S.C	San Juan del Rio	Queretaro	Mexico	76800
1171	Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C.	Culiacan	Sinaloa	Mexico	80020
1172	Hospital Angeles Culiacan (Emergencies Only)	Culiacan	Sinaloa	Mexico	80020
1173	Centro de Estudios de Investigacion Metabolicos y Cardiovasculares S.C.	Tampico	Tamaulipas	Mexico	89000
1174	Centro de Especialidades Medicas del Estado de Veracruz	Xalapa	Veracruz	Mexico	91020
1175	Instituto Biomedico De Investigacion A.C.	Aguascalientes		Mexico	20127
1176	Centro de Investigacion Cardiometabolica de Aguascalientes S.A. de C.V.	Aguascalientes		Mexico	20230
1177	Centro Hospitalario Mac, S.A. de C.V. (Emergencies)	Aguascalientes		Mexico	20230
1178	Hospital Cardiologica Aguescalientes	Aguascalientes		Mexico	20230
1179	Unidad de Investigacion en Salud de Chihuahua S.C.	Chihuahua		Mexico	31203
1180	Investigacion en Salud y Metabolismo S.C.	Chihuahua		Mexico	31215
1181	Consultorio Medico de Especialidad Dr. Demetrio Kosturakis Garcia	Chihuahua		Mexico	31217
1182	Investigacion en Salud y Metabolismo S.C	Chihuahua		Mexico	31217
1183	Instituto Nacional de Ciencia Medicas y Nutricion Salvador Zubiran	Distrito Federal		Mexico	14000
1184	Lahoja Asociacion para la Investigacion y Farmacovigilancia S.C.	Durango		Mexico	34000
1185	Cardioprevent, S.C.	Durango		Mexico	34080
1186	Pharmacology and Clinical Research S.A. de C.V.	Queretaro		Mexico	76000
1187	Cardioarritmias e Investigacion S.C.	San Luis Potosi		Mexico	78200
1188	Hospital Lomas de San Luis Intemacional (Emergencies)	San Luis Potosi		Mexico	78218
1189	"Hospital Central ""Dr. Ignacio Morones Prieto"""	San Luis Potosi		Mexico	78240
1190	Centro Especializado En Diabetes Y Metabolismo	Veracruz		Mexico	91910
1191	Tjongerschans Ziekenhuis	Heerenveen	Friesland	Netherlands	8441 PW
1192	Zuyderland MC	Sittard-Geleen	Limburg	Netherlands	6162 BG
1193	Isala	Zwolle	Overijssel	Netherlands	8025 AB
1194	St. Franciscus Gasthuis	Rotterdam	Zuid-holland	Netherlands	3045 PM
1195	Het Lange Land Ziekenhuis	Zoetermeer	Zuid-holland	Netherlands	2725 NA
1196	Noordwest Ziekenhuisgroep	Alkmaar		Netherlands	1815 JD
1197	EB Flevoresearch	Almere		Netherlands	1311 RL
1198	Meander Medical Center	Amersfoort		Netherlands	3813 TZ
1199	Meander Medisch Centrum	Amersfoort		Netherlands	3813 TZ
1200	Amstelland Hospital	Amstelveen		Netherlands	1186 AM
1201	Bovenij Ziekenhuis	Amsterdam		Netherlands	1034 CS
1202	OLVG, locatie West	Amsterdam		Netherlands	1061 AE
1203	VU University Medical Center	Amsterdam		Netherlands	1081HV
1204	Onze Lieve Vrouwe Gasthuis	Amsterdam		Netherlands	1091 AC
1205	Academic Medical Center	Amsterdam		Netherlands	1105 AZ
1206	Gelre Hospitals	Apeldoorn		Netherlands	7334 DZ
1207	Rode Kruis Ziekenhuis	Beverwijk		Netherlands	1942 LE
1208	Tergooi Ziekenhuis	Blaricum		Netherlands	1261 AN
1209	Andro Medical Research B.V.	Breda		Netherlands	4811 SW
1210	Amphia Ziekenhuis	Breda		Netherlands	4818 CK
1211	Reinier de Graaf ziekenhuis	Delft		Netherlands	2625 AD
1212	Hedramed	Den Haag		Netherlands	2526 HW
1213	Hedramed	Den Haag		Netherlands	2526HW
1214	Hagaziekenhuis	Den Haag		Netherlands	2545 CH
1215	HMC (Haaglanden Medisch Centrum) Bronovo	Den Haag		Netherlands	2597 AX
1216	Deventer Ziekenhuis	Deventer		Netherlands	7416SE
1217	Van Weel Bethesda Hospital	Dirksland		Netherlands	3247 BW
1218	Slingeland Ziekenhuis	Doetinchem		Netherlands	7009 BL
1219	Albert Schweitzer Hospital	Dordrecht		Netherlands	3318 AT
1220	Ziekenhuis Gelderse Vallei	Ede		Netherlands	6716 RP
1221	Andromed Eindhoven	Eindhoven		Netherlands	5611 NV
1222	Heartcentre Catharina Hospital	Eindhoven		Netherlands	5623 EJ
1223	Medisch Spectrum Twente	Enschede		Netherlands	7512 KZ
1224	Beatrix Ziekenhuis	Gorinchem		Netherlands	4204 AA
1225	Groene Hart Ziekenhuis	Gouda		Netherlands	2803 HH
1226	University Medical Center Groningen	Groningen		Netherlands	9713 GZ
1227	Martini Ziekenhuis	Groningen		Netherlands	9728 NT
1228	Spaarne Gasthuis	Haarlem		Netherlands	2035 RC
1229	St. Jansdal Ziekenhuis	Harderwijk		Netherlands	3844 DG
1230	Zuyderland Medisch Centrum	Heerlen		Netherlands	6419 PC
1231	Zuyderland	Heerlen		Netherlands	6419PC
1232	Treant Zorggroep, location Bethesda	Hoogeveen		Netherlands	7909 AA
1233	Vascular Research Centre	Hoorn		Netherlands	1624 NP
1234	Quality Care Research	Kloosterhaar		Netherlands	7694 AC
1235	Medisch Centrum Leeuwarden	Leeuwarden		Netherlands	8934 AD
1236	Leiden University Medical Center	Leiden		Netherlands	2333 ZA
1237	Alrijne Ziekenhuis	Leiden		Netherlands	2334 CK
1238	Alrijne Ziekenhuis	Leiderdorp		Netherlands	2353 GA
1239	GCM Maarssenbroek	Maarssen		Netherlands	3607 KN
1240	Maastricht University Medical Center	Maastricht		Netherlands	6229 HX
1241	Isala Diaconessenhuis	Meppel		Netherlands	7943 KA
1242	St Antonius Hospital	Nieuwegein		Netherlands	3435 CM
1243	Radboud University Nijmegen Medical Centre	Nijmegen		Netherlands	6525 GA
1244	Canisius Wilhelmina Ziekenhuis	Nijmegen		Netherlands	6532 SZ
1245	Waterland Hospital	Purmerend		Netherlands	1441 RN
1246	Andro Medical Research B.V	Rotterdam		Netherlands	3021 HC
1247	Rotterdam Research Institute	Rotterdam		Netherlands	3039 BD
1248	St. Fransiscus Gasthuis	Rotterdam		Netherlands	3045 PM
1249	Ikazia Ziekenhuis	Rotterdam		Netherlands	3083 AN
1250	D&A Research and Genetics	Sneek		Netherlands	8601 ZR
1251	Ziekenhuis Rivierenland	Tiel		Netherlands	4002 WP
1252	Elisabeth-TweeSteden Ziekenhuis (previously named St. Elisabeth Ziekenhuis)	Tilburg		Netherlands	5022 GC
1253	St. Elisabeth Ziekenhuis	Tilburg		Netherlands	5022 GC
1254	Elisabeth TweeSteden Ziekenhuis (ETZ)	Tilburg		Netherlands	5042 AD
1255	Bernhoven Ziekenhuis	Uden		Netherlands	5406 PT
1256	EB Utrecht	Utrecht		Netherlands	3511 NH
1257	Universitair Medisch Centrum (UMC) Utrecht - Locatie AZU	Utrecht		Netherlands	3584 CX
1258	University Medical Center Utrecht	Utrecht		Netherlands	3584 CX
1259	Maxima Medisch Centrum	Veldhoven		Netherlands	5504 DB
1260	VieCuri Medisch Centrum	Venlo		Netherlands	5912 BL
1261	Twee Steden Ziekenhuis	Waalwijk		Netherlands	5141 BM
1262	Albert Schweitzer Hospital	Zwijndrecht		Netherlands	3331 LZ
1263	Optimal Clinical Trials	Grafton	Auckland	New Zealand	1010
1264	Henderson Medical Centre	Henderson	Auckland	New Zealand	0612
1265	Middlemore Hospital	Otahuhu	Auckland	New Zealand	1640
1266	North Shore Hospital	Takapuna	Auckland	New Zealand	0622
1267	Hawke's Bay Hospital	Frimley	Hastings	New Zealand	4120
1268	Auckland City Hospital	Auckland		New Zealand	1023
1269	Lipid and Diabetes Research Group	Christchurch		New Zealand	8011
1270	Southern Clinical Trials Shirley Ltd	Christchurch		New Zealand	8011
1271	Southern Clinical Trials Riccarton	Christchurch		New Zealand	8041
1272	RMC Medical Research Ltd.	Dunedin		New Zealand	9012
1273	Taranaki Base Hospital	New Plymouth		New Zealand	4310
1274	Rotorua Hospital	Rotorua		New Zealand	3010
1275	Clinical Horizons NZ Ltd.	Tauranga		New Zealand	3112 New Zealand
1276	Clinical Trials Unit,Bay of Plenty(BOP) Clinicla School	Tauranga		New Zealand	3112
1277	Papamoa Pines Medical Centre	Tauranga		New Zealand	3118
1278	Clinical Horizons NZ Ltd	Tauranga		New Zealand	3144
1279	Wellington Hospital	Wellington		New Zealand	6021
1280	Jeleniogorskie Centrum Chorob Serca, Przychodnia Kardiologiczna, Poradnia Kardiologiczna	Jelenia Gora	Dolnoslaskie	Poland	58-506
1281	Zdrowie s.c. Agnieszka i Donald Drozdz	Wroclaw	Dolnoslaskie	Poland	51-314
1282	Halina Serafin NZOZ Centrum Medyczne SERAFIN-MED	Zarow	Dolnoslaskie	Poland	58-130
1283	NZOZ Vitamed	Bydgoszcz	Kujawsko-pomorskie	Poland	85-079
1284	Nzoz Centrum Medyczne Kermed	Bydgoszcz	Kujawsko-pomorskie	Poland	85-231
1285	Specjalistyczna Praktyka Lekarska Piotr Kubalski	Grudziadz	Kujawsko-pomorskie	Poland	86-300
1286	Specjalistyczne Gabinety Lekarskie "Medicor Plus" - Jerzy Kopaczewski	Wloclawek	Kujawsko-pomorskie	Poland	87-800
1287	Gabinet Lekarski Malgorzata Saryusz-Wolska	Lodz	Lodzkie	Poland	90-132
1288	Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o. Jednostka 02	Lodz	Lodzkie	Poland	90-368
1289	"Prywatny Gabinet Kardiologiczny" Dr N.Med. Maciej Kosmider	Lodz	Lodzkie	Poland	91-490
1290	Niepubliczny Zaklad Opieki Zdrowotnej CEREO-MED Sp. z o.o.	Lodz	Lodzkie	Poland	92-003
1291	Prywatny Gabinet Lekarski Dr n. med. Michal Ogorek	Piotrkow Trybunalski	Lodzkie	Poland	97-300
1292	Centrum Medyczne Ogrodowa Sp. z o.o.	Skierniewice	Lodzkie	Poland	96-100
1293	Clinical Best Solutions	Lublin	Lubelskie	Poland	20-045
1294	Optimamed Specjalistyczne Gabinety Lekarskie	Lublin	Lubelskie	Poland	20-091
1295	KO-MED Centra Kliniczne Lublin II	Lublin	Lubelskie	Poland	20-362
1296	KO-MED Centra Kliniczne Pulawy	Pulawy	Lubelskie	Poland	24-100
1297	KO-MED Centra Kliniczne Zamosc	Zamosc	Lubelskie	Poland	22-400
1298	Landa Specjalistyczne Gabinety Lekarskie	Krakow	Malopolskie	Poland	30-015
1299	Krakowski Szpital Specjalistyczny im. Jana Pawla II	Krakow	Malopolskie	Poland	31- 202
1300	Szpital Specjalistyczny im. J. Dietla w Krakowie, Oddzial Kardiologii	Krakow	Malopolskie	Poland	31-121
1301	Centrum Medyczne Zdrowa J. Trebacz, W. Zajdel Spolka jawna	Krakow	Malopolskie	Poland	31-216
1302	CENTRUM MEDYCZNE A-Z Clinic	Krakow	Malopolskie	Poland	31-315
1303	Krakowskie Centrum Medyczne Sp. z o.o.	Krakow	Malopolskie	Poland	31-501
1304	Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie,	Krakow	Malopolskie	Poland	31-501
1305	Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie, Ambulatoria	Krakow	Malopolskie	Poland	31-531
1306	NZOZ Centrum Zdrowia i Profilaktyki Dabie Sp. z.o.o.	Krakow	Malopolskie	Poland	31-567
1307	Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne ProMiMed sp z o.o., sp.k.	Krakow	Malopolskie	Poland	31-637
1308	NeuroCor Banaszkiewicz, Kulaga, Ostrowska, Tomaszewski lekarze spolka partnerska	Myslenice	Malopolskie	Poland	32-400
1309	INTERCARD Sp. z. o. o. Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii w Nowym Targu	Nowy Targ	Malopolskie	Poland	34-400
1310	Medicome Sp. z o.o.	Oswiecim	Malopolskie	Poland	32-600
1311	Centrum Szybkiej Diagnostyki Kardiologicznej Kardiomed M. Zabowka E. Zabowka	Tarnow	Malopolskie	Poland	33-100
1312	Specjalistyczny Gabinet Lekarski Internistyczno-Kardiologiczny Boguslaw Derlaga	Tarnow	Malopolskie	Poland	33-100
1313	Synexus Polska Sp. z o.o. Oddzial w Katowicach	Katowice	Mazowieckie	Poland	40-040
1314	Niepubliczny Zaklad Opieki Zdrowotnej Specjalistyczna Przychodnia Lekarska "MEDIKARD"	Plock	Mazowieckie	Poland	09-402
1315	Centrum Medyczne Piaski Filia nr 9	Warszawa	Mazowieckie	Poland	01-875
1316	Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego	Warszawa	Mazowieckie	Poland	02-637
1317	Wojskowy Instytut Medyczny,Centralny Szpital Kliniczny Ministerstwa Obronty Narodowej	Warszawa	Mazowieckie	Poland	04-141
1318	Instytut Kardiologii im	Warszawa	Mazowieckie	Poland	04-628
1319	Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o.	Warszawa	Mazowieckie	Poland	04-730
1320	Szpital Specjalistyczny w Brzozowie, Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza Oddzial	Brzozow	Podkarpackie	Poland	36-200
1321	INTERCARD Sp. z o.o. Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii w Krosnie	Krosno	Podkarpackie	Poland	38400
1322	EMED Centrum Uslug Medycznych Ewa Smialek	Rzeszow	Podkarpackie	Poland	35205
1323	"OSTEO-MEDIC" s.c. Artur Racewicz, Jerzy Supronik	Bialystok	Podlaskie	Poland	15-351
1324	Podlaski Osrodek Kardiologii Janusz Korecki	Bialystok	Podlaskie	Poland	15-875
1325	Synexus Polska Sp. z o.o. Oddzial w Gdansku	Gdansk	Pomorskie	Poland	80-382
1326	Niepubliczny Zaklad Opieki Zdrowotnej Gdanskie Centrum Zdrowia, Poradnia Kardiologiczna	Gdansk	Pomorskie	Poland	80-542
1327	Centrum Badan Klinicznych Pi-House, Poradnia Diabetologiczna	Gdansk	Pomorskie	Poland	80-546
1328	Medica Pro Familia Sp. z o.o. Spolka Komandytowo Akcyjna, Oddzial w Gdyni	Gdynia	Pomorskie	Poland	81-338
1329	Synexus Polska Sp. z o.o. Oddzial w Gdyni	Gdynia	Pomorskie	Poland	81-384
1330	NZOZ "PRO CORDIS" Sopockie Centrum Badan Kardiologicznych	Gdynia	Pomorskie	Poland	81-423
1331	Gabinet Kardiologiczno - lnternistyczny	Gdynia	Pomorskie	Poland	81-472
1332	Centrum Medyczne "SOPMED" Sp. z o.o.	Sopot	Pomorskie	Poland	81-756
1333	Indywidualna Specjalistyczna Praktyka Lekarska Malgorzata Biedrzycka	Starogard Gdanski	Pomorskie	Poland	83-200
1334	Samodzielny Publiczny Zaklad Opieki Zdrowotnej Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu	Bytom	Slaskie	Poland	41-902
1335	Bogna Gabrylewicz Andrzej Ochala Unimed s.c.	Katowice	Slaskie	Poland	40-083
1336	Pro Familia Altera Poradnia Wielospecjalistyczna	Katowice	Slaskie	Poland	40-648
1337	NZOZ Terapia Optima	Katowice	Slaskie	Poland	40-752
1338	Przychodnia Specjalistyczna Samodzielny Publiczny ZOZ w Rudzie Slaskiej,	Ruda Slaska	Slaskie	Poland	41-709
1339	NZOZ "Medyk"Sp. z o. o.	Wola	Slaskie	Poland	43-225
1340	Prywatny Gabinet Lekarski Marianna Janion	Kielce	Swietokrzyskie	Poland	25-315
1341	Wojewodzki Szpital Zespolony w Elblagu, Oddzial Kardiologiczny z Pododdzialem Kardiologii Inwazyjnej	Elblag	Warminsko-mazurskie	Poland	82-300
1342	Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota	Ostroda	Warminsko-mazurskie	Poland	14-100
1343	Synexus Polska Sp. z o.o Oddzial w Poznaniu	Poznan	Wielkopolskie	Poland	60-702
1344	Nzoz "Twoja Przychodnia"	Poznan	Wielkopolskie	Poland	61-006
1345	Centrum Medyczne AMED	Warszawa	WOJ Mazowieckie	Poland	01-518
1346	SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi 251 Pomorska	Lodz	Wojewodztwo Lodzkie	Poland	92-213
1347	Marek Piepiorka Gabinet Kardiologiczno - lnternistyczny	Gdynia		Poland	81-472
1348	Nzoz Gall-Med	Krakow		Poland	30-053
1349	NZOZ Centrum Zdrowia i Profilaktyki Dabie Sp. z.o.o.	Krakow		Poland	31-567
1350	"TWOJA PRZYCHODNIA" Sp. Z o.o	Lublin		Poland	20-857
1351	Medicus w Opolu Sp z o. o.	Opole		Poland	45-706
1352	Centrum Zdrowia Metabolicznego Pawel Bogdanski	Poznan		Poland	60-592
1353	NZOZ PRZYCHODNIA SPECJALISTYCZNA Andrzej Wittek Henryk Rudzki s.c.	Ruda Slaska		Poland	41-709
1354	KO-MED Centra Kliniczne Staszow	Staszow		Poland	28-200
1355	Synexus Polska Sp. z o.o. Oddzial w Warszawie	Warszawa		Poland	01-192
1356	Centrum Medyczne Warszawskiego Uniwersytetu Medycznego Sp. z o.o	Warszawa		Poland	02-097
1357	Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego Klinika Kardiologii	Warszawa		Poland	04-628
1358	Synexus Polska Sp. z o.o. Oddzial we Wroclawiu	Wroclaw		Poland	50-088
1359	Centrum Opieki Diabetologiczno-Endokrynologicznej i Ginekologiczno-Polozniczej	Wroclaw		Poland	50-306
1360	Dobrostan Michal Bogacki	Wroclaw		Poland	53-301
1361	The Office of Roberto J. Ayala-Rios, MD - Research Center and Private Practice (DMRA LLC)	Anasco		Puerto Rico	00610
1362	Cardiometabolic Research Center, Inc.	Ponce		Puerto Rico	00717
1363	Endocrine Lipid Diabetes Research Institute	Ponce		Puerto Rico	00717
1364	Consultorio Medico Figueroa	San Juan		Puerto Rico	00917
1365	Pradnet Inc.	San Juan		Puerto Rico	00917
1366	Altamira Family Medicine And Research Institute	San Juan		Puerto Rico	00920
1367	Miguel Sosa-Padilla, MD-Private Practice	San Juan		Puerto Rico	00926-2832
1368	Centro de Diabetes para Puerto Rico	San Juan		Puerto Rico	00935
1369	Pitesti-Arges County Emergency Hospital	Pitesti	Arges	Romania	110084
1370	Medical Practice SRL	Oradea	Bihor	Romania	410032
1371	County Clinical Emergency Hospital Oradea	Oradea	Bihor	Romania	410169
1372	County Emergency Hospital Deva	Deva	Hunedoara	Romania	330084
1373	Centrul Medical Sf. Stefan	Timisoara	JUD. Timis	Romania	300125
1374	Dr. Pop Calin Florin - Cabinet Cardiologie	Baia Mare	Maramures	Romania	430130
1375	Podoleanu G. Cristian-Gheorghe-Calin - Cardiology Medical Practice	Targu Mures	Mures	Romania	540143
1376	Diabmed Dr. Popescu Alexandrina SRL, Diabet, Nutritie, Boli Metabolice	Ploiesti	Prahova	Romania	100163
1377	Dr. Busegeanu Mihaela Private Practice	Ploiesti	Prahova	Romania	100342
1378	Institute of Cardiovascular Diseases Timisoara	Timisoara	Timis	Romania	300310
1379	Euromedica Hospital	Baia Mare		Romania	430032
1380	Spitalul Clinic Judetean De Urgenta Braila(Braila County Clincal Emergency Hospital)	Braila		Romania	810249
1381	S.C. Polimed Dacia S.R.L.	Brasov		Romania	500209
1382	Centrul Medical de Diagnostic si Tratament Ambulator Neomed	Brasov		Romania	500283
1383	Data Plus Medical Clinic	Bucharest		Romania	010192
1384	"Prof. Dr. N.C. Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases,	Bucharest		Romania	020045
1385	Med Plus SRL (Med Plus Ltd.)	Bucharest		Romania	061118
1386	S.C. Centrul Medical "Sanatatea Ta" S.R.L.	Bucharest		Romania	20614
1387	Spitalul Universitar De Urgenta Militar Central, Dr. Carol Davila	Bucuresti		Romania	010825
1388	Spitalul Clinic Colentina, Departament Cardiologie	Bucuresti		Romania	020125
1389	SC Clinica Medicala Synexus SRL, Medicina Interna	Bucuresti		Romania	021611
1390	SC Centrul Medical Policlinico Di Monza SRL, Cardiologie	Bucuresti		Romania	021967
1391	SC Policlinica CCBR SRL	Bucuresti		Romania	030463
1392	Spitalul Clinic Judetean de Urgenta Cluj-Napoca, Diabet Zaharat, Nutritie si Boli Metabolice	Cluj		Romania	400006
1393	Dr. Mistodie Cristina Victoria MD, Office of	Galati		Romania	800098
1394	S.C. Diamed Obesity S.R.L.	Galati		Romania	800291
1395	County Emergency Hospital Satu Mare Diabetes, Nutrition And Metabolic Diseases Department	Satu Mare		Romania	440055
1396	County Clinical Emergency Hospital Sibiu	Sibiu		Romania	550245
1397	Cardio Med SRL	Targu Mures		Romania	540124
1398	Centrul Medical Dr. Negrisanu SRL, Diabet Zaharat, Nutritie si Boli Metabolice	Timisoara		Romania	300456
1399	State Budgetary Healthcare Institution "Research Institution - Regional Clinical Hospital #1	Krasnodar	Krasnodar Region	Russian Federation	350086
1400	State Budgetary Healthcare Institution Of Moscow Region "Lubertsy Regional Hospital #2"	Lubertsy	Moscow Region	Russian Federation	140006
1401	Federal State Budgetary Institution of Healthcare Hospital of Russian Academy of Sciences	Troitsk	Moscow Region	Russian Federation	142190
1402	State Budgetary Institution "Ryazan Regional Clinical Hospital"	Ryazan	Ryazan Region	Russian Federation	390039
1403	Saint Petersburg State Budgetary Institution of Healthcare Municipal hospital	Saint-Petersburg	Sestroretsk	Russian Federation	197706
1404	FSBEI of HE Kazan State Medical University on the base of SBHI Clinical Hospital No.2	Kazan	Tatarstan Republic	Russian Federation	420033
1405	SBEI of HPE Kazan State Medical University on the base of SBHI Clinical Hospital No.2	Kazan	Tatarstan Republic	Russian Federation	420033
1406	Municipal Budgetary State Healthcare Institution "City Clinical Hospital #6"	Chelyabinsk		Russian Federation	454047
1407	Non-State Institution of Healthcare "Railway Clinical Hospital at station Chelyabinsk of open	Chelyabinsk		Russian Federation	454092
1408	State Budgetary Healthcare Institution "Region Clinical Hospital #3"	Chelyabinsk		Russian Federation	454136
1409	Municipal Autonomous Institution "City Clinical Hospital #14"	Ekaterinburg		Russian Federation	620039
1410	Regional Budgetary Healthcare Institution "Cardiology Dispensary"	Ivanovo		Russian Federation	153012
1411	State Budgetary Institution of Healthcare of Kaluga Region "Kaluga Regional Hospital"	Kaluga		Russian Federation	428007
1412	Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University"	Kazan		Russian Federation	420012
1413	State Autonomous Healthcare Institution	Kazan		Russian Federation	420064
1414	"SAHI of Kemerovo ""Regional Clinical Hospital of Emergency Medical Care n.a. M.A Podgorbunsky """	Kemerovo		Russian Federation	650000
1415	Municipal Budgetary Institution of Healthcare	Kemerovo		Russian Federation	650000
1416	Federal state budgetary institution Research institute of complex problems	Kemerovo		Russian Federation	650002
1417	FSHI "Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia across Kemerovo region	Kemerovo		Russian Federation	650099
1418	Kirov Regional State Budgetary Healthcare Institution "Kirov City Clinical Hospital #1"	Kirov		Russian Federation	610014
1419	Regional Budgetary Healthcare Institution "Kursk City Clinical Emergency Hospital"	Kursk		Russian Federation	305035
1420	Non-State Institution of Healthcare "Central Clinical Hospital #6 OAO "RZhD"	Moscow		Russian Federation	109388
1421	Federal State Budgetary Institution "State Research Center for Preventive Medicine" of the Ministry	Moscow		Russian Federation	109990
1422	SBHI of Moscow city "City Clinical Hospital #15 n.a. O.M. Filatova"	Moscow		Russian Federation	111539
1423	SBEI of HPE I. M. Sechenov First Moscow State Medical University, UKB #2	Moscow		Russian Federation	119435
1424	State Healthcare Institution "City Clinical Hospital #51 of Healthcare Department of Moscow City"	Moscow		Russian Federation	121309
1425	Federal State Budgetary Institution "Central Clinical Hospital with Polyclinic"	Moscow		Russian Federation	121359
1426	Federal State Budgetary Institution "Russian Cardiology Research And Production Complex" Of Ministry	Moscow		Russian Federation	121552
1427	Russian Cardiology Research And Production Complex of Ministry of Health of Russian Federation	Moscow		Russian Federation	121552
1428	Moscow State Healthcare Institution "City clinical hospital n.a. S.P.Botkin"	Moscow		Russian Federation	125284
1429	SBIH "City Clinical Hospital #81 Departments of Healthcare of Moscow"	Moscow		Russian Federation	127644
1430	Federal State Budget Institution "Out-patient Clinic #3" of Russian Federation,	Moscow		Russian Federation	129090
1431	State Regional Budgetary Healthcare Institution	Murmansk		Russian Federation	183047
1432	State Budgetary Healthcare Institution of Nizhegorodskaya Region	Nizhniy Novgorod		Russian Federation	603076
1433	Federal State Budgetary Institution "Research Institute of Therapy and Preventive Medicine" of	Novosibirsk		Russian Federation	630089
1434	SBRIHPE "Novosibirsk State Medical University" of MHSD of RF	Novosibirsk		Russian Federation	630091
1435	"Reafan" LLC	Novosibirsk		Russian Federation	630099
1436	"SBHI of Novosibirsk ""City Clinical Hospital of Emergency Medical Care # 2"""	Novosibirsk		Russian Federation	630102
1437	Municipal Budgetary Institution of Healthcare of Novosibirsk	Novosibirsk		Russian Federation	630102
1438	State Budgetary Institution of Healthcare of Novosibirsk region City Clinical Hospital of Emergency	Novosibirsk		Russian Federation	630102
1439	State Budgetary Institution of Healthcare"Penzenskaya Regional clinical hospital n.a N.N Burdenko"	Penza		Russian Federation	440026
1440	SBHI of Saint-Petersburg "City Hospital # 38 n.a. N.A. Semashko"	Pushkin		Russian Federation	196601
1441	Federal State Budgetary Educational Institution of Higher Education	Rostov-on-Don		Russian Federation	344022
1442	State Budgetary Educational Institution Of Higher Professional Education	Rostov-on-Don		Russian Federation	344022
1443	State Budgetary Educational Institution of Higher Professional Education	Rostov-on-Don		Russian Federation	344068
1444	Federal State Budgetary Institution	Saint Petersburg		Russian Federation	197341
1445	Limited Liability Company International Medical Centre SOGAZ	Saint-Petersburg		Russian Federation	191186
1446	Saint-Petersburg State Budgetary Institution of Healthcare "City Hospital #23"	Saint-Petersburg		Russian Federation	192148
1447	Saint-Petersburg State Budgetary Healthcare Institution "City Alexandrovskaya Hospital"	Saint-Petersburg		Russian Federation	193312
1448	Federal state budget institution of healthcare Saint-Petersburg clinical hospital of Russian Academy	Saint-Petersburg		Russian Federation	194017
1449	Limited Liability Company "Reavita"	Saint-Petersburg		Russian Federation	194354
1450	"Limited Liability Company ""Institute of Medical Research"""	Saint-Petersburg		Russian Federation	196084
1451	Limited Liability Company "Institute of Medical research"	Saint-Petersburg		Russian Federation	196084
1452	LLC "Institution of medical studies"	Saint-Petersburg		Russian Federation	196084
1453	City Hospital # 38 n.a. Semashko	Saint-Petersburg		Russian Federation	196601
1454	SBEI of HPE "First Pavlov State Medical University of St. Petersburg" of the MOH of the RF	Saint-Petersburg		Russian Federation	197022
1455	Federal State Budgetary Institution "Advisory Diagnostic Center and Polyclinic"	Saint-Petersburg		Russian Federation	197110
1456	Saint-Petersburg State Budgetary Healthcare Institution "City Hospital #15"	Saint-Petersburg		Russian Federation	198205
1457	State Budgetary Healthcare Institution "Samara Regional Clinical Cardiology Dispensary"	Samara		Russian Federation	443070
1458	MHI "City Clinical Hospital #12" of the Healthcare Committee	Saratov		Russian Federation	410039
1459	State Institution of Healthcare "Regional Clinical Hospital"	Saratov		Russian Federation	410053
1460	State Budget Educational Institution of Higher Professional Education	Smolensk		Russian Federation	214019
1461	Federal State Budgetary Educational Institution of Higher Education	St. Petersburg		Russian Federation	197022
1462	Tyumen Cardiology Research Center-branch of the Tomsk NRMC	Tomsk		Russian Federation	634009
1463	GBOU VPO Siberian State Medical University Ministry of Healthcare of the Russian Federation	Tomsk		Russian Federation	634050
1464	State Budgetary Educational Institution of Highest Professional Education "Siberian State Medical	Tomsk		Russian Federation	634050
1465	State Autonomous Institution of Healthcare of the Tyumen region Tyumen Institute of Therapy	Tyumen		Russian Federation	625000
1466	Affiliate of the Federal State Budgetary Institution Scientific Research Institute of Cardiology	Tyumen		Russian Federation	625026
1467	State Autonomous Healthcare Institution of Yaroslavl region	Yaroslavl		Russian Federation	150003
1468	FSBEI of HE "Yaroslavl State Medical University" MH of the Russian Federation	Yaroslavl		Russian Federation	150010
1469	State Budgetary Healthcare Institution of Yaroslavl Region "Clinical Hospital No. 10"	Yaroslavl		Russian Federation	150023
1470	State Healthcare Institution of Yaroslavl Region "Clinical Hospital #8"	Yaroslavl		Russian Federation	150030
1471	Nemocnica Ruzinov-Univerzitna Nemocnica Bratislava (UNB)	Bratislava	Bratislavsky	Slovakia	826 06
1472	Stredoslovensky Ustav Srdcovych A Cievnych Chorob A.S.	Banska Bystrica		Slovakia	974 01
1473	Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica	Banska Bystrica		Slovakia	975 17
1474	Alian s.r.o., kardiologicka ambulancia	Bardejov		Slovakia	08501
1475	METABOL KLINIK s. r.o., Ambulancia pre diabetologiu, poruchy latkovej premeny a vyzivy	Bratislava		Slovakia	811 08
1476	Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, l.intema klinika	Bratislava		Slovakia	81369
1477	Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, l.interna klinika	Bratislava		Slovakia	81369
1478	Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto	Bratislava		Slovakia	81369
1479	UN Bratislava, Nemocnica Ruzinov, V. interna klinika LFUK a UN Bratislava	Bratislava		Slovakia	826 06
1480	Kardiovaskularne centrum s.r.o.	Bratislava		Slovakia	83101
1481	Metabolicke centrum MUDr. Katariny Raslovej, s.r.o.	Bratislava		Slovakia	83101
1482	Narodny ustav srdcovych a cievnych chorob, a.s.	Bratislava		Slovakia	833 48
1483	Univerzitna Nemocnica Bratislava	Bratislava		Slovakia	83305
1484	Narodny ustav srdcovych a cievnych chorob, a.s.	Bratislava		Slovakia	83348
1485	KARDIO-SANUS spol., s.r.o.	Bratislava		Slovakia	84108
1486	UN Bratislava Nemocnica Sv. Cyrila a Metoda, kardiologicka ambulancia 1	Bratislava		Slovakia	851 07
1487	VERIA, s.r.o. -Kardiologicka ambulancia	Bratislava		Slovakia	85101
1488	Endiamed s.r.o. Nestatna diabetologicka a endokrinologicka ambulancia	Dolny Kubin		Slovakia	02601
1489	JM-Interna s.r.o., interna ambulancia	Dolny Kubin		Slovakia	02601
1490	CARDIO D&R s.r.o. , Kardiologicka ambulancia	Kosice		Slovakia	040 01
1491	AGTO., spol. s r. o.	Kosice		Slovakia	04011
1492	Cardio D&R spol.s.r.o., Kardiologicka ambulancia	Kosice		Slovakia	04022
1493	Medicentrum Heart, Spol. S.R.O	Kralovsky Chlmec		Slovakia	077 01
1494	CELL-B s.r.o. interna ambulancia	Levice		Slovakia	93405
1495	Liptovska nemocnica s poliklinikou MUDr.Ivana Stodolu Liptovsky Mikulas	Liptovsky Mikulas		Slovakia	031 23
1496	KARDIO 1 s.r.o.	Lucenec		Slovakia	984 39
1497	Klinika hematologie a transfuziologie, Univerzitna nemocnica Martin	Martin		Slovakia	03659
1498	MEDI M&M s.r.o., Ambulancia vnutorneho lekarstva	Moldava nad Bodvou		Slovakia	045 01
1499	MUDr. Kanderkova s.r.o., Diabetologicka ambulancia	Namestovo		Slovakia	02901
1500	Kardiocentrum Nitra s.r.o., kardiologicka ambulancia	Nitra		Slovakia	94901
1501	Fakultna Nemocnica s poliklinikou Nove Zamky	Nove Zamky		Slovakia	940 34
1502	Mediab s.r.o. Diabetologicka ambulancia	Pezinok		Slovakia	90201
1503	BENIMED s.r.o.	Piestany		Slovakia	921 01
1504	Medispol S.R.O.	Presov		Slovakia	08001
1505	Medilex s.r.o. Interna ambulancia	Rimavska Sobota		Slovakia	979 01
1506	Kardioamb s.r.o.	Rimavska Sobota		Slovakia	97901
1507	DIAMEL, s.r.o., Diabetologicka ambulancia	Trencin		Slovakia	911 01
1508	BV Medical, s.r.o. Diabetologicka ambulancia,	Trnava		Slovakia	917 01
1509	Kardiologicka ambulancia	Trnava		Slovakia	917 01
1510	Medivasa, s.r.o.	Zilina		Slovakia	010 01
1511	Nash Ranjith Research Centre	Merebank	Durban	South Africa	4052
1512	IATROS International	Bloemfontein	FREE State	South Africa	9301
1513	JOSHA Research	Bloemfontein	FREE State	South Africa	9301
1514	Welkom Clinical trial Centre	Welkom	FREE State	South Africa	9460
1515	Midrand Medical Centre	Halfway House	Gauteng	South Africa	1685
1516	Sunward Park Hospital	Johannesburg	Gauteng	South Africa	1459
1517	Sunninghill Hospital	Johannesburg	Gauteng	South Africa	2157
1518	I Engelbrecht Research (Pty) Ltd	Lyttelton	Gauteng	South Africa	0157
1519	Charlotte Maxeke Johannesburg Academic Hospital	Parktown	Gauteng	South Africa	2193
1520	Jongaie Research	Pretoria West	Gauteng	South Africa	0183
1521	Medipark Centre for Clinical Research	Pretoria	Gauteng	South Africa	0158
1522	Synexus Watermeyer Clinical Research Centre	Pretoria	Gauteng	South Africa	0184
1523	Roodepoort Medicross Clinical Research Centre	Roodepoort	Gauteng	South Africa	1724
1524	Wits Clinical Research	Soweto	Gauteng	South Africa	2013
1525	Medi-Clinic Heart Hospital	Sunnyside	Gauteng	South Africa	0083
1526	Sunninghill Hospital	Sunninghill	Johannesburg	South Africa	2191
1527	Glastonbury Medical Research Centre	Durban	Kwazulu-natal	South Africa	4001
1528	Suite 502	Durban	Kwazulu-natal	South Africa	4001
1529	Dr Ganesh c/o Dr NB Maharaj	Durban	Kwazulu-natal	South Africa	4091
1530	Limpopo Clinical Research Initiative	Thabazimbi	Limpopo	South Africa	0380
1531	Zinakekele Medical centre	Moloto	Mpumalanga	South Africa	1022
1532	Drs Joynt Venter & Associates	Witbank (eMalahleni)	Mpumalanga	South Africa	1035
1533	Dr JM Engelbrecht Trial Site-Vergelegen Mediclinic	Cape Town	Western CAPE	South Africa	7130
1534	Tiervlei Trial Centre	Cape Town	Western CAPE	South Africa	7530
1535	Synopsis Research cc	Cape Town	Western CAPE	South Africa	7700
1536	Helderberg Research Institute	Somerset West	Western CAPE	South Africa	7130
1537	Synexus Helderberg Clinical Research Centre	Somerset West	Western CAPE	South Africa	7130
1538	Global Clinical Trials (Pty) Ltd.	Arcadia, Pretoria		South Africa	0001
1539	Unitas Hospital	Centurion		South Africa	0157
1540	Clinresco Centres (Pty) Ltd-Central Professional Suits	Gauteng		South Africa	1619
1541	Centre For Diabetes And Endocrinology	Johannesburg		South Africa	2198
1542	Paarl Research Centre	Paarl		South Africa	7646
1543	TREAD Research cc	Parow		South Africa	7500
1544	Clinical Projects Research SA (Pty) Ltd	Worcester		South Africa	6850
1545	Hospital Clinico Universitario de Santiago de Compostela	Santiago de Compostela	A Coruna	Spain	15706
1546	Hospital Universitario de Santiago de Compostela	Santiago de Compostela	A Coruna	Spain	15706
1547	Hospital Virgen De Los Lirios	Alcoy	Alicante	Spain	03804
1548	Hospital General Comarcal de Elda Virgen de la Salud	Elda	Alicante	Spain	03600
1549	Hospital Regional Universitario de Malaga	Malaga	Andalucia	Spain	29010
1550	Hospital Universitario Virgen del Rocio	Sevilla	Andalucia	Spain	41013
1551	Centro de Salud El Cristo	Oviedo	Asturias	Spain	33006
1552	Centro Salud Paulino Prieto	Oviedo	Asturias	Spain	33009
1553	Cap Florida	L'Hospitalet De Llobregat	Barcelona-cataluna	Spain	08905
1554	Hospital General de Granollers	Granollers	Barcelona/cataluña	Spain	08400
1555	Hospital Universitari de Bellvitge	L'Hospitalet de Llobregat	Barcelona	Spain	08907
1556	Hospital Universitario de Bellvitge	L'Hospitalet de Llobregat	Barcelona	Spain	08907
1557	CAP La Mina	Sant Adria De Besos	Barcelona	Spain	08930
1558	EAP Vic	Vic	Barcelona	Spain	08500
1559	Hospital Universitario Marques de Valdecilla	Santander	Cantabria	Spain	39008
1560	Institut Catala De La Salut - Hospital Universitari Arnau De Vilanova (Huav)	Lleida	Catalonia	Spain	25198
1561	Hospital Universitari de Tarragona Joan XXIII	Tarragona	Catalonia	Spain	43007
1562	Hospital Universitario San Juan de Alicante	San Juan De Alicante (Alicante)	Comunidad Valenciana	Spain	03550
1563	Albera Salut	Peralada	Gerona	Spain	17491
1564	Hospital De Figueres	Figueres	Girona-catalonia	Spain	17600
1565	Hospital Comarcal d'Inca	Inca	Illes Balears	Spain	07300
1566	Clinica Juaneda	Palma de Mallorca	Islas Baleares	Spain	07014
1567	Hospital Son Llatzer	Palma de Mallorca	Islas Baleares	Spain	07198
1568	Hospital Arquitecto Marcide	El Ferrol	LA Coruna	Spain	15405
1569	H. U. Principe de Asturias	Alcala De Henares	Madrid	Spain	28805
1570	Hospital Principe de Asturias	Alcala De Henares	Madrid	Spain	28805
1571	Hospital Universitario Principe de Asturias	Alcala De Henares	Madrid	Spain	28805
1572	Hospital Universitario Fundacion Alcorcon	Alcorcon	Madrid	Spain	28922
1573	Hospital Universitario Puerta de Hierro - Majadahonda	Majadahonda	Madrid	Spain	28222
1574	Hospital Universitario Puerta de Hierro	Majadahonda	Madrid	Spain	28222
1575	Complejo Hospitalario de Navarra	Pamplona	Navarra	Spain	31008
1576	Consultorio de Colloto	Colloto	Oviedo Asturias	Spain	33010
1577	Hospital Universitario de Cruces	Barakaldo	PAIS Vasco	Spain	48903
1578	Hospital Universitario Sant Joan de Reus	Reus	Tarragona	Spain	43204
1579	Hospital General de Requena	Requena	Valencia	Spain	46340
1580	Hospital Abente y Lago	A Coruna		Spain	15001
1581	Complejo Hospitalario Universitario A Coruna	A Coruna		Spain	15006
1582	Complejo Hospitalario Universitario de Albacete	Albacete		Spain	02006
1583	Hospital General Universitario de Alicante; Servicio Cardiologia	Alicante		Spain	03010
1584	Hospital Virgen del Mar	Almeria		Spain	04120
1585	Cap Disset De Setembre (Sant Cosme I Sant Damia)	Barcelona/Cataluna		Spain	08820
1586	Hospital General De Granollers	Barcelona/Cataluña		Spain	08400
1587	Parc de Salut mar ¿ Hospital del Mar	Barcelona		Spain	08003
1588	Parc De Salut Mar-Hospital Del Mar	Barcelona		Spain	08003
1589	Centre Teknon	Barcelona		Spain	08022
1590	EAP Sardenya	Barcelona		Spain	08025
1591	Hospital de la Santa Creu i Sant pau	Barcelona		Spain	08025
1592	Hospital Universitari Vall d'Hebron	Barcelona		Spain	08035
1593	CAP Centelles	Barcelona		Spain	08540
1594	Fundacio Hospital de I'Esperit Sant	Barcelona		Spain	08923
1595	H. General Universitario de Ciudad Real	Ciudad Real		Spain	13005
1596	Hospital Universitario Reina Sofia	Cordoba		Spain	14004
1597	Complexo Hospitalario Universitario Arquitecto Marcide-Profesor Novoa Santos De Ferrol	Ferrol		Spain	15401
1598	Hospital Universitario San Cecilio de Granada	Granada		Spain	18012
1599	Hospital Universitario Virgen de las Nieves (HUVN)	Granada		Spain	18014
1600	Hospital Universitari Arnau de Vilanova	Lleida		Spain	25198
1601	Hospital Universitario Lucus Augusti	Lugo		Spain	27003
1602	Hospital Universitario de La Princesa	Madrid		Spain	28006
1603	Hospital General Universitario Gregorio Maranon	Madrid		Spain	28007
1604	Hospital Carlos III	Madrid		Spain	28029
1605	Hospital Universitario Ramon y Cajal	Madrid		Spain	28034
1606	Fundacion Jimenez Diaz	Madrid		Spain	28040
1607	Hospital Universitario Fundacion Jimenez Diaz	Madrid		Spain	28040
1608	Hospital Universitario La Paz; Unidad Metabolico-Vascular	Madrid		Spain	28046
1609	Hospital Universitario Quiron Madrid	Madrid		Spain	28223
1610	Hospital Universitario Virgen de la Victoria	Malaga		Spain	29006
1611	Hospital Regional Universitario de Malaga	Malaga		Spain	29009
1612	Hospital Universitario Virgen De La Victoria	Malaga		Spain	29010
1613	Hospital General Universitario Morales Meseguer	Murcia		Spain	30008
1614	Clinica Nuevas Tecnologias en Diabetes y Endocrinologia	Sevilla		Spain	41003
1615	Hospital Universitario Virgen Macarena	Sevilla		Spain	41009
1616	Hospital Universitario Virgen del Rocio	Sevilla		Spain	41013
1617	Hospital Universitario Virgen de Valme	Sevilla		Spain	41014
1618	CAP Muralles	Tarragona		Spain	43002
1619	Hospital General Universitario de Valencia	Valencia		Spain	46014
1620	Hospital Alvaro Cunqueiro (Hospital Meixoerio)	Vigo		Spain	36312
1621	Hospital Clinico Universitario Miguel Servet; Medicina Interna	Zaragoza		Spain	50009
1622	Karolinska Universitetssjukhuset Huddinge	Stockholm	Huddinge	Sweden	141 86
1623	Kasernens Läkarservice AB	Eksjö		Sweden	57535
1624	Clinical Trial Center (CTC)/Centrum foer klinisk proevning	Goteborg		Sweden	413 45
1625	Sahlgrenska Universitetssjukhuset	Goteborg		Sweden	41345
1626	Centrum for klinisk provning-Sahlgrenska Universitetssjukhus	Gothenburg		Sweden	41345
1627	Pharmasite AB	Helsingborg		Sweden	25220
1628	Centralsjukhuset Karlstad	Karlstad		Sweden	65185
1629	Centralsjukhuset Kristianstad	Kristianstad		Sweden	291 85
1630	Capio Citykliniken Hjartmottagning	Lund		Sweden	221 21
1631	Probar E Lund AB	Lund		Sweden	222 22
1632	Karlkliniken, Skanes Universitetssjukhus i Malmo	Malmo		Sweden	205 02
1633	Pharmasite	Malmo		Sweden	211 52
1634	Forskningsenheten, Medicinmottagningen Sahlgrenska Universitetssjukhuset/Molndal, Hus J	Molndal		Sweden	431 80
1635	Ostersunds Sjukhus	Ostersund		Sweden	83183
1636	Dalecarlia Clinical Research Center	Rattvik		Sweden	79530
1637	Skelleftea Lasarett	Skelleftea		Sweden	93186
1638	Citydiabetes	Stockholm		Sweden	111 57
1639	Karolinska Trial Alliance, KTA Prim	Stockholm		Sweden	113 24
1640	Södersjukhuset Ab	Stockholm		Sweden	118 83
1641	Karolinska Universitetssjukhuset	Stockholm		Sweden	17176
1642	Hjartkliniken	Stockholm		Sweden	188 82
1643	Akademiska Sjukhuset	Uppsala		Sweden	75185
1644	Vastmanlands Sjukhus Vasteras	Vasteras		Sweden	721 89
1645	Universitatsspital	Basel	Basel Stadt	Switzerland	4031
1646	Diagene Laboratories	Reinach	Basel Switzerland	Switzerland	4153
1647	Fondazione Diabete Lugano	Lugano	Ticino	Switzerland	6900
1648	Policlinique Medicale Universitaire	Lausanne	Vaud	Switzerland	1011
1649	Centre Hospitalier Universitaire Vaudois (CHUV)	Lausanne	VD	Switzerland	1011
1650	Kantonsspital Winterthur	Winterthur	Zurich	Switzerland	8401
1651	Hopitaux Universitaires de Geneve	Geneve		Switzerland	1211
1652	Cardiocentro Ticino	Lugano		Switzerland	CH-6900
1653	Luzerner Kantonsspital Luzern	Luzern 16		Switzerland	CH-6000
1654	Kantonsspital St. Gallen	St. Gallen		Switzerland	CH-9007
1655	China Medical University Hospital	Taichung	Taiwan R O C	Taiwan	40447
1656	Chung Shan Medical University Hospital	Taichung	Taiwan ROC	Taiwan	40201
1657	Kaohsiung Medical University Chung-Ho Memorial Hospital - New	Kaohsiung		Taiwan	807
1658	National Cheng Kung University (NCKU) Hospital	Tainan		Taiwan	70403
1659	National Cheng Kung University Hospital	Tainan		Taiwan	70403
1660	National Taiwan University Hospital	Taipei		Taiwan	10002
1661	MacKay Memorial Hospital	Taipei		Taiwan	10449
1662	Taipei Veterans General Hospital	Taipei		Taiwan	11217
1663	Division of Cardiology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol	Bangkoknoi	Bangkok	Thailand	10700
1664	Clinical Research Center, Phramongkutklao Hospital	Rajathevee	Bangkok	Thailand	10400
1665	Endocrine Unit, Department of Medicine, Phramongkutklao Hospital	Rajathevee	Bangkok	Thailand	10400
1666	Cardiology Unit, Department of Medicine, Faculty of Medicine,Ramathibodi Hospital,Mahidol University	Ratchathewi	Bangkok	Thailand	10400
1667	Division of Cardiology, Department of medicine,Faculty of Medicine, Srinagarind Hospital, Khon Kaen	Muang	Khon Kaen	Thailand	40002
1668	Division of Cardiology, Department of Medicine, Faculty of Medicine, Songklanagarind Hospital,	Hat Yai	Songkhla	Thailand	90110
1669	Heart Center, Songklanagarind Prince of Songkla University	Hat Yai	Songkla	Thailand	90110
1670	Division Of cardiology,Department of Medicine,Faculty Of Medicine,Chulalongkorn University	Bangkok		Thailand	10400
1671	Dokuz Eylul Univesitesi Tip Fakultesi Hastanesi	Izmir	Ankara	Turkey	35340
1672	Baskent University, Adana Yuregir Training & Research Hospital	Adana		Turkey	01250
1673	A.karahisar Kocatepe Universitesi Hastanesi Ahmet Necdet Sezer Uygulama ve Arastirma Hastanesi	Afyonkarahisar		Turkey	03200
1674	Diskapi Yildirim Beyazit Egitim ve Arastirma Hastanesi	Ankara		Turkey	06110
1675	Akdeniz Universitesi Tip Fakultesi Hastanesi	Antalya		Turkey	07058
1676	Akdeniz Universitesi Tip Fakultesi	Antalya		Turkey	07059
1677	Antalya Training & Research Hospital	Antalya		Turkey	07100
1678	Bursa Yuksek Ihtisas Egitim ve Arastirma Hastanesi	Bursa		Turkey	16320
1679	Gaziantep Universitesi Tip Fakultesi Sahinbey Egitim ve Arastirma Hastanesi	Gaziantep		Turkey	27310
1680	Bezmialem Vakif Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali	Istanbul		Turkey	34093
1681	Bezmialem Vakif Universitesi Tip Fakultesi Kardiyoloji Bolumu	Istanbul		Turkey	34093
1682	Istanbul Universitesi Istanbul Tip Fakultesi	Istanbul		Turkey	34093
1683	Istanbul Universitesi Kardiyoloji Enstitusu	Istanbul		Turkey	34096
1684	Yeditepe University School of Medicine	Istanbul		Turkey	34752
1685	Ege University, School of Medicine	Izmir		Turkey	35100
1686	Dokuz Eylul Universitesi Tip Fakultesi	Izmir		Turkey	35340
1687	Kocaeli University School Of Medicine-Kocaeli Universitesi Tip Fakultesi	Kocaeli		Turkey	41380
1688	Dumlupinar Universitesi Kutahya Evliya Celebi EAH	Kutahya		Turkey	43100
1689	Mersin University, School of Medicine	Mersin		Turkey	33343
1690	Recep Tayyip Erdogan University School of Medicine, Training & Research Hospital	Rize		Turkey	53020
1691	Synexus Thames Valley Clinical Research Centre	Reading	Berkshire	United Kingdom	RG2 0TG
1692	Westongrove Research Centre	Aylesbury	Buckinghamshire	United Kingdom	HP22 5LB
1693	Peterborough City Hospital	Peterborough	Cambridgeshire	United Kingdom	PE3 9GZ
1694	Morrab Surgery	Penzance	Cornwall	United Kingdom	TR18 4EL
1695	Brannel Surgery	St Austell	Cornwall	United Kingdom	PL26 7RL
1696	The Michael White Centre for Diabetes & Endocrinology, Hull Royal Infirmary	Hull	EAST Yorkshire	United Kingdom	HU3 2RW
1697	Queen's Hospital	Romford	Essex	United Kingdom	RM7 0AG
1698	Synexus Manchester Clinical Research Centre-Manchester Science Park	Manchester	Greater Manchester	United Kingdom	M15 6SX
1699	Royal Oldham Hospital	Oldham	Greater Manchester	United Kingdom	OL1 2JH
1700	St Francis Surgery	Chandlers Ford	Hampshire	United Kingdom	SO53 2ZH
1701	Lister Hospital	Stevenage	Hertfordshire	United Kingdom	SG1 4AB
1702	East and North Hertfordshire NHS Trust	Welwyn Garden City	Hertfordshire	United Kingdom	AL7 4HQ
1703	Howlands Clinic - Queen Elizabeth II Hospital	Welwyn Garden City	Hertfordshire	United Kingdom	AL7 4HQ
1704	Synexus Scotland Clinical Research Centre	Glasgow	Lanarkshire	United Kingdom	G20 0SP
1705	Layton Medical Centre	Blackpool	Lancashire	United Kingdom	FY3 7EN
1706	Synexus Lancashire Clinical Research Centre	Chorley	Lancashire	United Kingdom	PR7 7NA
1707	Salford Royal NHS Foundation Trust - Dermatology Centre	Salford	M6 8hd	United Kingdom	M6 8HD
1708	Synexus Merseyside Clinical Research Centre	Liverpool	Merseyside	United Kingdom	L22 0LG
1709	The Royal Liverpool and Broadgreen -University Hospitals NHS Trust	Liverpool	Merseyside	United Kingdom	L78XP
1710	Whitby Group Practice	Whitby	North Yorkshire	United Kingdom	YO21 1SD
1711	Albany House Medical Centre	Wellingborough	Northants	United Kingdom	NN84RW
1712	Southern Health & Social Care Trust, Craigavon Area Hospital	Portadown	Northern Ireland	United Kingdom	BT63 5QQ
1713	Synexus North East Clinical Research Centre - Hexham General Hospital	Hexham	Northumberland	United Kingdom	NE46 1QJ
1714	South Axholme Practice	Doncaster	South Yorkshire	United Kingdom	DN9 2HY
1715	Central Manchester University Hospitals NHS Foundation Trust	Manchester	South Yorkshire	United Kingdom	M13 9WL
1716	The Crouch Oak Family Practice	Addlestone	Surrey	United Kingdom	KT15 2BH
1717	Ely Bridge Surgery	Cardiff	Wales	United Kingdom	CF5 4AD
1718	Synexus Midlands Clinical Research Centre	Birmingham	WEST Midlands	United Kingdom	B15 2SQ
1719	City Hospital	Birmingham	WEST Midlands	United Kingdom	B18 7QH
1720	Heart of England NHS Trust	Birmingham	West Mids	United Kingdom	B9 5SS
1721	Prince Philip Hospital	Llanelli	WEST Wales	United Kingdom	SA14 8QF
1722	Royal Free London NHS Foundation Trust	Barnet		United Kingdom	EN5 3DJ
1723	Royal Victoria Hospital	Belfast		United Kingdom	BT12 6BA
1724	Laurie Pike Health Centre	Birmingham		United Kingdom	B6 6BB
1725	Heart of England NHS Foundation Trust, Dept. of Clinical Biochemistry & Immunology	Birmingham		United Kingdom	B9 5SS
1726	Royal Bolton Hospital - Bolton Nhs Foundation Trust	Bolton		United Kingdom	BL4 0JR
1727	Synexus Wales Clinical Research Centre	Cardiff		United Kingdom	CF14 5GJ
1728	Ashgate Medical Practice	Chesterfield		United Kingdom	S404AA
1729	Conquest Hospital - East Sussex Healthcare NHS Trust	East Sussex		United Kingdom	TN37 7RD
1730	Little Common Surgery	East Sussex		United Kingdom	TN39 4SP
1731	Sea Road Surgery	East Sussex		United Kingdom	TN40 1JJ
1732	Staploe Medical Centre	Ely		United Kingdom	CB7 5JD
1733	The Queen Elizabeth University Hospital- NHS Greater Glasgow and Clyde	Glasgow		United Kingdom	G51 4TF
1734	McGlone Practice Baillieston Health Centre	Glasgow		United Kingdom	G69 7AD
1735	Burbage Surgery	Hinckley		United Kingdom	LE10 2SE
1736	William Harvey Heart Centre (WHHC)	London		United Kingdom	EC1M 6BQ
1737	Royal Free Hospital	London		United Kingdom	NW3 2QG
1738	Peart-Rose Research Unit, Hammersmith Hospital, Imperial College NHS Trust	London		United Kingdom	W12 OHS
1739	The Red Porto cabin, The James Cook University Hospital	Middlesbrough		United Kingdom	TS4 3BW
1740	St Mary's Hospital	Newport		United Kingdom	PO30 5TG
1741	Wansford And Kings Cliffe Practice	Peterborough		United Kingdom	PE8 6PL
1742	Rothwell and Desborough Healthcare Group	Rothwell, Northants		United Kingdom	NN14 6JQ
1743	Abertawe Bro Morgannwg University Local Health Board	Swansea		United Kingdom	SA2 8PP
1744	Western Sussex Hospitals NHS Trust	Worthing		United Kingdom	BN11 2DH
1745	York Medical Group	York		United Kingdom	YO30 6AE
1746	Strensall Healthcare Centre	York		United Kingdom	YO32 5UA

Sponsors and Collaborators

• Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center, Pfizer

Study Documents (Full-Text)

• Study Protocol - Feb 12, 2016
• Statistical Analysis Plan - Dec 20, 2016

More Information

Additional Information:

• To obtain contact information for a study center near you, click here.

Publications

None provided.

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT01975376
• Other Study ID Numbers: B1481022; CV OUTCOMES 1; 2013-002646-36; CV OUTCOMES 2
• First Posted: Nov 3, 2013
• Last Update Posted: Jul 11, 2018
• Last Verified: Jun 1, 2018

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Pfizer: myocardial infarction; stroke; hyperlipidemia
• Additional relevant MeSH terms: Cardiovascular Diseases; Bococizumab

Study Results

Participant Flow

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Period Title: Overall Study
STARTED	8390	8394
Treated	8374	8386
COMPLETED	8164	8177
NOT COMPLETED	226	217

Baseline Characteristics

Arm/Group Title	Placebo	Bococizumab (PF-04950615)	Total
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Total of all reporting groups
Overall Participants	8390	8394	16784
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	63.3 (9.2)	63.3 (9.1)	63.3 (9.1)
Sex: Female, Male (Count of Participants)
Female	2223 26.5%	2207 26.3%	4430 26.4%
Male	6167 73.5%	6187 73.7%	12354 73.6%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	1758 21%	1746 20.8%	3504 20.9%
Not Hispanic or Latino	6631 79%	6642 79.1%	13273 79.1%
Unknown or Not Reported	1 0%	6 0.1%	7 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	354 4.2%	369 4.4%	723 4.3%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	392 4.7%	412 4.9%	804 4.8%
White	7315 87.2%	7280 86.7%	14595 87%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	329 3.9%	333 4%	662 3.9%

Outcome Measures

1. Primary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Major Cardiovascular (CV) Event
Description	Event rate per 100 participant-years for first occurrence of major CV event (adjudicated by Adjudication Committee) was reported. Major CV event was defined as any of the following: CV death (defined as sudden cardiac death, fatal myocardial infarction [MI], death due to heart failure, death due to stroke [fatal ischemic stroke or fatal stroke of undetermined etiology], or death due to other cardiovascular causes) non-fatal MI, non-fatal stroke, and hospitalization for unstable angina needing urgent revascularization. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of major CV event (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

Full analysis set (FAS): all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	3.02	3.01

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95 percent (%) Confidence Interval (CI) were from a Cox proportional hazards model stratified by geographic region and low density lipoprotein cholesterol (LDL-C) at pre-screening (less than [<] 100 milligrams per deciliters [mg/dL], greater than and equal to [>=] 100 mg/dL) with treatment as a co-variate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.930905
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95%; 0.80 to 1.22
	Parameter Dispersion	Type: Value:
	Estimation Comments

2. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of Cardiovascular Death, Non-Fatal Myocardial Infraction, or Non-Fatal Stroke
Description	Event rate per 100 participant-years for first occurrence of composite endpoint of CV death, non-fatal MI or non-fatal stroke (adjudicated by Adjudication Committee) was reported. Cardiovascular death was defined as sudden cardiac death, fatal MI, death due to heart failure, death due to stroke (fatal ischemic stroke or fatal stroke of undetermined etiology), or death due to other cardiovascular causes. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of the CV death, non-fatal MI or non-fatal stroke (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	2.49	2.59

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.784265
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.03
	Confidence Interval	(2-Sided) 95%; 0.82 to 1.30
	Parameter Dispersion	Type: Value:
	Estimation Comments

3. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of All-Cause Death, Non-Fatal Myocardial Infraction, Non-Fatal Stroke, or Hospitalization for Unstable Angina Needing Urgent Revascularization
Description	Event rate per 100 participant-years for first occurrence of composite endpoint of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for unstable angina needing urgent revascularization (adjudicated by Adjudication Committee) was reported. All-cause death was defined as the death due to any cause during the course of study. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of all-cause death, non-fatal MI, non-fatal stroke, or hospitalization for unstable angina needing urgent revascularization (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	3.51	3.48

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.892441
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.99
	Confidence Interval	(2-Sided) 95%; 0.81 to 1.20
	Parameter Dispersion	Type: Value:
	Estimation Comments

4. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of All-Cause Death, Non-Fatal Myocardial Infarction, or Non-Fatal Stroke
Description	Event rate per 100 participant-years for first occurrence of composite endpoint of all-cause death, non-fatal MI, or non-fatal stroke (adjudicated by adjudication committee) was reported. All-cause death was defined as the death due to any cause during the course of study. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of the all-cause death, non-fatal MI, or non-fatal stroke (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	2.98	3.06

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.845797
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.02
	Confidence Interval	(2-Sided) 95%; 0.83 to 1.26
	Parameter Dispersion	Type: Value:
	Estimation Comments

5. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Unstable Angina Needing Urgent Revascularization
Description	Event rate per 100 participant-years for first occurrence of hospitalization for unstable angina needing urgent revascularization (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of hospitalization for unstable angina needing urgent revascularization (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.57	0.47

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.431903
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.82
	Confidence Interval	(2-Sided) 95%; 0.49 to 1.36
	Parameter Dispersion	Type: Value:
	Estimation Comments

6. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Composite Endpoint of Cardiovascular Death, Non-Fatal Myocardial Infarction, Non-Fatal Stroke and Hospitalization for Unstable Angina
Description	Event rate per 100 participant-years for first occurrence of composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina (adjudicated by adjudication committee) was reported. Cardiovascular death was defined as sudden cardiac death, fatal MI, death due to heart failure, death due to stroke (fatal ischemic stroke or fatal stroke of undetermined etiology), or death due to other cardiovascular causes. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of cardiovascular death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	3.22	3.19

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.883797
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.98
	Confidence Interval	(2-Sided) 95%; 0.80 to 1.21
	Parameter Dispersion	Type: Value:
	Estimation Comments

7. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For Cardiovascular Death
Description	Event rate per 100 participant-years for cardiovascular death (adjudicated by adjudication committee) was reported. Cardiovascular death was defined as sudden cardiac death, fatal MI, death due to heart failure, death due to stroke (fatal ischemic stroke or fatal stroke of undetermined etiology), or death due to other cardiovascular causes. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of adjudicated and confirmed occurrence of cardiovascular death (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.52	0.64

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.455690
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.20
	Confidence Interval	(2-Sided) 95%; 0.74 to 1.95
	Parameter Dispersion	Type: Value:
	Estimation Comments

8. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Any Myocardial Infarction (Fatal or Non-Fatal)
Description	Event rate per 100 participant-years for first occurrence of any MI (fatal or non-fatal) (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of any MI (fatal or non-fatal) (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	1.56	1.74

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.469496
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.11
	Confidence Interval	(2-Sided) 95%; 0.84 to 1.48
	Parameter Dispersion	Type: Value:
	Estimation Comments

9. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For Fatal Myocardial Infarction
Description	Event rate per 100 participant-years for fatal MI (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of adjudicated and confirmed occurrence of fatal MI (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.03	0.05

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.633022
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.54
	Confidence Interval	(2-Sided) 95%; 0.26 to 9.23
	Parameter Dispersion	Type: Value:
	Estimation Comments

10. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Non-Fatal Myocardial Infarction
Description	Event rate per 100 participant-years for first occurrence of non-fatal MI (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of non-fatal MI (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	1.53	1.70

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.467650
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.11
	Confidence Interval	(2-Sided) 95%; 0.83 to 1.48
	Parameter Dispersion	Type: Value:
	Estimation Comments

11. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Any Stroke (Fatal or Non-Fatal)
Description	Event rate per 100 participant-years for first occurrence of any stroke (fatal or non-fatal) (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of any stroke (fatal or non-fatal) (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.71	0.38

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.015462
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.53
	Confidence Interval	(2-Sided) 95%; 0.32 to 0.89
	Parameter Dispersion	Type: Value:
	Estimation Comments

12. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Any Stroke (Fatal or Non-Fatal), of Any Etiology
Description	Event rate per 100 participant-years for first occurrence of any stroke (fatal or non-fatal), of any etiology (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of any stroke (fatal or non-fatal), of any etiology (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.79	0.43

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.011863
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.54
	Confidence Interval	(2-Sided) 95%; 0.33 to 0.88
	Parameter Dispersion	Type: Value:
	Estimation Comments

13. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For Fatal Stroke
Description	Event rate per 100 participant-years for fatal stroke (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of fatal stroke (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.10	0.05

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.316066
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.50
	Confidence Interval	(2-Sided) 95%; 0.12 to 2.00
	Parameter Dispersion	Type: Value:
	Estimation Comments

14. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Non-Fatal Stroke
Description	Event rate per 100 participant-years for first occurrence of non-fatal stroke (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of non-fatal stroke (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.62	0.33

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.020328
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.52
	Confidence Interval	(2-Sided) 95%; 0.30 to 0.91
	Parameter Dispersion	Type: Value:
	Estimation Comments

15. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Unstable Angina
Description	Event rate per 100 participant-years for first occurrence of hospitalization for unstable angina (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of hospitalization for unstable angina (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.78	0.64

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.367069
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.82
	Confidence Interval	(2-Sided) 95%; 0.53 to 1.27
	Parameter Dispersion	Type: Value:
	Estimation Comments

16. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Hospitalization for Congestive Heart Failure (CHF)
Description	Event rate per 100 participant-years for first occurrence of hospitalization for CHF (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of hospitalization for congestive heart failure (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.81	0.69

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.443081
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.85
	Confidence Interval	(2-Sided) 95%; 0.56 to 1.29
	Parameter Dispersion	Type: Value:
	Estimation Comments

17. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Coronary Revascularization
Description	Event rate per 100 participant-years for first occurrence of coronary revascularization (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of coronary revascularization (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	2.74	2.45

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.343817
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.90
	Confidence Interval	(2-Sided) 95%; 0.71 to 1.12
	Parameter Dispersion	Type: Value:
	Estimation Comments

18. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Coronary Artery Bypass Graft Surgery (CABG)
Description	Event rate per 100 participant-years for first occurrence of CABG (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of CABG (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	0.40	0.41

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.889065
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.04
	Confidence Interval	(2-Sided) 95%; 0.59 to 1.85
	Parameter Dispersion	Type: Value:
	Estimation Comments

19. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Percutaneous Coronary Intervention (PCI)
Description	Event rate per 100 participant-years for first occurrence of PCI (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of PCI (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	2.37	2.08

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.308388
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.88
	Confidence Interval	(2-Sided) 95%; 0.69 to 1.13
	Parameter Dispersion	Type: Value:
	Estimation Comments

20. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For First Occurrence of Any Arterial Revascularizations
Description	Event rate per 100 participant-years for first occurrence of any arterial revascularizations (adjudicated by adjudication committee) was reported. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of first adjudicated and confirmed occurrence of any arterial revascularizations (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	1.26	1.28

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.874835
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.03
	Confidence Interval	(2-Sided) 95%; 0.74 to 1.42
	Parameter Dispersion	Type: Value:
	Estimation Comments

21. Secondary Outcome

Title	Event Rate Per 100 Participant-Years For All-Cause Death
Description	Event rate per 100 participant-years for all-cause death (adjudicated by adjudication committee) was reported. All-cause death was defined as the death due to any cause during the course of study. Event rate was calculated as the number of events per 100 participant-years at risk.
Time Frame	From baseline until the date of adjudicated and confirmed occurrence of all-cause death (maximum duration: up to 3.4 years)

Outcome Measure Data

Analysis Population Description

FAS: all participants who were randomized, excluding who attempted to be randomized more than once into a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to be randomized in more than 1 CV outcomes trial and all participants enrolled at study Site 3027 where a quality-related event was identified.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Number (95% Confidence Interval) [Events Per 100 Participant-Years]	1.00	1.13

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Hazard ratio and 95% CI were from a Cox proportional hazards model stratified by geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL) with treatment as a covariate.
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.526269
	Comments
	Method	Log Rank
	Comments
Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	1.12
	Confidence Interval	(2-Sided) 95%; 0.79 to 1.60
	Parameter Dispersion	Type: Value:
	Estimation Comments

22. Secondary Outcome

Title	Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 14
Time Frame	Baseline, Week 14

Outcome Measure Data

Analysis Population Description

Analysis was performed on FAS. Here, "Number of participants analyzed "(N) signifies those participants who were evaluable for this outcome measure.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	6448	6439
Least Squares Mean (Standard Error) [Percent change]	3.40 (0.31)	-57.17 (0.31)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Lease Square (LS)- mean differences, associated 95% CI, and p-values were from a mixed model repeated measures (MMRM) model including observations through Week 70 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	-60.57
	Confidence Interval	(2-Sided) 95%; -61.43 to -59.71
	Parameter Dispersion	Type: Value:
	Estimation Comments

23. Secondary Outcome

Title	Nominal Change From Baseline in Low Density Lipoprotein Cholesterol at Week 14
Time Frame	Baseline, Week 14

Outcome Measure Data

Analysis Population Description

Analysis was performed on FAS. Here, "N" signifies number of participants who were evaluable for this outcome measure.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	6448	6439
Least Squares Mean (Standard Error) [mg/dL]	2.33 (0.28)	-52.37 (0.28)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	LS- mean differences and associated 95% CI, and p-values were from an MMRM model including observations through Week 70 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	-54.70
	Confidence Interval	(2-Sided) 95%; -55.48 to -53.92
	Parameter Dispersion	Type: Value:
	Estimation Comments

24. Secondary Outcome

Title	Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Last Post-Baseline Measurement
Time Frame	Baseline, last post-baseline measurement (any time up to Week 140)

Outcome Measure Data

Analysis Population Description

Analysis was performed on FAS. Here, "N" signifies number of participants who were evaluable for this outcome measure.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8240	8254
Least Squares Mean (Standard Error) [Percent Change]	5.05 (0.35)	-41.67 (0.35)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	LS- mean difference and associated 95% CI, and p-value were from an analysis of covariance (ANCOVA) model with fixed effects for treatment group, baseline value, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	-46.72
	Confidence Interval	(2-Sided) 95%; -47.68 to -45.76
	Parameter Dispersion	Type: Value:
	Estimation Comments

25. Secondary Outcome

Title	Percent Change From Baseline in Lipid Levels at Week 14
Description	Lipids included non-high density lipoprotein cholesterol (non-HDL-C), total cholesterol, very low density lipoprotein cholesterol (VLDL-C), remnant lipoprotein cholesterol (RLP-C), apolipoprotein B (Apo B), HDL-C and apolipoprotein A-I (Apo A-I).
Time Frame	Baseline, Week 14

Outcome Measure Data

Analysis Population Description

Analysis was performed on FAS. Here, number analyzed "n" signifies number of participants who were evaluable for the specified categories.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Non - HDL-C	3.21 (0.28)	-51.66 (0.28)
Total cholesterol	2.38 (0.20)	-34.13 (0.20)
VLDL - C	6.52 (0.45)	-13.65 (0.45)
RLP - C	9.23 (0.79)	-21.02 (0.79)
Apo B	2.80 (0.31)	-55.76 (0.31)
HDL - C	1.19 (0.16)	7.33 (0.16)
Apo A - I	1.21 (0.18)	4.74 (0.18)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Non-HDL-C: LS- mean differences, associated 95% CI, and p-values were from an MMRM model including observations through Week 70 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	-54.88
	Confidence Interval	(2-Sided) 95%; -55.66 to -54.09
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Total cholesterol: LS- mean differences, associated 95% CI, and p-values were from an MMRM model including observations through Week 70 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	-36.51
	Confidence Interval	(2-Sided) 95%; -37.07 to -35.95
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	VLDL-C: LS- mean differences, associated 95% CI, and p-values were from an MMRM model including observations through Week 70 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	-20.17
	Confidence Interval	(2-Sided) 95%; -21.42 to -18.93
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	RLP-C: LS- mean differences, associated 95% CI, and p-values were from an MMRM model including observations through Week 70 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-Mean Difference
	Estimated Value	-30.25
	Confidence Interval	(2-Sided) 95%; -32.44 to -28.07
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 5

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Apo B: LS -mean differences, associated 95% CI, and p-values were from an MMRM model including observations through Week 52 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-Mean Difference
	Estimated Value	-58.55
	Confidence Interval	(2-Sided) 95%; -59.42 to -57.69
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 6

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	HDL-C: LS- mean differences, associated 95% CI, and p-values were from an MMRM model including observations through Week 70 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-Mean Difference
	Estimated Value	6.14
	Confidence Interval	(2-Sided) 95%; 5.69 to 6.59
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 7

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Apo A-I: LS- mean differences, associated 95% CI, and p-values were from an MMRM model including observations through Week 52 with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction, geographic region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-Mean Difference
	Estimated Value	3.53
	Confidence Interval	(2-Sided) 95%; 3.02 to 4.03
	Parameter Dispersion	Type: Value:
	Estimation Comments

26. Secondary Outcome

Title	Percent Change From Baseline in Log-Transformed Lipoprotein (a) (Lp[a]) and Triglycerides at Week 14
Time Frame	Baseline, Week 14

Outcome Measure Data

Analysis Population Description

Analysis was performed on FAS. Here, number analyzed "n" signifies number of participants who were evaluable for the specified categories.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	8390	8394
Lp (a)	-1.3 (28.81)	-33.9 (29.62)
Triglycerides	0.6 (32.84)	-18.9 (28.44)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Lp (a): LS- mean differences and associated 95% CI, and p-values were from an MMRM model on the difference of log-transformed observations through Week 52 with fixed effects for treatment group, visit, treatment group*visit interaction, log-transformed baseline value, log-transformed baseline value*visit interaction, geographical region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	0.67
	Confidence Interval	(2-Sided) 95%; 0.66 to 0.68
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	Triglycerides: LS- mean differences and associated 95% CI, and p-values were from an MMRM model through Week 70 on the difference of log-transformed observations with fixed effects for treatment group, visit, treatment group*visit interaction, log-transformed baseline value, log-transformed baseline value*visit interaction, geographical region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	0.81
	Confidence Interval	(2-Sided) 95%; 0.80 to 0.81
	Parameter Dispersion	Type: Value:
	Estimation Comments

27. Secondary Outcome

Title	Percent Change From Baseline in Log-Transformed High Sensitivity C-Reactive Protein (Hs-CRP) at Week 14
Time Frame	Baseline, Week 14

Outcome Measure Data

Analysis Population Description

Analysis was performed on FAS. Here, "N" signifies number of participants who were evaluable for this outcome measure.

Arm/Group Title	Placebo	Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.	Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
Measure Participants	5931	5930
Mean (Standard Deviation) [Percent change]	-6.5 (88.28)	-1.1 (91.91)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Placebo, Bococizumab (PF-04950615)
	Comments	LS- mean differences and associated 95% CI, and p-values were from an MMRM model on the difference of log-transformed observations through Week 52 with fixed effects for treatment group, visit, treatment group*visit interaction, log-transformed baseline value, log-transformed baseline value*visit interaction, geographical region and LDL-C at pre-screening (<100 mg/dL, >=100 mg/dL).
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Mixed Effect Model Repeat Measurement
	Comments
Method of Estimation	Estimation Parameter	LS-mean difference
	Estimated Value	1.06
	Confidence Interval	(2-Sided) 95%; 1.03 to 1.10
	Parameter Dispersion	Type: Value:
	Estimation Comments

Adverse Events

Time Frame	Baseline up to 3.4 years
Adverse Event Reporting Description	Safety analysis set: all participants who randomized, had atleast 1 dose of study drug, excluding those attempted to randomize more than once in a bococizumab CV outcomes trial (B1481022/B1481038) or attempted to randomize in more than 1 CV outcomes trial, and all participants enrolled at study Site 3027 where a quality-related event was identified
Arm/Group Title	Placebo		Bococizumab (PF-04950615)
Arm/Group Description	Participants received single dose of placebo matched to PF-04950615 subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.		Participants received single dose of PF-04950615 150 milligrams, subcutaneous injection once every 2 weeks for upto 3 years. Participants were followed up to 40 days after the last dose.
All Cause Mortality
	Placebo		Bococizumab (PF-04950615)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	65/8374 (0.8%)		72/8386 (0.9%)
Serious Adverse Events
	Placebo		Bococizumab (PF-04950615)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	986/8374 (11.8%)		1060/8386 (12.6%)
Blood and lymphatic system disorders
Anaemia	8/8374 (0.1%)		6/8386 (0.1%)
Haemorrhagic anaemia	1/8374 (0%)		2/8386 (0%)
Iron deficiency anaemia	1/8374 (0%)		2/8386 (0%)
Leukocytosis	2/8374 (0%)		1/8386 (0%)
Lymphadenopathy	1/8374 (0%)		1/8386 (0%)
Pancytopenia	1/8374 (0%)		1/8386 (0%)
Cardiac disorders
Acute coronary syndrome	8/8374 (0.1%)		11/8386 (0.1%)
Acute left ventricular failure	1/8374 (0%)		0/8386 (0%)
Acute myocardial infarction	29/8374 (0.3%)		40/8386 (0.5%)
Angina pectoris	52/8374 (0.6%)		73/8386 (0.9%)
Angina unstable	84/8374 (1%)		65/8386 (0.8%)
Aortic valve stenosis	2/8374 (0%)		2/8386 (0%)
Arrhythmia	1/8374 (0%)		3/8386 (0%)
Arteriosclerosis coronary artery	4/8374 (0%)		2/8386 (0%)
Atrial fibrillation	32/8374 (0.4%)		27/8386 (0.3%)
Atrial flutter	9/8374 (0.1%)		3/8386 (0%)
Atrial tachycardia	0/8374 (0%)		1/8386 (0%)
Atrial thrombosis	0/8374 (0%)		1/8386 (0%)
Atrioventricular block complete	1/8374 (0%)		4/8386 (0%)
Atrioventricular block second degree	1/8374 (0%)		1/8386 (0%)
Bradycardia	3/8374 (0%)		7/8386 (0.1%)
Cardiac arrest	3/8374 (0%)		8/8386 (0.1%)
Cardiac discomfort	1/8374 (0%)		0/8386 (0%)
Cardiac disorder	0/8374 (0%)		1/8386 (0%)
Cardiac failure	19/8374 (0.2%)		21/8386 (0.3%)
Cardiac failure acute	2/8374 (0%)		3/8386 (0%)
Cardiac failure chronic	1/8374 (0%)		2/8386 (0%)
Cardiac failure congestive	32/8374 (0.4%)		24/8386 (0.3%)
Cardio-respiratory arrest	1/8374 (0%)		1/8386 (0%)
Cardiogenic shock	1/8374 (0%)		4/8386 (0%)
Coronary artery disease	31/8374 (0.4%)		30/8386 (0.4%)
Coronary artery dissection	0/8374 (0%)		1/8386 (0%)
Coronary artery insufficiency	0/8374 (0%)		1/8386 (0%)
Coronary artery occlusion	5/8374 (0.1%)		1/8386 (0%)
Coronary artery stenosis	4/8374 (0%)		5/8386 (0.1%)
Heart valve incompetence	1/8374 (0%)		0/8386 (0%)
Ischaemic cardiomyopathy	2/8374 (0%)		4/8386 (0%)
Left ventricular failure	1/8374 (0%)		2/8386 (0%)
Microvascular coronary artery disease	0/8374 (0%)		1/8386 (0%)
Myocardial infarction	32/8374 (0.4%)		35/8386 (0.4%)
Myocardial ischaemia	6/8374 (0.1%)		6/8386 (0.1%)
Palpitations	2/8374 (0%)		2/8386 (0%)
Pericardial effusion	0/8374 (0%)		2/8386 (0%)
Pericarditis	1/8374 (0%)		1/8386 (0%)
Sinus bradycardia	0/8374 (0%)		2/8386 (0%)
Sinus node dysfunction	0/8374 (0%)		2/8386 (0%)
Sinus tachycardia	0/8374 (0%)		1/8386 (0%)
Stress cardiomyopathy	1/8374 (0%)		0/8386 (0%)
Supraventricular tachycardia	1/8374 (0%)		6/8386 (0.1%)
Tachyarrhythmia	0/8374 (0%)		1/8386 (0%)
Tachycardia	1/8374 (0%)		2/8386 (0%)
Ventricular arrhythmia	0/8374 (0%)		2/8386 (0%)
Ventricular dysfunction	1/8374 (0%)		0/8386 (0%)
Ventricular fibrillation	0/8374 (0%)		3/8386 (0%)
Ventricular tachycardia	9/8374 (0.1%)		4/8386 (0%)
Congenital, familial and genetic disorders
Hereditary haemorrhagic telangiectasia	0/8374 (0%)		1/8386 (0%)
Ear and labyrinth disorders
Deafness unilateral	2/8374 (0%)		0/8386 (0%)
Eustachian tube dysfunction	1/8374 (0%)		0/8386 (0%)
Vertigo	4/8374 (0%)		3/8386 (0%)
Vestibular disorder	0/8374 (0%)		1/8386 (0%)
Endocrine disorders
Hyperparathyroidism	1/8374 (0%)		0/8386 (0%)
Hypothyroidism	1/8374 (0%)		0/8386 (0%)
Thyroid mass	0/8374 (0%)		2/8386 (0%)
Eye disorders
Angle closure glaucoma	0/8374 (0%)		1/8386 (0%)
Cataract	2/8374 (0%)		1/8386 (0%)
Diabetic retinopathy	1/8374 (0%)		1/8386 (0%)
Lens dislocation	0/8374 (0%)		1/8386 (0%)
Macular fibrosis	0/8374 (0%)		1/8386 (0%)
Optic ischaemic neuropathy	0/8374 (0%)		1/8386 (0%)
Retinal artery occlusion	0/8374 (0%)		1/8386 (0%)
Retinal detachment	3/8374 (0%)		1/8386 (0%)
Retinal exudates	0/8374 (0%)		1/8386 (0%)
Visual impairment	0/8374 (0%)		1/8386 (0%)
Vitreous haemorrhage	0/8374 (0%)		1/8386 (0%)
Gastrointestinal disorders
Abdominal discomfort	1/8374 (0%)		0/8386 (0%)
Abdominal distension	1/8374 (0%)		1/8386 (0%)
Abdominal hernia	1/8374 (0%)		0/8386 (0%)
Abdominal hernia obstructive	1/8374 (0%)		0/8386 (0%)
Abdominal pain	7/8374 (0.1%)		1/8386 (0%)
Abdominal pain lower	1/8374 (0%)		1/8386 (0%)
Abdominal pain upper	1/8374 (0%)		2/8386 (0%)
Abdominal wall haematoma	1/8374 (0%)		0/8386 (0%)
Anal polyp	1/8374 (0%)		0/8386 (0%)
Anal prolapse	0/8374 (0%)		1/8386 (0%)
Appendix disorder	0/8374 (0%)		1/8386 (0%)
Ascites	0/8374 (0%)		1/8386 (0%)
Chronic gastritis	0/8374 (0%)		1/8386 (0%)
Colitis	2/8374 (0%)		1/8386 (0%)
Colitis ischaemic	1/8374 (0%)		1/8386 (0%)
Colonic pseudo-obstruction	1/8374 (0%)		1/8386 (0%)
Constipation	1/8374 (0%)		3/8386 (0%)
Dental caries	1/8374 (0%)		0/8386 (0%)
Diarrhoea	2/8374 (0%)		1/8386 (0%)
Diverticulum intestinal	0/8374 (0%)		1/8386 (0%)
Diverticulum intestinal haemorrhagic	1/8374 (0%)		0/8386 (0%)
Duodenitis	0/8374 (0%)		1/8386 (0%)
Dyspepsia	1/8374 (0%)		1/8386 (0%)
Enteritis	0/8374 (0%)		1/8386 (0%)
Food poisoning	1/8374 (0%)		0/8386 (0%)
Gastric haemorrhage	2/8374 (0%)		0/8386 (0%)
Gastric perforation	0/8374 (0%)		1/8386 (0%)
Gastric polyps	1/8374 (0%)		0/8386 (0%)
Gastric ulcer	1/8374 (0%)		0/8386 (0%)
Gastric ulcer haemorrhage	0/8374 (0%)		1/8386 (0%)
Gastritis	0/8374 (0%)		3/8386 (0%)
Gastritis erosive	1/8374 (0%)		1/8386 (0%)
Gastroduodenitis	0/8374 (0%)		1/8386 (0%)
Gastrointestinal haemorrhage	6/8374 (0.1%)		5/8386 (0.1%)
Gastrointestinal necrosis	1/8374 (0%)		0/8386 (0%)
Gastrointestinal polyp haemorrhage	0/8374 (0%)		1/8386 (0%)
Gastrooesophageal reflux disease	0/8374 (0%)		3/8386 (0%)
Gingival bleeding	0/8374 (0%)		1/8386 (0%)
Haematemesis	1/8374 (0%)		0/8386 (0%)
Haemorrhoidal haemorrhage	1/8374 (0%)		1/8386 (0%)
Haemorrhoids	1/8374 (0%)		1/8386 (0%)
Hiatus hernia	0/8374 (0%)		2/8386 (0%)
Ileus	1/8374 (0%)		1/8386 (0%)
Impaired gastric emptying	1/8374 (0%)		3/8386 (0%)
Incarcerated umbilical hernia	0/8374 (0%)		1/8386 (0%)
Inguinal hernia	3/8374 (0%)		10/8386 (0.1%)
Intestinal haemorrhage	0/8374 (0%)		1/8386 (0%)
Intestinal ischaemia	1/8374 (0%)		0/8386 (0%)
Intestinal obstruction	1/8374 (0%)		0/8386 (0%)
Intestinal strangulation	1/8374 (0%)		0/8386 (0%)
Large intestine polyp	0/8374 (0%)		3/8386 (0%)
Lower gastrointestinal haemorrhage	1/8374 (0%)		2/8386 (0%)
Mechanical ileus	0/8374 (0%)		1/8386 (0%)
Melaena	1/8374 (0%)		0/8386 (0%)
Necrotising colitis	0/8374 (0%)		1/8386 (0%)
Obstruction gastric	0/8374 (0%)		1/8386 (0%)
Oesophageal spasm	0/8374 (0%)		1/8386 (0%)
Oesophageal stenosis	0/8374 (0%)		1/8386 (0%)
Oesophagitis	1/8374 (0%)		3/8386 (0%)
Pancreatitis	1/8374 (0%)		1/8386 (0%)
Pancreatitis acute	6/8374 (0.1%)		5/8386 (0.1%)
Peptic ulcer perforation	1/8374 (0%)		0/8386 (0%)
Rectal haemorrhage	2/8374 (0%)		2/8386 (0%)
Rectal polyp	0/8374 (0%)		2/8386 (0%)
Salivary gland enlargement	0/8374 (0%)		1/8386 (0%)
Short-bowel syndrome	0/8374 (0%)		1/8386 (0%)
Small intestinal obstruction	1/8374 (0%)		1/8386 (0%)
Small intestinal stenosis	0/8374 (0%)		1/8386 (0%)
Thrombosis mesenteric vessel	1/8374 (0%)		0/8386 (0%)
Tongue oedema	1/8374 (0%)		1/8386 (0%)
Ulcerative gastritis	1/8374 (0%)		0/8386 (0%)
Umbilical hernia	1/8374 (0%)		2/8386 (0%)
Upper gastrointestinal haemorrhage	1/8374 (0%)		2/8386 (0%)
Vomiting	2/8374 (0%)		0/8386 (0%)
General disorders
Asthenia	3/8374 (0%)		0/8386 (0%)
Cardiac death	1/8374 (0%)		0/8386 (0%)
Chest pain	16/8374 (0.2%)		15/8386 (0.2%)
Death	10/8374 (0.1%)		15/8386 (0.2%)
Electrocution	0/8374 (0%)		1/8386 (0%)
Fatigue	0/8374 (0%)		1/8386 (0%)
General physical health deterioration	0/8374 (0%)		1/8386 (0%)
Generalised oedema	0/8374 (0%)		1/8386 (0%)
Hyperplasia	1/8374 (0%)		0/8386 (0%)
Ill-defined disorder	1/8374 (0%)		0/8386 (0%)
Impaired healing	1/8374 (0%)		0/8386 (0%)
Inflammation	2/8374 (0%)		0/8386 (0%)
Injection site hypersensitivity	0/8374 (0%)		1/8386 (0%)
Injection site reaction	0/8374 (0%)		1/8386 (0%)
Mucosal inflammation	1/8374 (0%)		0/8386 (0%)
Multiple organ dysfunction syndrome	3/8374 (0%)		3/8386 (0%)
Necrosis	1/8374 (0%)		0/8386 (0%)
Non-cardiac chest pain	47/8374 (0.6%)		45/8386 (0.5%)
Oedema peripheral	0/8374 (0%)		1/8386 (0%)
Pain	0/8374 (0%)		2/8386 (0%)
Pelvic mass	1/8374 (0%)		0/8386 (0%)
Pyrexia	1/8374 (0%)		3/8386 (0%)
Sudden cardiac death	1/8374 (0%)		3/8386 (0%)
Sudden death	5/8374 (0.1%)		5/8386 (0.1%)
Systemic inflammatory response syndrome	1/8374 (0%)		0/8386 (0%)
Vascular stent restenosis	1/8374 (0%)		4/8386 (0%)
Vascular stent thrombosis	0/8374 (0%)		1/8386 (0%)
Hepatobiliary disorders
Bile duct stenosis	1/8374 (0%)		0/8386 (0%)
Bile duct stone	0/8374 (0%)		2/8386 (0%)
Biliary colic	1/8374 (0%)		1/8386 (0%)
Biliary dyskinesia	0/8374 (0%)		1/8386 (0%)
Cholangitis	0/8374 (0%)		2/8386 (0%)
Cholecystitis	8/8374 (0.1%)		8/8386 (0.1%)
Cholecystitis acute	2/8374 (0%)		5/8386 (0.1%)
Cholecystitis chronic	1/8374 (0%)		2/8386 (0%)
Cholecystocholangitis	0/8374 (0%)		1/8386 (0%)
Cholelithiasis	3/8374 (0%)		8/8386 (0.1%)
Drug-induced liver injury	1/8374 (0%)		0/8386 (0%)
Hepatic cirrhosis	0/8374 (0%)		1/8386 (0%)
Hepatic failure	1/8374 (0%)		1/8386 (0%)
Hepatitis	1/8374 (0%)		1/8386 (0%)
Non-alcoholic fatty liver	0/8374 (0%)		1/8386 (0%)
Immune system disorders
Anaphylactic shock	1/8374 (0%)		1/8386 (0%)
Hypersensitivity	0/8374 (0%)		3/8386 (0%)
Infections and infestations
Abdominal abscess	1/8374 (0%)		0/8386 (0%)
Abdominal wall abscess	1/8374 (0%)		0/8386 (0%)
Abscess limb	0/8374 (0%)		2/8386 (0%)
Abscess neck	1/8374 (0%)		0/8386 (0%)
Acute sinusitis	1/8374 (0%)		0/8386 (0%)
Anal abscess	1/8374 (0%)		3/8386 (0%)
Appendicitis	7/8374 (0.1%)		2/8386 (0%)
Arthritis bacterial	1/8374 (0%)		1/8386 (0%)
Arthritis infective	0/8374 (0%)		1/8386 (0%)
Bacterial sepsis	1/8374 (0%)		1/8386 (0%)
Bronchitis	8/8374 (0.1%)		1/8386 (0%)
Bursitis infective	0/8374 (0%)		1/8386 (0%)
Bursitis infective staphylococcal	1/8374 (0%)		0/8386 (0%)
Carbuncle	0/8374 (0%)		1/8386 (0%)
Cellulitis	13/8374 (0.2%)		11/8386 (0.1%)
Cellulitis of male external genital organ	0/6158 (0%)		1/6180 (0%)
Clostridium colitis	1/8374 (0%)		0/8386 (0%)
Clostridium difficile colitis	0/8374 (0%)		1/8386 (0%)
Clostridium difficile infection	1/8374 (0%)		0/8386 (0%)
Creutzfeldt-Jakob disease	0/8374 (0%)		1/8386 (0%)
Cystitis	0/8374 (0%)		1/8386 (0%)
Dermo-hypodermitis	1/8374 (0%)		0/8386 (0%)
Diabetic foot infection	1/8374 (0%)		4/8386 (0%)
Diverticulitis	7/8374 (0.1%)		5/8386 (0.1%)
Emphysematous pyelonephritis	0/8374 (0%)		1/8386 (0%)
Endocarditis	2/8374 (0%)		1/8386 (0%)
Endocarditis bacterial	1/8374 (0%)		0/8386 (0%)
Endocarditis enterococcal	1/8374 (0%)		0/8386 (0%)
Endometritis	1/8374 (0%)		0/8386 (0%)
Epididymitis	2/8374 (0%)		0/8386 (0%)
Erysipelas	3/8374 (0%)		4/8386 (0%)
Furuncle	0/8374 (0%)		1/8386 (0%)
Gangrene	2/8374 (0%)		3/8386 (0%)
Gastritis viral	0/8374 (0%)		1/8386 (0%)
Gastroenteritis	9/8374 (0.1%)		3/8386 (0%)
Gastroenteritis bacterial	1/8374 (0%)		0/8386 (0%)
Gastroenteritis salmonella	0/8374 (0%)		1/8386 (0%)
Gastroenteritis viral	1/8374 (0%)		0/8386 (0%)
Groin abscess	1/8374 (0%)		1/8386 (0%)
H1N1 influenza	1/8374 (0%)		0/8386 (0%)
Haematoma infection	1/8374 (0%)		0/8386 (0%)
Hepatitis E	1/8374 (0%)		0/8386 (0%)
Herpes zoster	2/8374 (0%)		0/8386 (0%)
Incision site infection	1/8374 (0%)		0/8386 (0%)
Infected bite	2/8374 (0%)		0/8386 (0%)
Infected fistula	1/8374 (0%)		0/8386 (0%)
Infected seroma	2/8374 (0%)		0/8386 (0%)
Infected skin ulcer	1/8374 (0%)		1/8386 (0%)
Infectious pleural effusion	1/8374 (0%)		0/8386 (0%)
Infective exacerbation of chronic obstructive airways disease	0/8374 (0%)		1/8386 (0%)
Influenza	0/8374 (0%)		3/8386 (0%)
Kidney infection	2/8374 (0%)		0/8386 (0%)
Klebsiella sepsis	0/8374 (0%)		1/8386 (0%)
Localised infection	1/8374 (0%)		3/8386 (0%)
Lower respiratory tract infection	2/8374 (0%)		2/8386 (0%)
Lower respiratory tract infection viral	0/8374 (0%)		1/8386 (0%)
Lung infection	0/8374 (0%)		1/8386 (0%)
Lyme disease	1/8374 (0%)		0/8386 (0%)
Nasopharyngitis	0/8374 (0%)		1/8386 (0%)
Orchitis	1/8374 (0%)		0/8386 (0%)
Osteomyelitis	0/8374 (0%)		8/8386 (0.1%)
Osteomyelitis bacterial	0/8374 (0%)		1/8386 (0%)
Osteomyelitis chronic	0/8374 (0%)		1/8386 (0%)
Otitis media	0/8374 (0%)		1/8386 (0%)
Paronychia	1/8374 (0%)		0/8386 (0%)
Penile infection	0/8374 (0%)		1/8386 (0%)
Periodontitis	0/8374 (0%)		1/8386 (0%)
Perirectal abscess	1/8374 (0%)		0/8386 (0%)
Peritonitis	1/8374 (0%)		0/8386 (0%)
Pneumonia	39/8374 (0.5%)		34/8386 (0.4%)
Pneumonia bacterial	0/8374 (0%)		1/8386 (0%)
Pneumonia viral	2/8374 (0%)		0/8386 (0%)
Post procedural cellulitis	1/8374 (0%)		0/8386 (0%)
Post procedural infection	1/8374 (0%)		0/8386 (0%)
Post procedural pneumonia	1/8374 (0%)		0/8386 (0%)
Prostatic abscess	1/6158 (0%)		0/6180 (0%)
Pyelonephritis	2/8374 (0%)		1/8386 (0%)
Pyelonephritis acute	0/8374 (0%)		2/8386 (0%)
Pyomyositis	1/8374 (0%)		0/8386 (0%)
Rectal abscess	1/8374 (0%)		1/8386 (0%)
Respiratory tract infection	1/8374 (0%)		1/8386 (0%)
Sepsis	8/8374 (0.1%)		7/8386 (0.1%)
Sepsis syndrome	2/8374 (0%)		0/8386 (0%)
Septic shock	5/8374 (0.1%)		2/8386 (0%)
Skin candida	0/8374 (0%)		1/8386 (0%)
Skin infection	0/8374 (0%)		1/8386 (0%)
Staphylococcal bacteraemia	1/8374 (0%)		0/8386 (0%)
Staphylococcal infection	1/8374 (0%)		2/8386 (0%)
Streptococcal infection	1/8374 (0%)		0/8386 (0%)
Subcutaneous abscess	0/8374 (0%)		2/8386 (0%)
Superinfection	1/8374 (0%)		0/8386 (0%)
Tonsillitis	1/8374 (0%)		0/8386 (0%)
Tracheitis	1/8374 (0%)		0/8386 (0%)
Tracheobronchitis	1/8374 (0%)		0/8386 (0%)
Tuberculosis	1/8374 (0%)		0/8386 (0%)
Upper respiratory tract infection	0/8374 (0%)		3/8386 (0%)
Urinary tract infection	13/8374 (0.2%)		15/8386 (0.2%)
Urosepsis	5/8374 (0.1%)		3/8386 (0%)
Vestibular neuronitis	0/8374 (0%)		1/8386 (0%)
Viral infection	1/8374 (0%)		1/8386 (0%)
Viral sepsis	0/8374 (0%)		1/8386 (0%)
Viral upper respiratory tract infection	0/8374 (0%)		1/8386 (0%)
Visceral leishmaniasis	1/8374 (0%)		0/8386 (0%)
Wound infection	1/8374 (0%)		1/8386 (0%)
Wound infection staphylococcal	0/8374 (0%)		1/8386 (0%)
Injury, poisoning and procedural complications
Acetabulum fracture	1/8374 (0%)		1/8386 (0%)
Anaemia postoperative	1/8374 (0%)		0/8386 (0%)
Animal bite	1/8374 (0%)		0/8386 (0%)
Ankle fracture	2/8374 (0%)		2/8386 (0%)
Arterial injury	1/8374 (0%)		0/8386 (0%)
Brain herniation	1/8374 (0%)		0/8386 (0%)
Burns second degree	0/8374 (0%)		1/8386 (0%)
Cardiac function disturbance postoperative	1/8374 (0%)		0/8386 (0%)
Cerebral ventricle collapse	1/8374 (0%)		0/8386 (0%)
Chest injury	0/8374 (0%)		1/8386 (0%)
Clavicle fracture	2/8374 (0%)		1/8386 (0%)
Concussion	2/8374 (0%)		1/8386 (0%)
Contusion	1/8374 (0%)		2/8386 (0%)
Coronary vascular graft occlusion	1/8374 (0%)		0/8386 (0%)
Craniocerebral injury	1/8374 (0%)		2/8386 (0%)
Eye injury	0/8374 (0%)		1/8386 (0%)
Fall	3/8374 (0%)		6/8386 (0.1%)
Femoral neck fracture	1/8374 (0%)		3/8386 (0%)
Femur fracture	0/8374 (0%)		4/8386 (0%)
Foot fracture	1/8374 (0%)		0/8386 (0%)
Gastrointestinal anastomotic leak	1/8374 (0%)		0/8386 (0%)
Gun shot wound	0/8374 (0%)		1/8386 (0%)
Head injury	2/8374 (0%)		1/8386 (0%)
Heat exhaustion	0/8374 (0%)		1/8386 (0%)
Hip fracture	5/8374 (0.1%)		5/8386 (0.1%)
Humerus fracture	1/8374 (0%)		2/8386 (0%)
Incisional hernia	2/8374 (0%)		1/8386 (0%)
Intentional overdose	1/8374 (0%)		0/8386 (0%)
Joint dislocation	1/8374 (0%)		1/8386 (0%)
Laceration	0/8374 (0%)		1/8386 (0%)
Ligament rupture	1/8374 (0%)		0/8386 (0%)
Limb injury	3/8374 (0%)		0/8386 (0%)
Lower limb fracture	1/8374 (0%)		2/8386 (0%)
Mallet finger	0/8374 (0%)		1/8386 (0%)
Meniscus injury	0/8374 (0%)		2/8386 (0%)
Multiple fractures	0/8374 (0%)		1/8386 (0%)
Multiple injuries	0/8374 (0%)		1/8386 (0%)
Muscle rupture	1/8374 (0%)		1/8386 (0%)
Muscle strain	0/8374 (0%)		1/8386 (0%)
Overdose	1/8374 (0%)		1/8386 (0%)
Patella fracture	1/8374 (0%)		1/8386 (0%)
Pelvic fracture	1/8374 (0%)		0/8386 (0%)
Peripheral artery restenosis	0/8374 (0%)		1/8386 (0%)
Post concussion syndrome	1/8374 (0%)		0/8386 (0%)
Post procedural complication	0/8374 (0%)		2/8386 (0%)
Post procedural haematoma	1/8374 (0%)		1/8386 (0%)
Post procedural haemorrhage	1/8374 (0%)		0/8386 (0%)
Post procedural oedema	1/8374 (0%)		0/8386 (0%)
Postoperative delirium	0/8374 (0%)		1/8386 (0%)
Postoperative thoracic procedure complication	1/8374 (0%)		0/8386 (0%)
Procedural complication	0/8374 (0%)		1/8386 (0%)
Procedural haemorrhage	1/8374 (0%)		0/8386 (0%)
Procedural hypertension	0/8374 (0%)		1/8386 (0%)
Procedural pain	2/8374 (0%)		0/8386 (0%)
Pubis fracture	0/8374 (0%)		1/8386 (0%)
Radius fracture	1/8374 (0%)		1/8386 (0%)
Rib fracture	4/8374 (0%)		4/8386 (0%)
Road traffic accident	7/8374 (0.1%)		1/8386 (0%)
Seroma	1/8374 (0%)		1/8386 (0%)
Skin abrasion	1/8374 (0%)		0/8386 (0%)
Skull fracture	0/8374 (0%)		2/8386 (0%)
Soft tissue injury	2/8374 (0%)		0/8386 (0%)
Spinal column injury	0/8374 (0%)		1/8386 (0%)
Spinal compression fracture	1/8374 (0%)		3/8386 (0%)
Spinal fracture	0/8374 (0%)		1/8386 (0%)
Subarachnoid haemorrhage	2/8374 (0%)		0/8386 (0%)
Subdural haematoma	4/8374 (0%)		3/8386 (0%)
Tendon injury	1/8374 (0%)		0/8386 (0%)
Tendon rupture	3/8374 (0%)		2/8386 (0%)
Thermal burn	1/8374 (0%)		0/8386 (0%)
Thoracic vertebral fracture	1/8374 (0%)		1/8386 (0%)
Tibia fracture	2/8374 (0%)		0/8386 (0%)
Toxicity to various agents	0/8374 (0%)		1/8386 (0%)
Traumatic intracranial haemorrhage	0/8374 (0%)		1/8386 (0%)
Ulna fracture	0/8374 (0%)		1/8386 (0%)
Upper limb fracture	4/8374 (0%)		1/8386 (0%)
Vascular bypass dysfunction	0/8374 (0%)		1/8386 (0%)
Vascular graft occlusion	2/8374 (0%)		0/8386 (0%)
Vascular pseudoaneurysm	2/8374 (0%)		1/8386 (0%)
Vena cava injury	1/8374 (0%)		0/8386 (0%)
Wound	0/8374 (0%)		1/8386 (0%)
Wound dehiscence	1/8374 (0%)		1/8386 (0%)
Wrist fracture	0/8374 (0%)		2/8386 (0%)
Investigations
Alanine aminotransferase increased	1/8374 (0%)		2/8386 (0%)
Aspartate aminotransferase increased	1/8374 (0%)		2/8386 (0%)
Blood creatine phosphokinase increased	1/8374 (0%)		2/8386 (0%)
Blood glucose decreased	0/8374 (0%)		1/8386 (0%)
Blood glucose increased	1/8374 (0%)		0/8386 (0%)
Blood pressure decreased	0/8374 (0%)		1/8386 (0%)
Blood pressure diastolic decreased	1/8374 (0%)		0/8386 (0%)
Cardiac stress test abnormal	0/8374 (0%)		1/8386 (0%)
Electrocardiogram abnormal	1/8374 (0%)		0/8386 (0%)
Gamma-glutamyltransferase increased	0/8374 (0%)		1/8386 (0%)
Heart rate abnormal	0/8374 (0%)		1/8386 (0%)
Hepatic enzyme increased	1/8374 (0%)		0/8386 (0%)
Hepatitis C virus test positive	0/8374 (0%)		1/8386 (0%)
International normalised ratio abnormal	0/8374 (0%)		1/8386 (0%)
International normalised ratio decreased	0/8374 (0%)		1/8386 (0%)
Liver function test abnormal	1/8374 (0%)		0/8386 (0%)
Liver function test increased	0/8374 (0%)		5/8386 (0.1%)
Stress echocardiogram abnormal	1/8374 (0%)		0/8386 (0%)
Weight decreased	0/8374 (0%)		1/8386 (0%)
Metabolism and nutrition disorders
Dehydration	4/8374 (0%)		7/8386 (0.1%)
Diabetes mellitus	0/8374 (0%)		4/8386 (0%)
Diabetes mellitus inadequate control	4/8374 (0%)		2/8386 (0%)
Diabetes with hyperosmolarity	0/8374 (0%)		1/8386 (0%)
Diabetic ketoacidosis	4/8374 (0%)		0/8386 (0%)
Fluid overload	1/8374 (0%)		0/8386 (0%)
Gout	2/8374 (0%)		0/8386 (0%)
Hyperglycaemia	0/8374 (0%)		5/8386 (0.1%)
Hyperkalaemia	3/8374 (0%)		1/8386 (0%)
Hyperosmolar hyperglycaemic state	1/8374 (0%)		0/8386 (0%)
Hypervolaemia	1/8374 (0%)		1/8386 (0%)
Hypoglycaemia	5/8374 (0.1%)		2/8386 (0%)
Hypokalaemia	1/8374 (0%)		3/8386 (0%)
Hypomagnesaemia	1/8374 (0%)		0/8386 (0%)
Hyponatraemia	1/8374 (0%)		1/8386 (0%)
Hypovolaemia	1/8374 (0%)		0/8386 (0%)
Insulin-requiring type 2 diabetes mellitus	1/8374 (0%)		0/8386 (0%)
Ketoacidosis	0/8374 (0%)		1/8386 (0%)
Lactic acidosis	1/8374 (0%)		0/8386 (0%)
Metabolic acidosis	0/8374 (0%)		1/8386 (0%)
Obesity	0/8374 (0%)		1/8386 (0%)
Type 2 diabetes mellitus	4/8374 (0%)		4/8386 (0%)
Vitamin B12 deficiency	0/8374 (0%)		1/8386 (0%)
Musculoskeletal and connective tissue disorders
Arthralgia	2/8374 (0%)		1/8386 (0%)
Arthritis	3/8374 (0%)		6/8386 (0.1%)
Arthropathy	0/8374 (0%)		1/8386 (0%)
Back pain	5/8374 (0.1%)		5/8386 (0.1%)
Bone lesion	1/8374 (0%)		0/8386 (0%)
Bursitis	1/8374 (0%)		1/8386 (0%)
Cervical spinal stenosis	3/8374 (0%)		1/8386 (0%)
Costochondritis	0/8374 (0%)		1/8386 (0%)
Diabetic arthropathy	0/8374 (0%)		1/8386 (0%)
Gouty arthritis	1/8374 (0%)		0/8386 (0%)
Intervertebral disc degeneration	0/8374 (0%)		1/8386 (0%)
Intervertebral disc disorder	1/8374 (0%)		0/8386 (0%)
Intervertebral disc protrusion	6/8374 (0.1%)		4/8386 (0%)
Knee deformity	0/8374 (0%)		1/8386 (0%)
Lumbar spinal stenosis	0/8374 (0%)		4/8386 (0%)
Muscle tightness	0/8374 (0%)		1/8386 (0%)
Muscular weakness	2/8374 (0%)		0/8386 (0%)
Musculoskeletal chest pain	3/8374 (0%)		10/8386 (0.1%)
Musculoskeletal pain	1/8374 (0%)		3/8386 (0%)
Myalgia	1/8374 (0%)		1/8386 (0%)
Neck pain	1/8374 (0%)		1/8386 (0%)
Osteoarthritis	18/8374 (0.2%)		22/8386 (0.3%)
Osteolysis	0/8374 (0%)		1/8386 (0%)
Osteonecrosis	1/8374 (0%)		1/8386 (0%)
Osteoporotic fracture	0/8374 (0%)		1/8386 (0%)
Pain in extremity	2/8374 (0%)		2/8386 (0%)
Rhabdomyolysis	1/8374 (0%)		2/8386 (0%)
Rheumatoid arthritis	1/8374 (0%)		0/8386 (0%)
Rotator cuff syndrome	3/8374 (0%)		6/8386 (0.1%)
Spinal column stenosis	2/8374 (0%)		3/8386 (0%)
Spinal osteoarthritis	3/8374 (0%)		2/8386 (0%)
Spinal pain	1/8374 (0%)		0/8386 (0%)
Spondylitis	1/8374 (0%)		0/8386 (0%)
Spondylolisthesis	1/8374 (0%)		1/8386 (0%)
Synovial cyst	0/8374 (0%)		2/8386 (0%)
Tendonitis	1/8374 (0%)		1/8386 (0%)
Trigger finger	0/8374 (0%)		1/8386 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma	1/8374 (0%)		1/8386 (0%)
Adenocarcinoma gastric	0/8374 (0%)		3/8386 (0%)
Adenocarcinoma of colon	0/8374 (0%)		1/8386 (0%)
Anal squamous cell carcinoma	0/8374 (0%)		1/8386 (0%)
B-cell lymphoma	2/8374 (0%)		0/8386 (0%)
Benign gastrointestinal neoplasm	0/8374 (0%)		1/8386 (0%)
Bile duct cancer	1/8374 (0%)		0/8386 (0%)
Bladder cancer	5/8374 (0.1%)		4/8386 (0%)
Bladder cancer recurrent	1/8374 (0%)		0/8386 (0%)
Bladder neoplasm	0/8374 (0%)		3/8386 (0%)
Bladder papilloma	1/8374 (0%)		0/8386 (0%)
Bladder transitional cell carcinoma	3/8374 (0%)		0/8386 (0%)
Bladder transitional cell carcinoma stage I	0/8374 (0%)		1/8386 (0%)
Bone cancer	0/8374 (0%)		1/8386 (0%)
Breast cancer	2/8374 (0%)		3/8386 (0%)
Breast cancer recurrent	1/8374 (0%)		0/8386 (0%)
Cholesteatoma	1/8374 (0%)		0/8386 (0%)
Chronic myelomonocytic leukaemia	1/8374 (0%)		0/8386 (0%)
Clear cell renal cell carcinoma	2/8374 (0%)		0/8386 (0%)
Colon cancer	1/8374 (0%)		0/8386 (0%)
Colon cancer metastatic	0/8374 (0%)		2/8386 (0%)
Colon cancer stage III	1/8374 (0%)		0/8386 (0%)
Colorectal cancer	2/8374 (0%)		0/8386 (0%)
Gastric adenoma	0/8374 (0%)		1/8386 (0%)
Gastric cancer	1/8374 (0%)		1/8386 (0%)
Gastrointestinal stromal tumour	0/8374 (0%)		1/8386 (0%)
Gastrointestinal tract adenoma	0/8374 (0%)		1/8386 (0%)
Gastrooesophageal cancer	2/8374 (0%)		0/8386 (0%)
Glioblastoma multiforme	0/8374 (0%)		2/8386 (0%)
Intestinal adenocarcinoma	1/8374 (0%)		0/8386 (0%)
Intraocular melanoma	1/8374 (0%)		0/8386 (0%)
Large cell lung cancer	0/8374 (0%)		1/8386 (0%)
Laryngeal cancer	1/8374 (0%)		0/8386 (0%)
Lip and/or oral cavity cancer stage 0	0/8374 (0%)		1/8386 (0%)
Lipoma	1/8374 (0%)		0/8386 (0%)
Liposarcoma	0/8374 (0%)		1/8386 (0%)
Lung adenocarcinoma	2/8374 (0%)		0/8386 (0%)
Lung adenocarcinoma metastatic	1/8374 (0%)		0/8386 (0%)
Lung cancer metastatic	2/8374 (0%)		0/8386 (0%)
Lung neoplasm	2/8374 (0%)		1/8386 (0%)
Lung neoplasm malignant	3/8374 (0%)		5/8386 (0.1%)
Lung squamous cell carcinoma stage III	0/8374 (0%)		1/8386 (0%)
Lymphoma	1/8374 (0%)		0/8386 (0%)
Malignant melanoma	3/8374 (0%)		3/8386 (0%)
Maxillofacial sinus neoplasm	0/8374 (0%)		1/8386 (0%)
Meningioma	1/8374 (0%)		0/8386 (0%)
Mesothelioma	1/8374 (0%)		0/8386 (0%)
Metastases to bone	1/8374 (0%)		2/8386 (0%)
Metastases to liver	1/8374 (0%)		4/8386 (0%)
Metastases to lymph nodes	0/8374 (0%)		1/8386 (0%)
Metastases to peritoneum	0/8374 (0%)		1/8386 (0%)
Metastases to spine	0/8374 (0%)		1/8386 (0%)
Metastatic malignant melanoma	1/8374 (0%)		0/8386 (0%)
Metastatic neoplasm	1/8374 (0%)		0/8386 (0%)
Metastatic squamous cell carcinoma	1/8374 (0%)		0/8386 (0%)
Nasal neoplasm	0/8374 (0%)		1/8386 (0%)
Neuroendocrine carcinoma	0/8374 (0%)		1/8386 (0%)
Non-small cell lung cancer	1/8374 (0%)		1/8386 (0%)
Oesophageal adenocarcinoma	1/8374 (0%)		0/8386 (0%)
Ovarian adenoma	0/2216 (0%)		1/2206 (0%)
Pancreatic carcinoma	2/8374 (0%)		2/8386 (0%)
Pancreatic neoplasm	1/8374 (0%)		1/8386 (0%)
Plasma cell myeloma	1/8374 (0%)		3/8386 (0%)
Prostate cancer	12/6158 (0.2%)		13/6180 (0.2%)
Prostate cancer metastatic	1/6158 (0%)		1/6180 (0%)
Prostatic adenoma	1/6158 (0%)		0/6180 (0%)
Rectal adenoma	2/8374 (0%)		0/8386 (0%)
Rectal cancer	1/8374 (0%)		2/8386 (0%)
Renal cancer	4/8374 (0%)		1/8386 (0%)
Renal cancer recurrent	1/8374 (0%)		0/8386 (0%)
Renal cell carcinoma	1/8374 (0%)		0/8386 (0%)
Small cell lung cancer	1/8374 (0%)		1/8386 (0%)
Soft tissue neoplasm	0/8374 (0%)		1/8386 (0%)
Squamous cell carcinoma	2/8374 (0%)		2/8386 (0%)
Squamous cell carcinoma of lung	1/8374 (0%)		0/8386 (0%)
Squamous cell carcinoma of the cervix	1/2216 (0%)		0/2206 (0%)
Tonsil cancer	1/8374 (0%)		0/8386 (0%)
Transitional cell carcinoma	0/8374 (0%)		1/8386 (0%)
Uterine leiomyoma	2/2216 (0.1%)		1/2206 (0%)
Nervous system disorders
Axonal neuropathy	1/8374 (0%)		0/8386 (0%)
Balance disorder	1/8374 (0%)		0/8386 (0%)
Basal ganglia haemorrhage	1/8374 (0%)		0/8386 (0%)
Brain stem infarction	1/8374 (0%)		0/8386 (0%)
Carotid arteriosclerosis	0/8374 (0%)		1/8386 (0%)
Carotid artery disease	0/8374 (0%)		1/8386 (0%)
Carotid artery occlusion	0/8374 (0%)		1/8386 (0%)
Carotid artery stenosis	8/8374 (0.1%)		14/8386 (0.2%)
Carpal tunnel syndrome	0/8374 (0%)		2/8386 (0%)
Cauda equina syndrome	1/8374 (0%)		1/8386 (0%)
Cerebellar haemorrhage	1/8374 (0%)		1/8386 (0%)
Cerebellar infarction	0/8374 (0%)		1/8386 (0%)
Cerebral artery occlusion	2/8374 (0%)		0/8386 (0%)
Cerebral haematoma	1/8374 (0%)		0/8386 (0%)
Cerebral haemorrhage	2/8374 (0%)		3/8386 (0%)
Cerebral infarction	1/8374 (0%)		3/8386 (0%)
Cerebral venous thrombosis	1/8374 (0%)		0/8386 (0%)
Cerebrovascular accident	6/8374 (0.1%)		3/8386 (0%)
Cervical radiculopathy	1/8374 (0%)		0/8386 (0%)
Chorea	1/8374 (0%)		0/8386 (0%)
Coma	1/8374 (0%)		0/8386 (0%)
Cubital tunnel syndrome	0/8374 (0%)		1/8386 (0%)
Diabetic neuropathy	1/8374 (0%)		0/8386 (0%)
Dizziness	3/8374 (0%)		8/8386 (0.1%)
Embolic stroke	1/8374 (0%)		0/8386 (0%)
Encephalopathy	2/8374 (0%)		0/8386 (0%)
Epilepsy	0/8374 (0%)		4/8386 (0%)
Facial paresis	1/8374 (0%)		2/8386 (0%)
Haemorrhage intracranial	0/8374 (0%)		1/8386 (0%)
Haemorrhagic cerebral infarction	1/8374 (0%)		0/8386 (0%)
Haemorrhagic stroke	2/8374 (0%)		2/8386 (0%)
Headache	1/8374 (0%)		4/8386 (0%)
Hemiparesis	1/8374 (0%)		3/8386 (0%)
Hypoaesthesia	1/8374 (0%)		1/8386 (0%)
Hypoglycaemic coma	1/8374 (0%)		0/8386 (0%)
Intraventricular haemorrhage	0/8374 (0%)		1/8386 (0%)
Ischaemic stroke	28/8374 (0.3%)		20/8386 (0.2%)
Lacunar infarction	1/8374 (0%)		0/8386 (0%)
Lacunar stroke	1/8374 (0%)		0/8386 (0%)
Loss of consciousness	3/8374 (0%)		0/8386 (0%)
Lumbar radiculopathy	1/8374 (0%)		1/8386 (0%)
Lumbosacral radiculopathy	0/8374 (0%)		2/8386 (0%)
Migraine	0/8374 (0%)		1/8386 (0%)
Nerve compression	3/8374 (0%)		0/8386 (0%)
Nervous system disorder	1/8374 (0%)		0/8386 (0%)
Paraesthesia	1/8374 (0%)		1/8386 (0%)
Partial seizures	1/8374 (0%)		1/8386 (0%)
Polyneuropathy	0/8374 (0%)		1/8386 (0%)
Post stroke epilepsy	0/8374 (0%)		1/8386 (0%)
Presyncope	6/8374 (0.1%)		4/8386 (0%)
Radiculopathy	2/8374 (0%)		0/8386 (0%)
Sciatica	2/8374 (0%)		3/8386 (0%)
Seizure	6/8374 (0.1%)		3/8386 (0%)
Syncope	13/8374 (0.2%)		17/8386 (0.2%)
Thalamus haemorrhage	1/8374 (0%)		0/8386 (0%)
Transient global amnesia	1/8374 (0%)		0/8386 (0%)
Transient ischaemic attack	19/8374 (0.2%)		21/8386 (0.3%)
Vascular dementia	1/8374 (0%)		0/8386 (0%)
Vertigo CNS origin	1/8374 (0%)		0/8386 (0%)
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous	0/2216 (0%)		1/2206 (0%)
Product Issues
Device battery issue	0/8374 (0%)		1/8386 (0%)
Device dislocation	2/8374 (0%)		3/8386 (0%)
Psychiatric disorders
Acute psychosis	0/8374 (0%)		1/8386 (0%)
Alcohol withdrawal syndrome	1/8374 (0%)		0/8386 (0%)
Alcoholism	1/8374 (0%)		0/8386 (0%)
Anxiety	1/8374 (0%)		1/8386 (0%)
Confusional state	2/8374 (0%)		1/8386 (0%)
Conversion disorder	1/8374 (0%)		0/8386 (0%)
Delirium	2/8374 (0%)		0/8386 (0%)
Depression	2/8374 (0%)		4/8386 (0%)
Depression suicidal	0/8374 (0%)		1/8386 (0%)
Factitious disorder	0/8374 (0%)		1/8386 (0%)
Major depression	1/8374 (0%)		2/8386 (0%)
Mental status changes	1/8374 (0%)		1/8386 (0%)
Personality disorder	1/8374 (0%)		0/8386 (0%)
Suicidal ideation	1/8374 (0%)		2/8386 (0%)
Suicide attempt	1/8374 (0%)		2/8386 (0%)
Renal and urinary disorders
Acute kidney injury	18/8374 (0.2%)		14/8386 (0.2%)
Acute prerenal failure	1/8374 (0%)		0/8386 (0%)
Calculus urethral	1/8374 (0%)		0/8386 (0%)
Chronic kidney disease	2/8374 (0%)		2/8386 (0%)
Cystitis noninfective	1/8374 (0%)		0/8386 (0%)
Haematuria	2/8374 (0%)		3/8386 (0%)
Hydronephrosis	0/8374 (0%)		1/8386 (0%)
Ischaemic nephropathy	0/8374 (0%)		1/8386 (0%)
Nephritis	0/8374 (0%)		1/8386 (0%)
Nephrolithiasis	4/8374 (0%)		6/8386 (0.1%)
Nephropathy	1/8374 (0%)		0/8386 (0%)
Renal artery stenosis	1/8374 (0%)		0/8386 (0%)
Renal cortical necrosis	1/8374 (0%)		0/8386 (0%)
Renal disorder	1/8374 (0%)		0/8386 (0%)
Renal failure	3/8374 (0%)		2/8386 (0%)
Renal impairment	2/8374 (0%)		0/8386 (0%)
Renal ischaemia	1/8374 (0%)		0/8386 (0%)
Stag horn calculus	0/8374 (0%)		1/8386 (0%)
Stress urinary incontinence	1/8374 (0%)		0/8386 (0%)
Ureterolithiasis	4/8374 (0%)		2/8386 (0%)
Urethral obstruction	0/8374 (0%)		1/8386 (0%)
Urinary bladder haemorrhage	1/8374 (0%)		0/8386 (0%)
Urinary incontinence	1/8374 (0%)		0/8386 (0%)
Urinary retention	1/8374 (0%)		2/8386 (0%)
Urinary tract obstruction	0/8374 (0%)		1/8386 (0%)
Reproductive system and breast disorders
Benign prostatic hyperplasia	5/6158 (0.1%)		1/6180 (0%)
Cystocele	1/2216 (0%)		0/2206 (0%)
Fallopian tube obstruction	0/2216 (0%)		1/2206 (0%)
Genital prolapse	0/2216 (0%)		1/2206 (0%)
Menorrhagia	1/2216 (0%)		0/2206 (0%)
Ovarian cyst	1/2216 (0%)		0/2206 (0%)
Prostatic dysplasia	1/6158 (0%)		0/6180 (0%)
Prostatic obstruction	0/6158 (0%)		1/6180 (0%)
Prostatitis	1/6158 (0%)		1/6180 (0%)
Prostatomegaly	1/6158 (0%)		0/6180 (0%)
Rectocele	1/2216 (0%)		0/2206 (0%)
Uterine polyp	0/2216 (0%)		1/2206 (0%)
Uterine prolapse	1/2216 (0%)		0/2206 (0%)
Vaginal haemorrhage	1/2216 (0%)		0/2206 (0%)
Vaginal prolapse	0/2216 (0%)		1/2206 (0%)
Vaginal ulceration	0/2216 (0%)		1/2206 (0%)
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema	2/8374 (0%)		1/8386 (0%)
Acute respiratory failure	5/8374 (0.1%)		3/8386 (0%)
Asthma	0/8374 (0%)		3/8386 (0%)
Atelectasis	1/8374 (0%)		1/8386 (0%)
Bronchial disorder	0/8374 (0%)		1/8386 (0%)
Bronchial hyperreactivity	1/8374 (0%)		0/8386 (0%)
Bronchiectasis	1/8374 (0%)		0/8386 (0%)
Bronchospasm	1/8374 (0%)		0/8386 (0%)
Chronic obstructive pulmonary disease	11/8374 (0.1%)		22/8386 (0.3%)
Chronic respiratory failure	1/8374 (0%)		0/8386 (0%)
Dyspnoea	13/8374 (0.2%)		10/8386 (0.1%)
Dyspnoea exertional	1/8374 (0%)		4/8386 (0%)
Emphysema	1/8374 (0%)		1/8386 (0%)
Epistaxis	2/8374 (0%)		7/8386 (0.1%)
Haemoptysis	2/8374 (0%)		1/8386 (0%)
Hypoxia	2/8374 (0%)		2/8386 (0%)
Interstitial lung disease	1/8374 (0%)		0/8386 (0%)
Lung disorder	1/8374 (0%)		0/8386 (0%)
Nasal disorder	1/8374 (0%)		0/8386 (0%)
Nasal turbinate hypertrophy	1/8374 (0%)		0/8386 (0%)
Oropharyngeal swelling	1/8374 (0%)		0/8386 (0%)
Pleural effusion	1/8374 (0%)		2/8386 (0%)
Pleurisy	1/8374 (0%)		1/8386 (0%)
Pleuritic pain	0/8374 (0%)		1/8386 (0%)
Pneumomediastinum	0/8374 (0%)		1/8386 (0%)
Pneumonia aspiration	0/8374 (0%)		1/8386 (0%)
Pneumonitis	0/8374 (0%)		1/8386 (0%)
Pneumothorax	0/8374 (0%)		3/8386 (0%)
Pulmonary artery thrombosis	0/8374 (0%)		1/8386 (0%)
Pulmonary embolism	1/8374 (0%)		8/8386 (0.1%)
Pulmonary hypertension	0/8374 (0%)		1/8386 (0%)
Pulmonary mass	1/8374 (0%)		0/8386 (0%)
Pulmonary oedema	4/8374 (0%)		1/8386 (0%)
Respiratory distress	1/8374 (0%)		1/8386 (0%)
Respiratory failure	5/8374 (0.1%)		5/8386 (0.1%)
Sinus disorder	0/8374 (0%)		1/8386 (0%)
Skin and subcutaneous tissue disorders
Angioedema	1/8374 (0%)		2/8386 (0%)
Cutaneous vasculitis	1/8374 (0%)		0/8386 (0%)
Decubitus ulcer	0/8374 (0%)		1/8386 (0%)
Dermatitis allergic	0/8374 (0%)		1/8386 (0%)
Diabetic foot	1/8374 (0%)		2/8386 (0%)
Petechiae	1/8374 (0%)		0/8386 (0%)
Psoriasis	0/8374 (0%)		2/8386 (0%)
Rash generalised	0/8374 (0%)		1/8386 (0%)
Skin lesion	1/8374 (0%)		0/8386 (0%)
Skin necrosis	0/8374 (0%)		1/8386 (0%)
Skin reaction	1/8374 (0%)		0/8386 (0%)
Skin ulcer	1/8374 (0%)		4/8386 (0%)
Social circumstances
Pregnancy of partner	1/6158 (0%)		1/6180 (0%)
Surgical and medical procedures
Hospitalisation	0/8374 (0%)		1/8386 (0%)
Vascular disorders
Accelerated hypertension	1/8374 (0%)		0/8386 (0%)
Aneurysm	1/8374 (0%)		1/8386 (0%)
Aortic aneurysm	9/8374 (0.1%)		5/8386 (0.1%)
Aortic stenosis	1/8374 (0%)		1/8386 (0%)
Arterial stenosis	1/8374 (0%)		0/8386 (0%)
Arteriosclerosis	2/8374 (0%)		2/8386 (0%)
Arteriovenous fistula	0/8374 (0%)		1/8386 (0%)
Arteritis	1/8374 (0%)		1/8386 (0%)
Brachiocephalic vein stenosis	1/8374 (0%)		0/8386 (0%)
Circulatory collapse	2/8374 (0%)		1/8386 (0%)
Deep vein thrombosis	2/8374 (0%)		1/8386 (0%)
Dry gangrene	0/8374 (0%)		1/8386 (0%)
Embolism arterial	1/8374 (0%)		0/8386 (0%)
Extremity necrosis	1/8374 (0%)		0/8386 (0%)
Femoral artery aneurysm	0/8374 (0%)		1/8386 (0%)
Granulomatosis with polyangiitis	0/8374 (0%)		1/8386 (0%)
Haematoma	2/8374 (0%)		2/8386 (0%)
Hypertension	6/8374 (0.1%)		8/8386 (0.1%)
Hypertensive crisis	3/8374 (0%)		2/8386 (0%)
Hypertensive emergency	1/8374 (0%)		0/8386 (0%)
Hypotension	6/8374 (0.1%)		8/8386 (0.1%)
Hypovolaemic shock	0/8374 (0%)		1/8386 (0%)
Iliac artery occlusion	1/8374 (0%)		0/8386 (0%)
Infarction	1/8374 (0%)		0/8386 (0%)
Intermittent claudication	4/8374 (0%)		1/8386 (0%)
Ischaemia	0/8374 (0%)		1/8386 (0%)
Lymphoedema	2/8374 (0%)		0/8386 (0%)
Orthostatic hypotension	2/8374 (0%)		2/8386 (0%)
Peripheral arterial occlusive disease	7/8374 (0.1%)		11/8386 (0.1%)
Peripheral artery aneurysm	0/8374 (0%)		1/8386 (0%)
Peripheral artery dissection	1/8374 (0%)		0/8386 (0%)
Peripheral artery occlusion	2/8374 (0%)		1/8386 (0%)
Peripheral artery stenosis	5/8374 (0.1%)		12/8386 (0.1%)
Peripheral ischaemia	4/8374 (0%)		9/8386 (0.1%)
Peripheral vascular disorder	7/8374 (0.1%)		8/8386 (0.1%)
Peripheral venous disease	1/8374 (0%)		0/8386 (0%)
Post thrombotic syndrome	0/8374 (0%)		1/8386 (0%)
Shock haemorrhagic	0/8374 (0%)		1/8386 (0%)
Subclavian artery occlusion	1/8374 (0%)		0/8386 (0%)
Subclavian artery stenosis	1/8374 (0%)		0/8386 (0%)
Varicose vein	1/8374 (0%)		0/8386 (0%)
Vasculitis	1/8374 (0%)		0/8386 (0%)
Venous thrombosis limb	1/8374 (0%)		0/8386 (0%)
Other (Not Including Serious) Adverse Events
	Placebo		Bococizumab (PF-04950615)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1570/8374 (18.7%)		2015/8386 (24%)
Gastrointestinal disorders
Diarrhoea	133/8374 (1.6%)		169/8386 (2%)
General disorders
Injection site reaction	88/8374 (1.1%)		588/8386 (7%)
Infections and infestations
Nasopharyngitis	289/8374 (3.5%)		283/8386 (3.4%)
Upper respiratory tract infection	193/8374 (2.3%)		183/8386 (2.2%)
Metabolism and nutrition disorders
Type 2 diabetes mellitus	195/8374 (2.3%)		217/8386 (2.6%)
Musculoskeletal and connective tissue disorders
Arthralgia	197/8374 (2.4%)		208/8386 (2.5%)
Back pain	203/8374 (2.4%)		217/8386 (2.6%)
Myalgia	160/8374 (1.9%)		170/8386 (2%)
Nervous system disorders
Headache	136/8374 (1.6%)		171/8386 (2%)
Vascular disorders
Hypertension	303/8374 (3.6%)		270/8386 (3.2%)

Limitations/Caveats

As specified in statistical analysis plan, due to discontinuation of the bococizumab clinical development program, health care resource utilization endpoints were not evaluated.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.